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General introduction  
 
Earlier and more accurate diagnosis and improved observation and treatment have resulted 
in an increased number of people that has been successfully treated for cancer. In the 
Netherlands, it is expected that from 2000 to 2015 the number of cancer survivors will 
increase from 366.000 to 692.000. This means that in fifteen years’ time the number of 
cancer survivors will have almost doubled.1 Despite the fact that these persons have been 
cured from cancer, many survivors still face distressing physical, emotional and social 
consequences as a result of their illness and/or treatment. For these persons cancer must be 
managed as a chronic disease.  
One of the long-term problems cancer survivors face is postcancer fatigue. Fatigue as a 
side-effect during cancer treatment attracted considerable research attention in the past 
decennia.2-4 Fatigue is now recognized as one of the most common and distressing side 
effects of cancer treatment, occurring among patients undergoing surgery, radiation, 
chemotherapy and stem cell transplantation. Fatigue persists for months or years after 
completion of curative treatment in a substantial minority of the cancer survivors.1-2,5-8 Interest 
in the problem of postcancer fatigue is growing among clinicians and researchers, and is 
consistent with a greater awareness of the importance of quality of life as an outcome in 
oncology. 
Postcancer fatigue is a multidimensional concept with several modes of expression. It 
decreases a patient’s ability to perform common daily activities by affecting mood, 
decreasing concentration and attention, and limiting physical activity. As such, postcancer 
fatigue has an enormous detrimental effect on quality of life.1-2,9-10  
Up to now, the nature of the underlying pathophysiology of somatically unexplained 
postcancer fatigue remains unclear. Hypotheses have been proposed about increased 
proinflammatory cytokine activity and dysregulation in hypothalamic-pituitary-adrenal axis 
responsiveness, however, contradictory findings still exist.3   
 
 
Expert Centre Chronic Fatigue  
The Expert Centre Chronic Fatigue is a multidisciplinary collaboration of internists, 
virologists, neurologists, neurophysiologists, neuroscientists, oncologists and psychologist 
from several departments of the Radboud University Nijmegen Medical Centre. The Expert 
Centre has focussed on the study of chronic fatigue syndrome since 1990.11-14 During the 
years the research extended to chronic fatigue in several other specific patients groups.12,15-18 
Since 1996 research is conducted on the subject of postcancer fatigue.19 These studies dealt 
with the natural presence and course of fatigue and made clear that fatigue long after 
curative treatment for cancer is a severe problem for at least a quarter of the cancer 
survivors. The relation between postcancer fatigue and initial disease and treatment 
characteristics was investigated. No associations were found, except that patients who did 
not have had adjuvant treatment at all, and for whom surgery was without complications, 
seemed to experience persistent postcancer fatigue less often than other survivors.8 
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Complaints of severe fatigue were associated with considerable limitations in daily life, for 
instance in the areas of work, household activities, social interactions or recreation and 
pastime. Results of a longitudinal study with regard to the association between fatigue 
severity and psychological and physical variables indicated that low self-efficacy, elevated 
feelings of anxiety, serious limitations in role functioning, low sense of optimism and 
somatisation were associated with the persistence of the fatigue complaints.19  
 
Postcancer fatigue: precipitating and perpetuating factors 
Because no relationship has been found between the majority of former disease and 
treatment characteristics and postcancer fatigue,2,3,5,8,20-22 we believe it is useful to make a 
distinction between precipitating factors and perpetuating factors of fatigue after cancer. The 
assumption is that cancer itself and/or cancer treatment may have triggered fatigue 
(precipitating factors), but other factors are responsible for persistence of fatigue complaints 
(perpetuating factors). Based on the literature, own studies19 and our clinical experience a 
cognitive behavioural intervention was developed based on factors assumed to play a role in 
the perpetuation of the fatigue, such as poor or inappropriate coping skills, a heightened fear 
of a recurrence of the cancer, dysfunctional fatigue-related cognitions, dysregulatory sleep-
wake cycles, dysregulatory activity patterns, and insufficient social support and interactions. 
Cognitive behaviour therapy (CBT) is a general form of psychotherapy directed at changing 
condition-related cognitions and behaviours. CBT appeared to be effective in conditions such 
as panic disorder, depression, obsessive-compulsive disorder, irritable bowel syndrome and 
chronic fatigue syndrome.14,23-24 CBT is directed at cognitions and behaviours relevant for 
each specific disorder, which implies that CBT for postcancer fatigue is not the same as CBT 
for depression, or CBT for chronic fatigue syndrome. An important part of this dissertation is 
concerned with the evaluation of CBT for postcancer fatigue, such as the treatment protocol, 
the efficacy and the long term results. 
 
Outline of the dissertation 
This dissertation consists of nine chapters. The longitudinal study described in Chapter 2 
investigated the course of fatigue during a two-year period. This chapter reports on whether 
fatigue is a persistent problem, and whether persistent fatigue is related to former treatment 
modalities. In addition, predictors of postcancer fatigue were studied.  
The results from Chapter 2 and previous studies of the Expert Centre Chronic Fatigue19 
revealed several perpetuating factors of persistent postcancer fatigue. This made it possible 
to develop a CBT-treatment protocol aimed at these factors. The treatment protocol of this 
intervention is presented in Chapter 3. The protocol encompasses six modules that coincide 
with the six factors assumed to perpetuate the symptoms of fatigue. The rationale of each 
module is discussed, followed by the relevant assessment instrument and the proposed 
course of action. For purposes of illustration, each module ends with a case example.  
The efficacy of CBT for fatigue in cancer survivors was investigated in a randomized-
controlled trial where the effects of the therapy were compared with a waiting list condition. 
The results of CBT on fatigue severity, functional impairment and psychological well-being 
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are reported in Chapter 4.  
The long term effects were examined in cancer survivors who completed CBT and are 
described in Chapter 5. Furthermore, possible predictors of recovery at follow-up are 
reported in this chapter.  
Servaes et al (2003)8 found that patients with less intensive treatment were less at risk for 
persistent fatigue. A stem cell transplantation (SCT) is the opposite; it is a highly aggressive 
and demanding medical intervention. So, the main objective of Chapter 6 was to investigate 
the prevalence of fatigue in this population. In addition, we analysed the relationship between 
medical variables and postcancer fatigue and if the model of perpetuating factors of 
postcancer fatigue derived from previous studies in cancer survivors without SCT, was 
applicable in SCT survivors as well.  
To get a better understanding of the nature of (postcancer) fatigue, Chapter 7 and Chapter 8 
are focussed on the use of novel measurements of fatigue. Studies on (postcancer) fatigue 
demonstrate the enormous influence of fatigue, like a low quality of life, many impairments in 
daily life, diminished concentration, depression, anxiety etc. Since fatigue has such a 
profound effect on many aspects of quality of life, it would also be valuable to know which 
impact fatigue has in a patients’ life,  the suffering due to fatigue. In Chapter 7 we assess in a 
simple, graphic way the burden of suffering due to fatigue with the Pictorial Representation of 
Illness Measure (PRISM) in different fatigued patient groups.  
Until now studies on (postcancer) fatigue use instruments to measure fatigue in a 
quantitative way, like fatigue severity. However, patients often describe their fatigue in 
different ways, with different words. To assess different perceptions of fatigue, we developed 
an adjective checklist, the Fatigue Quality List (FQL). Chapter 8 reports about the 
development and psychometric testing of this instrument.  
Finally, Chapter 9 entails a general discussion, titled: What is known about postcancer 
fatigue? A literature review. The results of the studies presented in the preceding chapters 
will be placed into the perspective of the existing literature of postcancer fatigue. 
Furthermore, directions for future research will be discussed. 
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ABSTRACT 
We investigated whether fatigue is a persistent problem, and whether persistent fatigue is 
related to former treatment modalities. In addition, we studied the predictors of persistent 
fatigue. 
At baseline (n=150, mean time since cancer treatment = 29 months) patients were asked to 
fill out several questionnaires on psychological, physical, social, cognitive and behavioral 
aspects (Ann Oncol 2002; 13: 589-598). During the two years after baseline patients were 
asked to fill out monthly a fatigue questionnaire (CIS-fatigue). Hundred-twenty-one patients 
completed the study, 10 dropped out and 19 had a disease recurrence. 
Twenty-four percent of the  patients experienced persistent severe fatigue complaints during 
the 2-year observation period. Persistent fatigue seemed to be related to the duration of 
former treatment but unrelated to type of surgery, type of adjuvant therapy and time since 
treatment finished. High anxiety, high impairment in role functioning and low sense of control 
over fatigue symptoms at baseline were predictors of persistent fatigue.       
Fatigue appears to be a persistent problem for a quarter of a sample of disease-free breast 
cancer patients during a 2-year period. The predictors of persistent fatigue found in this study 
can be helpful for the development of interventions to reduce post-treatment fatigue. 
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INTRODUCTION 
Fatigue is a well-known problem of cancer patients during active treatment. The malignancy 
itself, the treatment and its side effects like anemia all have impact on fatigue. Many quality 
of life instruments use the complaint fatigue as an important independent factor to 
differentiate between more or less harmful interventions or to measure the clinical 
importance of expensive supportive treatments like additional use of erythropoietin. When 
the patient has been cured, cancer treatment is stopped and the hemoglobin level has been 
normalized, it is expected that all complaints subside within a reasonable period of time.  
However, based on cross-sectional studies, we may conclude that fatigue is a frequent 
complaint in former cancer patients even up to ten years after successful treatment for  
cancer.1-5 So far, most longitudinal studies that have been published focused on fatigue 
complaints in cancer patients while they were undergoing active treatment for cancer6-9 and 
in the year after completion of treatment.10-13 Few longitudinal studies have been performed 
in which fatigue is examined over a longer period of time in cancer survivors.14-17 In none of 
these studies the course of fatigue has been investigated. 
In a previous cross-sectional study we investigated and discussed the prevalence and 
correlates of severe fatigue in a group of disease-free breast cancer patients.18 Results 
indicated that severe fatigue was a problem for nearly 40 percent of a sample of 150 breast 
cancer survivors who completed cancer treatment a mean of 29 months earlier, compared to 
11% in a matched sample of women without a cancer history. Fatigue was measured with a 
multidimensional assessment method. Based on previous research in fatigued patients with 
several chronic diseases, this method has identified nine dimensions, namely fatigue 
severity, psychological well-being, functional impairment in daily life, sleep disturbance, 
physical activity, neuropsychological impairment, social functioning/ social support, self-
efficacy and causal attributions.19 These dimensions appeared to be relatively independent, 
meaning that each dimension uniquely contributed to the description of a patient. A 
regression analyses on the cross-sectional data indicated that depression, physical inactivity, 
the need to sleep and rest during the day and the tendency to attribute fatigue symptoms to 
the breast cancer experience, contributed significantly to the severity of fatigue.18  
The present longitudinal study focuses on the follow-up of this same cohort of women during 
a two-year period. During these two years, patients filled out every month a fatigue 
questionnaire. We will try to answer three questions in a prospective way: 
1. Is severe fatigue a persistent problem in disease-free breast cancer patients long 
after treatment for cancer? 
2. Is persistent fatigue related to former treatment modalities? 
3. To what extent are psychological well-being, functional impairment, sleep 
disturbances, physical activity, neuropsychological functioning, social functioning, 
social support, self-efficacy and causal attributions able to predict persistent fatigue? 
Furthermore, we will exploratory describe the course of fatigue for those patients that had a 
disease recurrence during the two years of our study. 
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METHODS  
Sample 
In order to select a relatively homogeneous group of patients for this study, patients had to 
be premenopausal and younger than 50 years by time of primary diagnosis. All these 
patients have been treated according to the same protocol, the Comprehensive Cancer 
Center East for premenopausal breast cancer patients. At the baseline assessment,18 
patients had completed treatment for breast cancer a minimum of 6 months earlier and had 
no evidence of disease recurrence. During the two years of this study patients went to their 
own oncologist for medical follow-up. Patients with a disease recurrence during this two-year 
period were not included in the analyses to answer the three research questions, but were 
described separately. 
 
Recruitment procedure 
Patients were recruited from one university hospital and 6 regional hospitals. All patients who 
met the eligibility criteria at the university hospital and at three regional hospitals, were 
initially informed about the study by mail with an introductory letter from their oncologist. At 
the other three regional hospitals, patients were informed by their oncologist during control-
visits. In the following week, patients were contacted by telephone by the psychologist-
researcher (P.S.). Those patients who agreed to take part in the study were invited to our 
department of the Radboud University Nijmegen Medical Center for a baseline 
measurement.18 After this baseline assessment, patients filled out a fatigue questionnaire at 
the end of every month for a two-year period. The ethics committee of all participating 
hospitals agreed with this study. 
 
Measurement 
At the baseline measurement we investigated all nine dimensions by validated 
questionnaires. Furthermore, patients performed two standardized tests to assess 
neuropsychological functioning. In addition, they were asked to fill out a daily Self 
Observation List and to wear an actometer during a period of 12 days at home and to fill out 
a fatigue questionnaire (Checklist Individual Strength) at the end of every month, during a 
two-year period.  
All measures are mentioned below. For a more extensive description of the measures we 
refer to the articles in which the baseline data of the present study are described.18,20
 
Fatigue severity has been measured by the fatigue severity subscale (CIS-fatigue) of the 
Checklist Individual Strength (CIS).19,21 The CIS-fatigue consists of 8 items and each item is 
scored on a 7-point Likert scale. A score of 35 or higher on the subscale fatigue severity 
indicates severe feelings of fatigue.19 A score between 27 and 35 indicates heightened 
experience of fatigue.22 Because patients filled out the CIS at the end of every months during 
the two years of our study we calculated a mean CIS-fatigue score over 24 months, which 
we refer to as the ‘persistent fatigue score’. Patients with a persistent fatigue score of 35 or 
higher are referred to as persistently severely fatigued.  
 
Course of postcancer fatigue      21 
Psychological well-being has been measured with the Beck Depression Inventory for primary 
care (BDI-pc),23  the Spielberger Trait Anxiety Inventory (STAI),24  the Rosenberg Self 
Esteem Scale (RSE),25  the Symptom Checklist (SCL-90),26  and the emotional functioning 
subscale of the Quality of Life Questionnaire- C30 of the European Organisation for 
Research and Treatment of Cancer (QLQ- C30).27  
 
Functional impairment has been measured with the subscales home management, work, and 
recreation and pastimes from the Sickness Impact Profile (SIP)28 and the role functioning 
subscale of the QLQ- C30. In addition, hours of work (outside the home and household 
activities) are registered in the Self Observation List. 
 
Sleep disturbances have been measured with the Groninger Sleep Quality Scale (GSQS).29 
In the present study we decided to delete two items because these items strongly overlap 
with fatigue complaints (GSQS-2; Cronbach’s alpha = 0.87). Furthermore, the sleep/rest 
subscale of the SIP and the sleep subscale of the SCL were used. Finally, quality of sleep is 
registered daily in the Self Observation List.  
 
Physical activity has been measured with the physical functioning subscale of the QLQ-C30, 
the mobility and ambulation subscales of the SIP. In addition, physical activity is registered 
once a day in the Self Observation List. Finally, actual physical activity has been measured 
with the actometer.30,31   
 
Neuropsychological functioning has been measured with the cognitive functioning subscale 
of the QLQ-C30 and the alertness behavior subscale of the SIP. Furthermore, actual 
neuropsychological functioning is measured by the Complex Reaction Time task (CRT)32  
and the Symbol Digit subtest of the WAIS.33  
 
Social functioning and Social support have been measured with the social functioning 
subscale of the QLQ-C30, the social interaction subscale of the SIP and the van Sonderen 
Social Support Inventory (SSL).34  
 
Self efficacy has been measured with the Self Efficacy Scale (SES). The SES consisted of 
five questions that measured sense of control with respect to fatigue.35,36
 
Causal attributions with regard to fatigue complaints have been measured with the Causal 
Attribution List (CAL).  This questionnaire consists of 9 items divided over two subscales, 
psychological (e.g. ruminate, sleep problems) and breast cancer related attributions (e.g. 
surgery for breast cancer, adjuvant therapy for breast cancer).  
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Statistical analysis 
Data analysis was performed using SPSS (version 8.0). Paired sample t-tests were 
performed to analyze differences between baseline and follow-up percentages of severe 
fatigue. T-tests, and general linear model (GLM)- general factorial have been performed to 
test differences between groups.  Pearson correlations between the persistent fatigue score 
and the baseline measures were used as preparatory analyses in order to examine the 
contribution of the baseline measures to persistent fatigue. Those measures that correlated 
highest with the persistent fatigue score were used as independent variables in a linear  
regression analyses (enter-method).   
 
RESULTS 
Description of the sample 
At baseline, 150 disease-free breast cancer patients participated in this study. Numbers and 
reasons for non-participation have been described in our previous publication.18 From these 
150 participating patients, 10 patients dropped out for several reasons during the two-year 
period of this study (e.g. taking part in research takes too much time, family circumstances). 
Furthermore, 19 women had a disease recurrence during the two-year period. Hundred-
twenty-one patients thus completed the study. Compliance with respect to the completion of 
the monthly fatigue questionnaires was high. Fifty-six percent of the patients (n=68) returned 
all 24 monthly questionnaires. Twenty-seven percent of the patients (n=33) returned 20 to 23 
questionnaires, and 17 percent returned 16 to 19 questionnaires (n=20). There was no 
difference in the number of monthly questionnaires returned by patients with or without 
persistent fatigue complaints (respectively an average of 22.0 (s.d.= 3.0) vs 22.3 (s.d.= 3.0),  
P  =0.680) 
Information on baseline demographic and medical characteristics of the patients can be 
found in Table 1. A division has been made between those women who stayed disease-free, 
those who had a disease recurrence during our study and those who dropped out for other 
reasons. The only significant difference between the three groups is that the first group is  
older than the third group. 
 
Research questions 
Is severe fatigue a persistent problem in disease-free breast cancer patients long after 
treatment? 
For the total group of disease-free breast cancer patients the mean CIS-fatigue score at 
baseline was 28.9 (s.d.=13.5), and at follow-up 25.0 (s.d.=13.2) (P <0.001). The correlation 
between baseline and follow-up CIS-fatigue scores is 0.65 (P <0.01). Both the mean baseline 
and follow-up CIS-fatigue scores are significantly higher than the mean scores of a matched 
group of healthy women without a cancer history (CIS-fatigue 19.4 (s.d.= 11.0)).18 The 
number of severely fatigued disease-free breast cancer patients was 47 (39%) at baseline. In 
addition, 21 patients (17%) experienced heightened fatigue. At follow-up, the number of 
severely fatigued patients was 28 (23%) and 26 patients experienced heightened fatigue 
(22%).  
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Table 1 
 
Baseline demographic characteristics and medical characteristics 
 
 Disease-free breast 
cancer patients 
N=121
Patients with a 
tumor relapse N=19 
Drop-outs for other 
reasons N=10
Mean age 46.7 (SD 5.9) 43.3 (SD 6.2) 41.8 (SD 8.3)
Marital status  
     married 106     88% 16     84% 8     80%
     unmarried 4       3% 2       1% 1     10%
     divorced 8       7% 1       5% 1     10%
     widowed 3       2% -            - -            -
Higher education (>= 12 years) 45     37% 8     42% 4     40%
Employment  
     paid work outside home 75     62% 10     53% 7     70%
     home management 106     88% 15     79% 7     70%
     disablement insurance act 15     12% 1       5% 2     20%
Surgery  
     mastectomy 78     65% 12     63%  5     50%
     lumpectomy 43     35% 7     37% 5     50%
Adjuvant therapy  
     no adjuvant therapy 18     15% 1       6% -            -
     only radiotherapy 24     20% 5     26% 2     20%
     only chemotherapy 28     23% 4     21% 1     10% 
     radiotherapy and chemotherapy 51     42% 9     47% 7     70%
Duration of treatment (months)1 Mean 6 (SD 3) Mean 6 (SD 3) Mean 6 (SD 2)  
     < 1 month 16     13% -            - 2     20%
     > 1 month, < 6 months 38     32% 12     63% 5     50%
     > 6 months 67     55% 7     37% 3     30%
Time since treatment (months)2 Mean 30 (SD 18) Mean 25 (SD 13) Mean 26 (SD 18)
     between 6-12 months ago 12     10% 2     11% 1     10%
     between 13-24 months ago 44     36% 10     52% 4     40%
     between 25-36 months ago 26     22%       3     16% 1     10%
     between 37- 48 months ago 17     14% 3     16% 3     30%
     between 49-60 months ago                11       9% -            - 1     10%
     more than 60 months ago                11       9% 1       5% -            -
 
1. defined as the period from the time of surgery until the end of adjuvant therapy 
2. defined as the period from the end of adjuvant therapy until the day of the baseline measurement1 
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The percentage of women who experienced heightened or severe fatigue had thus 
decreased from 56 to 45 percent (P <0.01). In Table 2 we indicated the number (and 
percentages) of patients that were classified as severely, heightened or not fatigued at follow 
-up, on basis of their classification as severely, heightened or not fatigued at baseline. 
Almost half of the patients (49%) that were identified as severely fatigued at baseline were 
also identified as severely fatigued at follow-up. In addition, 28 percent of these patients was 
identified as heightened fatigued at follow-up. Furthermore, most patients (85%) that were 
identified as not fatigued at baseline were also identified as not fatigued at follow-up.    
  
Table 2 
 
Numbers (and percentages) of patients that were classified as severely, heightened or not fatigued at 
follow-up, on basis of their classification as severely, heightened or not fatigued at baseline 
 
n percentage 
severe fatigue at baseline (n=47)  
     severe fatigue at follow-up 23  49%
     heightened fatigue at follow-up 13  28%
     no fatigue at follow-up 11  23%
heightened fatigue at baseline (n=21) 
     heightened fatigue at follow-up  8  38%
     no fatigue at follow-up 11  52%
     severe fatigue at follow-up  2  10%
no fatigue at baseline  (n=53) 
     no fatigue at follow-up 45  85%
     heightened fatigue at follow-up  5  9%
     severe fatigue at follow-up  3  6%
 
 
The monthly CIS-fatigue scores of the total sample are depicted in Figure 1. In addition, the 
monthly CIS-fatigue scores are displayed for those women who were severely fatigued at 
baseline, and for those who were not severely fatigued at baseline. Results indicate that the 
monthly fatigue score dropped a little within a two-year period. For the total group of 121 
disease-free breast cancer patients, the monthly fatigue score dropped from 27 at first 
measurement to 25 at last measurement. This descent is due to the descent of fatigue 
scores in patients who were severely fatigued at baseline. Their monthly fatigue score 
dropped from 38 to 34. Monthly fatigue scores of patients who were not severely fatigued at 
baseline remained equal. 
The persistent fatigue score, which is the mean of all monthly fatigue scores, was 25.9 (s.d.= 
11.1) for the total sample. Further, the number of patients with a persistent fatigue score of 
35 or higher was 29 (24%). In addition, 25 patients (21%) had a persistent fatigue score  
between 27 and 35. 
 
Course of postcancer fatigue      25 
Figure 1 
 
Mean CIS-fatigue scores over 24 months of the total group (n=121; —  ● ),  patients who were 
severely fatigued at baseline (n=47; —  ■ ) and patients who were not severely fatigued at baseline 
(n=74; —  ▲ ) 
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Is persistent fatigue related to former treatment modalities? 
The mean persistent fatigue score did not differ significantly for those patients who 
underwent mastectomy (24.8 (s.d.=11.6)) and those who underwent lumpectomy (28.1 
(s.d.=10.4)) (P  =0.130).  
Also for patients with different types of adjuvant therapy the mean persistent fatigue score 
was not statistically different, although patients who did not receive any kind of adjuvant 
therapy at all had a relatively low persistent fatigue score. The mean persistent fatigue score 
was 28.2 (s.d.=11.4) for patients who received radiotherapy, 24.9 (s.d.=11.4) for patients 
who received chemotherapy, 27.1 (s.d.=11.1) for patients who received both radiotherapy 
and chemotherapy, and 21.7 (s.d.=10.5) for patients who did not receive adjuvant therapy (P 
=0.244). Patients that used tamoxifen during a two year period (n=11) had equal fatigue 
scores to patients that did not use tamoxifen. Their fatigue score were respectively 23.5 
(s.d.=11.8) and 26.2 (s.d.=11.2) (P =0.436).   
Furthermore, there appeared to be a relation between persistent fatigue and the duration of 
cancer treatment. The mean persistent fatigue score was 19.5 (s.d.=8.7) for patients who 
finished treatment within one month, 27.0 (s.d.=11.3) for patients who finished treatment 
within 6 months and 27.0 (s.d.=11.3) for patients who were treated for cancer for more than 6 
months (P =0.045).  Finally, we found no relation between persistent fatigue and time since 
treatment finished (P =0.997).  
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To what extent are psychological well-being, functional impairment, sleep disturbances, 
physical activity, neuropsychological functioning, social functioning, social support, self-
efficacy and causal attributions able to predict persistent fatigue? 
Results of the preparatory analyses indicated that within the different dimensions one or 
more baseline measures correlated significantly with the persistent fatigue score. In 
summary (highest correlations are described), women with higher persistent fatigue scores 
report more psychological distress (Trait anxiety (STAI) r =0.612, P <0.001), functional 
impairment (Role functioning (QLQ-C30), r = -0.537, P <0.001), sleep disturbances (Sleep 
(SCL) r =0.438, P <0.001), physical impairment (physical functioning (QLQ-C30) r = -0.477, 
P <0.001), neuropsychological impairment (Cognitive functioning (QLQ-C30) r = -0.514,  
P <0.001) and more problems with regard to social functioning and social support (social 
functioning (QLQ-C30) r = -0.444, P <0.001). Furthermore these women had a lower sense 
of control (self efficacy (SES) r =  -0.489, P <0.001) and stronger psychological attributions 
with respect to their fatigue complaints (psychological attributions (CAL) r =  -0.479,  
P <0.001).  
The regression analyses (Table 3) showed that 51% of the persistent fatigue score was 
predicted by the baseline CIS-fatigue score. The other selected measures predicted an 
additional 9%. Apart from a high baseline CIS-fatigue score, high persistent fatigue was also 
predicted by low self-efficacy. Thus, less perceived control over symptoms predicted higher 
persistent fatigue. Because the CIS-fatigue score at baseline had the largest contribution to 
the prediction of the persistent fatigue score, a second regression analysis was performed 
without the baseline CIS-fatigue score. Fifty-three percent of the persistent fatigue score was  
 
Table 3 
  
Linear regression analyses to predict the persistent fatigue score (range 8-56);  with baseline CIS-
fatigue score (A) and without baseline CIS-fatigue score (B) 
A B 
Beta adj R2 Beta adj R2 
Fatigue (CIS)  .377*** .510  
Trait anxiety (STAI)  .136  .324**  
Role functioning (QLQ-C30) -.153 -.271**  
Sleep (SCL)  .053  .058  
Physical functioning (QLQ-C30) -.085 -.140  
Cognitive functioning (QLQ-C30) -.084 -.063  
Social functioning (QLQ-C30)  .103  .182  
Amount of negative interactions (SSL-N)  .022 -.005  
Self-efficacy (SES) -.214** -.303***  
Psychological attributions (CAL) -.148 .090 -.156 .525 
total adj R2 .600  .525 
*    p < .05 
**   p < .01 
*** p  < .001 
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predicted by the selected measures. Higher persistent fatigue scores were significantly 
predicted by lower self-efficacy, more anxiety and more limitations in role functioning at 
baseline. 
 
Description of the course of fatigue in those women who had a disease recurrence 
The mean CIS-fatigue score at baseline for those women who had a disease recurrence 
within the two year period of our study was 23.9 (SD 14.5) at baseline. Further, the number 
of severely fatigued patients at baseline was five (26%) and one patient (5%) experienced 
heightened fatigue. 
In Figure 2 mean monthly fatigue scores are depicted for the 19 women who had a disease-
recurrence during the study period. The CIS-fatigue scores rose from 23 (12 months before 
the diagnosis of a disease recurrence) to 31 in the month that the disease recurrence was 
diagnosed. Within the group of disease-free breast cancer patients who did not have a 
disease recurrence a matched ‘control group’ was constituted (n=19). The group with and 
without disease recurrence were matched on the baseline CIS-fatigue score. In addition, the 
two groups were comparable with respect to type of surgery, age, adjuvant therapy, duration 
of treatment and time since treatment. In figure 2 the mean monthly fatigue scores are 
depicted for this matched group. There was no clear rise of the monthly CIS-fatigue scores in 
this control group of persistent disease-free women. Their monthly CIS-fatigue score varied 
from 19 to 26. 
 
 
 
Figure 2 
 
Mean monthly fatigue scores for women who developed a tumor relapse (n=19; —  ● ) in the 12 
months before the tumor relapse was diagnosed compared to a matched control group (n=19; - - - ■ )  
 
Tumor relapse: n=19 at time 0; n=16 at time –3; n=14 at time –6; n=11 at time –9; n=10 at time -12 
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DISCUSSION 
The unique quality of this study lies in the fact that we studied fatigue in disease-free breast 
cancer patients during a longer period of time. Because of that we were able to take a closer 
look at the course of fatigue complaints and we were able to identify those patients that 
experienced persistent fatigue complaints.  
Based on the monthly fatigue scores we concluded that severe fatigue is a persistent 
problem for 24% of a group of disease-free breast cancer patients. This is a decrease with 
respect to the baseline assessment, at which 38% of the disease-free breast cancer patients 
experienced severe fatigue 2.5 years after curative treatment ended.18 Bower et al.17 also 
found a decrease of patients with severe fatigue in a longitudinal study, namely from 35% 
(3.5 years after treatment) to 21% (6.3 years after treatment). In one of our previous 
publications a sample of patients with bone or soft tissue tumour were also assessed two 
times in a period of two years. In this sample of patients who finished cancer treatment with 
an average of 6 years ago (range 1 to 15 years), the percentage of severe fatigue remained 
about equal, namely 28% to 26%.16 Hjermstad et al.14 investigated disease-free cancer 
patients 16 years and 24 years after treatment for cancer. In this longitudinal study the 
percentage of fatigued cancer survivors also remained about equal, that is 25% to 28%. 
These results seem to suggest that fatigue complaints continue to decrease during the first 3 
– 4 years after curative treatment. For about a quarter of the cancer survivors fatigue 
remains a continuous problem with profound effects on functional status, like role functioning, 
work, home management and recreation and pastimes.  
The duration of severe fatigue was determined prospectively by calculating the mean CIS-
fatigue score over the 24 months that patients filled out the fatigue questionnaire. Patients 
with a fatigue score of 35 or higher were referred to as ‘persistently severely fatigued’. We 
realize that this technique has some shortcomings, for example, a few months of very high 
fatigue might place a person in the ‘persistently severely fatigued’ category even if most of 
her monthly scores fell below the cut point of 35. Because of this shortcoming we additionally 
calculated the persistent fatigue score according to another approach. We calculated the 
percentage of times that scores fell above the cut-point of 35. However, this technique has 
some shortcomings as well. For example, a person that has many fatigue scores just under 
35, will not be labeled as persistently fatigued, while this is probably untrue. In spite of the 
shortcomings of both techniques it is reassuring to know that the Pearson correlation 
between these differently obtained persistent fatigue scores turned out to be very high; 0.90 
(P <0.000). 
Most studies find no strong association between cancer treatments and fatigue in long-term 
cancer survivors.5,37  However in the current study we found that patients who did not receive 
any kind of adjuvant therapy and who did not experience any kind of complications during 
treatment, i.e. those patients that completed treatment for cancer within one month, were at 
lower risk for persistent fatigue. A possible explanation for the low persistent fatigue scores in 
patients whose treatment duration was short may be due to the fact that they had not been 
subjected to the harmful effects of adjuvant therapy and/or multiple operations (and 
anesthetics) because of complications. In addition, for this group of patients the period of 
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great uncertainty had been limited and they had been spared many hours of traveling to and 
from the hospital, which can cause exhaustion as well. Some other studies also found 
evidence for the assumption that patients with more aggressive treatments are more at risk 
for persistent fatigue.16,17,38
Breast cancer patients often become menopausal as a result of chemotherapy.  Menopausal 
symptoms seem to be both more prevalent and more severe in cancer survivors than in 
healthy women,39,40 and can therefore be of influence on the persistent of fatigue. In a 
subgroup of 80 patients we measured with the self-observation list the intensity of hot flashes 
four times a day during a 12-day period. Patients with severe fatigue had a higher score than 
non-fatigued patients. This difference approached significance (P < 0.071). 
Some studies suggest an association between fatigue and adjuvant hormonal therapy.39,40 
Patients in our study were treated for cancer according to the guidelines of that time and 
therefore only a minority of the breast cancer patients (n=11) was treated with tamoxifen. In 
this small group no differences in fatigue were found between patients with or without 
tamoxifen. 
Due to the recruitment procedure it is possible that a selection bias exists in this study. In our 
previous publication about this cohort of breast cancer survivors, we looked at differences 
between responders and nonresponders with respect to background variables.18 Reasons for 
non-participations were e.g. takes too much time, too emotional, problems with transport, too 
tired etc. Nonresponders (41%) did not differ from the responders with regard to age, type of 
surgery, radiotherapy and time since treatment completion. Nonresponders received 
chemotherapy less often: 41% compared with 66% (χ2 tests;  P <0.001). Therefore, duration 
of treatment was significantly lower for nonresponders (4 compared with 6 months for 
responders; P <0.001). Because of these differences it is possible that the responders 
experience more fatigue and the percentage of fatigue in breast cancer survivors might be 
worse than in reality. However, the percentages found in our studies were similar to 
percentages in other longitudinal and cross-sectional studies on fatigue in disease-free 
cancer patients.14,16,17,41,42  
With respect to the relation between severe fatigue and disease recurrence it is important to 
note that at baseline severe fatigue was found both in patients who had a disease recurrence 
and in patients who remained disease-free. In our study the mean CIS-fatigue score and the 
percentage of severely fatigued patients at baseline were even lower in the group of patients 
who had a disease recurrence than in the patients that remained disease-free. In clinical 
practice severe fatigue complaints can thus not be interpreted as an indicator of a possible 
disease recurrence. However, there seems to be a rise of the fatigue score in the months 
preceding the diagnosis of the disease recurrence. Nevertheless, we should be careful in 
interpreting this finding because the group of women who had a disease recurrence is small.   
In understanding off-treatment fatigue in disease-free cancer patients it is important to make 
a distinction between initiating factors and perpetuating factors of fatigue. This model 
appeared to be useful in patients with chronic fatigue syndrome (CFS),35,36 but can be 
applied in fatigued cancer survivors too. We know that fatigue arises during the active 
treatment of cancer in nearly all patients. For about a quarter of the cancer survivors 
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persistent fatigue becomes an invalidating long lasting side effect of the cancer 
treatment.5,14,17,37,42  Because almost no relations were found between initial disease- and 
treatment variables and off-treatment  fatigue,5,37 other factors seem to be responsible for the 
persistence of fatigue complaints.   
In this study persistent fatigue was very well predicted by the questionnaires that we used to 
measure psychological well-being, functional impairment, sleep disturbances, physical 
activity, neuropsychological functioning, social functioning, social support, self-efficacy and 
causal attributions. With use of several selected baseline measures, the percentage of 
explained variance was 60 percent. Based on the results of the current study we might 
expect that low sense of control, anxiety and impairment might be important perpetuating 
factors. 
In managing fatigue in cancer survivors exercise has been proposed in the literature as a 
useful strategy.43-45 However, to our knowledge there have been no published randomised 
controlled intervention studies in which the main object was to reduce fatigue complaints in 
cancer survivors. For CFS patients, cognitive behavior therapy (CBT) has proven to be 
successful in reducing fatigue complaints.36,46,47 CBT may also be a useful intervention in 
reducing postcancer fatigue. Servaes et al.1,48 made clear that the perpetuating factors in 
former cancer patients differ from factors in the CFS model and interindividual differences 
are larger in fatigued cancer survivors than in CFS patients. Therefore, CBT for postcancer 
fatigue should be adapted to each individual cancer survivor and directed, among others, at 
the predictors of persistent fatigue found in this follow-up study.  
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ABSTRACT 
Fatigue during cancer treatment is a common complaint in cancer patients being treated with 
curative intent. Physically unexplained fatigue long after cessation of the clinical treatment (1 
year or more) has only recently received attention. Research has shown that this postcancer 
fatigue tends to become chronic in an estimated 25% of all cancer survivors, with serious, 
associated implications for their daily lives. Clinicians generally have little to offer in terms of 
a remedy, especially due to the lack of somatic leads. Research conducted by our own 
institute and the literature have identified several factors assumed to play a role in the 
perpetuation of the fatigue, such as poor or inappropriate coping skills, a heightened fear of a 
recurrence of the cancer, dysfunctional fatigue-related cognitions, dysregulatory sleep-wake 
cycles, dysregulatory activity patterns, and insufficient social support and interactions. 
Cognitive behaviour therapy (CBT) targeting these so-called perpetuating factors has been 
found to reduce the symptoms of fatigue. In this report we present the treatment protocol for 
CBT specifically designed for the treatment of persistent postcancer fatigue. 
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INTRODUCTION 
During their clinical treatment many cancer patients mention complaints of fatigue, with 
proportions of as high as 99% having been reported.1, 2 In an estimated 25% of all cancer 
survivors the fatigue symptoms are sustained long (at least one year) after treatment 
completion and have become chronic without any apparent somatic causes.3-7 Research has 
shown that this persistent, postcancer fatigue has serious consequences for the daily lives of 
these former cancer patients.1-2
For a proper understanding of chronic fatigue following successful curative cancer treatment 
we need to make a distinction between precipitating or initiating factors on the one hand and 
perpetuating factors on the other. Such a distinction has earlier been shown indispensable in 
studies into chronic fatigue syndrome (CFS).8 That disease and treatment characteristics 
have been demonstrated to be unrelated to the severity of the postcancer fatigue argues in 
favour of making a similar distinction in this population.1-3,5,9-11 In other words, the proposed 
precipitating factors for fatigue occurring during cancer treatment, i.e. the disease itself and 
its treatment, do no longer explain the persistent post-treatment fatigue. Although it is 
plausible to assume that the fatigue was originally educed by the treatment, over time other 
factors must have come into play causing the symptoms to be maintained. 
Research and clinical experience have since shed more light on these perpetuating factors in 
cancer survivors. Thus, if a patient copes poorly with the diagnosis of cancer and the 
subsequent clinical treatment, the fatigue is likely to be sustained, as can happen when the 
disease-free patient suffers from a pervasive fear of a recurrence of the cancer.5,10 
Furthermore, all kinds of aggravating rather than alleviating fatigue-related thoughts and 
perceptions, henceforth referred to as cognitions, may be implicated, an example of which is 
catastrophising, which exacerbates existing symptoms.12 A patient’s deviant sleep-wake 
cycle may also affect the complaints and over- as well as inactivity – both often observed in 
former cancer patients – tend to worsen the fatigue.1-2,10 Finally, cancer survivors often report 
the sensation of not being understood by their social environment, which feeling can 
additionally intensify their fatigue.13
It is the rationale of a cognitive behaviour therapy (CBT) specifically designed for the 
treatment of CFS that an intervention that addresses a patient’s perpetuating factors will help 
reduce fatigue levels. The CBT approach has indeed been successfully applied in various 
CFS populations.14-17 A comparison of the defining characteristics of chronically fatigued 
cancer survivors and patients diagnosed with CFS has enabled us to identify which aspects 
of the CFS treatment programme warranted modification before it could be applied in cancer 
survivors. A major, a priori distinguishing feature is that in postcancer fatigue there is a clear 
and for each patient similar time of onset, viz. in the course of the oncological treatment, 
which seems to point to the presence of a similar, precipitating factor. In CFS the point of 
onset is not always clear and, if known, tends to vary per patient. The fatigue-related 
attributions of the two patient groups are hence already quite dissimilar. Another essential 
difference is the greater variation in the dimensions of the fatigue in disease-free cancer 
patients.19 The degree of physical activity among cancer survivors, for instance, tends to vary 
widely, whereas the activity levels in CFS patients are less heterogeneous. Also, relative to 
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cancer survivors, CFS patients have been found to have higher fatigue scores, to experience 
more limitations in their daily functioning, to be less physically active, to report more intense 
pain and have a lower sense of control over their fatigue complaints.  
On the strength of mentioned differences we concluded that a psychotherapeutic programme 
aimed at chronically fatigued, disease-free cancer patients clearly needed to differ on 
essential aspects and had to be far more tailored than CBT programmes targeting patients 
with CFS. The efficacy of such a newly-designed, individualised CBT approach for fatigued 
cancer survivors has recently been demonstrated in a randomised controlled trial (RCT).20 
The current report provides the protocol for the treatment. We will subsequently place the 
CBT into its proper perspective and conclude with directions for future research. 
 
Patient-specific CBT for persistent postcancer fatigue  
The treatment protocol encompasses six modules that coincide with the six factors assumed 
to perpetuate the symptoms of fatigue (see Figure 1). Note that these are not the same for 
each patient. To determine the key factors for each patient, in addition to an interview, the 
patient completes several assessment instruments. Based on the tools’ norm scores it is 
determined whether the patient has a deviant or problem score. Subsequently, founded on 
the outcomes of the assessment instruments and the patient-therapist interview, a custom-
built treatment plan is drawn up comprising only patient-relevant modules. The tailored 
programme hence aims at changing the patient’s specific perpetuating factors. 
At the start of the programme patients are given room to relate their story after which the 
therapist explains the treatment and treatment goals in general terms. Since severely 
fatigued cancer survivors often tend to attribute their complaints to their having had cancer or 
to the subsequent treatment they have undergone, in the first session each patient is 
explained the difference between precipitating (triggering) and perpetuating (maintaining) 
factors.13 It is also opportune to inform the patient of relevant scientific studies: research has 
shown that medical factors such as cancer type and treatment type have no bearing on post- 
cancer fatigue. This may help patients to come to terms with the fact that, although the initial 
complaints started during and in relation to their medical treatment, they are now sustained 
by other factors. Next, the outcomes of the assessment instruments are discussed and the 
patient’s individual treatment goals formulated. Throughout the programme the patient is 
given home assignments that are reviewed during the sessions.  
In the protocol below the treatment modules are described in the order in which they are 
usually carried out (the masculin pronoun is used to denote both male and female patient). 
First, the rationale of each module is discussed, followed by the relevant assessment 
instrument and the proposed course of action. For purposes of illustration, each module ends 
with a case example. Preceding the module descriptions, the case histories on which these 
are based are given. 
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Figure 1 
 
The six modules of the treatment protocol for postcancer fatigue  
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Two case histories 
Case history Mr. O. 
O. is a 38-year-old married man with two daughters (15 and 9 yrs) and a son (12 yrs). He is 
head of sales in a company manufacturing orthopaedic aids. O. was diagnosed with 
testicular cancer seven years ago for which he underwent surgery and four successive 
chemotherapy treatments. During the chemotherapeutic sessions the patient reported feeling 
progressively more fatigued. After treatment completion the fatigue did not abate and now, 
after several years, the patient still feels fatigued. 
O. feels impeded by his fatigue. He has given up playing tennis and no longer tinkers with 
motorbikes. Since the previous year, instead of working fulltime, he has cut his hours to 80%.  
He has been seeing a psychologist with whom he has mainly discussed ways to cope with 
his fatigue. Although he appreciated the sessions, improvements were minimal. The fatigue 
persisted. 
 
Case history Mrs. T. 
T. is a 45-year-old woman who underwent surgery for ovarian cancer twice with subsequent 
chemotherapy five years ago. The patient first became fatigued in the course of the 
treatment. Rather than improving, after treatment completion she felt even more fatigued. 
The fatigue persisted. T. is married with two children aged 12 and 15 years. Her husband is a 
great source of support and frequently takes care of the family’s evening meal and the daily 
shopping.  
At the time, T. found the clinical treatment extremely taxing. Though earlier still active as a 
remedial teacher, due to the treatment and the fatigue she failed to manage working her 
usual (24) hours. She is now on full disability. 
 
 
Module: Poor coping with cancer and cancer treatment 
Rationale 
Having developed cancer and having undergone treatment for the disease may both 
constitute traumatic events in a person’s life. Coping with these events takes time. Clinical 
practice has shown that cancer survivors may need the entire first year following treatment 
end to do so. During this post-treatment period one should therefore not talk poor coping with 
cancer and cancer treatment. Only when the patient continues to be (pre)occupied with what 
has happened to him (long) after this period should poor coping patterns be considered. In 
this event, we may be dealing with so-called posttraumatic symptoms that sustain the 
fatigue.21-22 Sometimes the deficient coping mechanisms and the accompanying fatigue are 
reactivated by events in the patient’s immediate environment, for instance, upon learning that 
someone he knows has been diagnosed with cancer. 
Assessment 
The extent to which patients have coped with their cancer can be assessed with the Impact 
of Event Scale (IES).23-24 The patient instructions are adjusted to accommodate for cancer 
and cancer treatment. The questionnaire consists of two subscales, i.e. intrusion and 
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avoidance. We take a high score on both subscales (>10 for each separate scale and > 20 
for the combined scales) to be a sign that the patient has both heightened cognitions and 
feelings associated with his reliving the diagnostic and clinical treatment stages and displays 
marked avoidant behaviour. If this applies, the present module is indicated.  
Procedure  
The aim of the module is to help the patient give the facts of having had cancer and his 
cancer treatment their proper place in his life, thus taking away the need or urge to keep 
reliving or actively avoiding memories of the events. In order to reduce these propensities, 
the patient first needs to be exposed to the past events. To this end, the therapist and patient 
should go over the patient’s experiences in terms of events and impact in great detail. 
Targeted writing assignments (e.g. having the patient write down his experiences) as well as 
tailored suggestions to talk about specific events with spouse or others close to the patient 
form part of the process. 
Case example       
During the first session O. discloses that he is often confronted with vivid memories of the 
moment he was told he had cancer. O.: “I was devastated. For quite a while I kept thinking I 
was going to die. I was afraid that the chemo would not work for me. My wife and relatives 
kept trying to lift my spirits. I didn’t dare tell them how scared I was. When the chemo proved 
to take effect, everyone was relieved, including me. I no longer felt I could tell them how bad I 
was still feeling; I was getting well, was being cured, wasn’t I? I keep thinking about it and it 
still distresses me. I can still see the doctor’s face when he told me we were dealing with 
cancer. I don’t talk about it with my wife; we’re glad it’s all over and I don’t want to complicate 
things for her for no apparent reason.”  
 
 
Module: Excessive fear of disease recurrence  
Rationale 
Typically, feelings of anxiety in cancer survivors are higher than before the diagnosis, 
especially when a follow-up visit draws near. In some patients anxiety levels may be 
continually and excessively elevated. Their anxiety pertains to a fear of recurrence of their 
cancer with associated concerns about potential treatments and deteriorating condition, 
evolving into a fear of dying.5,10,25   
Assessment 
To gauge the patient’s fear of disease recurrence we propose a modified version of the 
Cancer Acceptance Scale (CAS).5, 9 It presents the patient with two statements: “I worry 
about the cancer returning” and “I am anxious about my health”. Both are rated on a 4-point 
scale ranging from ‘Does not apply to me at all’ to ‘Completely applies to me’. We take a total 
score of ≥ 5 to indicate undue fear of recurrence.   
Procedure 
The module aims at preventing the worries concerning a possible recurrence of the cancer 
from dictating the patient’s life. Crucial to this part of the intervention is to identify and 
explicate the cognitions underlying the patient’s fear. These can subsequently be weighed 
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against what the attending oncologist earlier told the patient about the likelihood of a 
recurrence. This reality check may help the patient put things into perspective. In addition, 
encouraging the patient to adopt cognitions relating to the patient’s current situation may 
contribute to curbing his daily anxiety. 
Case example 
Mrs. T: “It is always there, in the background. I know I’ve always been a bit of a worrier, 
really, but when the thought that I might get cancer again enters my mind, I start to feel all 
panicky. The fear tends to crop up most when I’m thinking of my kids. It consumes me”. 
 
 
Module: Dysfunctional cognitions  
Rationale 
This module is concerned with various dysfunctional fatigue-related cognitions. Patients may 
be unable to accept their fatigue-induced impairments and refuse to adapt their life patterns 
to the new condition, hence exacerbating the symptoms. It is known from the literature that 
disease-free cancer patients suffering from severe fatigue more frequently revert to 
catastrophising as their coping strategy, i.e. they tend to have an excessively negative 
orientation towards their fatigue.12 This coping style is also seen in people suffering from 
chronic pain.26-27 Fatigue-related catastrophising cognitions sustain or even magnify the 
symptoms. Self-efficacy, reflecting the extent to which a patient feels or thinks he can or 
cannot control his symptoms, may also be implicated and appears pivotal in cancer 
survivors, in whom a low or negative self-efficacy has been related to increases in fatigue 
levels.13 Similar findings have been reported for patients diagnosed with CFS and multiple 
sclerosis, in whom negative self-efficacy proved to directly affect the severity of the fatigue.18
Assessment  
The Fatigue Catastrophising Scale, an adaptation of the Pain Catastrophising Scale, is used 
to evaluate the extent of catastrophising thoughts relating to fatigue.28 The self-report 
questionnaire comprises three subscales, i.e. helplessness (6 items), magnifying (3 items) 
and ruminating (4 items), which are each answered on a 5-point scale. The latter two are 
used , Scores of 2 or higher are taken to reflect excessive magnifying and a score of or 
exceeding 7 unwarranted ruminating. Self-efficacy is assessed using the modified Self-
Efficacy Scale (SES) for fatigue.15,18 Its seven items are rated on a 4-point scale and scores 
of 19 or lower indicate negative self-efficacy. If one of the two scales yields a problem score, 
it is recommended to incorporate the module in the programme.  
Procedure 
The module’s goal is to enable the patient to use more conducive and fatigue-reducing 
cognitions. By helping him to gain insight into the way catastrophising thoughts can 
exacerbate the complaints, the patient is motivated to replace these with more realistic and 
beneficial cognitions. Through Socratic dialogues unhelpful thoughts that tend to render the 
patient helpless can be modified into more appropriate, helpful cognitions that advance his 
self-reliance and self-efficacy.  
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Case example 
T. relates all the things she has undertaken to divest herself of the fatigue. Mrs. T.: “I have 
tried everything there is to try. Nothing worked. I will never get rid it. I have no control over it 
whatsoever. I actually won’t be able to cope with it much longer”. 
 
 
Module:  Dysregulatory sleep-wake cycle 
Rationale 
The patient’s circadian pattern may have become disrupted by his keeping irregular bedtime 
and wake-up times, which may in turn have additionally provoked problems with falling 
asleep and sleep disturbances. Lying down or sleeping during the day may also lead to 
irregular or disturbed nocturnal sleeping patterns. Persisting sleep problems and irregular 
sleep patterns are common in cancer survivors and both tend to perpetuate the fatigue.1,2  
Possibly, the dysregulations have been caused by coping difficulties or fears of disease 
recurrence. If so, these factors need to be addressed concurrently.  
Assessment 
To chart a patient’s circadian patterns use can be made of a Self-Observation List, a 
standardised journal the patients keeps for two weeks to record, among other aspects, his 
bedtime and get-up times and sleep quality.13 The patient notes down his resting and 
sleeping times daily. When plotted in a bar chart the irregularities in the patient’s sleep-wake 
patterns are easily visualised (see Figure 2). By also having the patient record each morning 
how he has slept the night before, the quality of his sleep can be determined and problems 
identified. Response options include: I have slept well, I had trouble falling asleep, I had a 
restless sleep, I woke up early, I did not feel rested when I woke up. If the patient has 
problems sleeping or dysregulated sleep-wake cycles, the module is considered relevant.  
Procedure 
The module aims at establishing a consistent sleep-wake pattern with regular bedtime and 
wake-up times. This requires explaining the patient how he can (re)set his ‘biological clock’. It 
may be helpful to illustrate this by explaining the consequences of jetlag, working shifts or 
changing daylight saving times (shifts between ‘summer’ and ‘winter’ time). Introducing and 
encouraging adequate sleep-hygiene practices may also be opportune (e.g. the bed should 
be reserved for sleeping; it is advisable to adopt regular going-to-bed preparations; do not 
get up when you wake up at night). 
Case example  
T. goes to bed at variable times depending on how she is feeling. She usually gets up early 
in the morning on account of the children and then returns to bed. On the days she works 
(i.e. restricted hours and on a therapeutic basis), as soon as she comes home she lies down 
on the couch where she usually dozes off. 
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Figure 2 
 
Self-Observation List: bed times ( —       ) and wake-up times ( —  ● ) of 12 days 
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Module:  Dysregulatory activities and return to work  
Rationale 
Especially in activity levels fatigued cancer survivors tend to show wide inter-individual 
differences.13,19 Some are physically overactive; an overly active disease-free cancer patient 
tends to overtax himself continuously, with all the consequential physical and emotional 
adverse effects. Conversely, some patients will exhibit an excessively low activity pattern, 
reflected in an habitual lack of physical activity. Here, a fear that activity will aggravate the 
fatigue may be implicated or it may simply be a matter of habit. Both over and inactivity may 
perpetuate the symptoms of fatigue10,29 Patients may also display excessively high or low 
activity patterns in their mental (reading, working at the PC, doing crosswords) and social 
activities (e.g. visiting or entertaining friends) that may both also affect their fatigue levels.   
Assessment 
An actometer is used to assess the patient’s actual level of activity – to supplement his self-
reported activity patterns (see below). The device has the size of a box of matches and is 
worn around the ankle for two weeks (day and night) to record the number of movements the 
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patient makes at five-minute intervals. With dedicated software various parameters can be 
computed and plotted. One of the crucial actometer variables in our treatment context is the 
mean daily physical activity across twelve days and nights: the higher the outcome score, the 
greater the overall extent of the activities the patient has displayed. Based on these mean 
day scores two problematic daily activity patterns can be distinguished: passive and relatively 
active.13,15,29,30  In the two-week period the actometer is worn, the patient also rates (the 
extent of) his daily endeavours, comprising both physical and other activities, on the Self-
Observation List. The current module is usually not indicated for patients with a mean 
actometer score ranging between 80 and 90  
Procedure  
It is the aim to first help the relatively active patient to establish a base level. By base level is 
meant that the patient reduces his level of physical (and possibly also mental and social) 
activities by learning to respect his limitations, and hereby adopting and sustaining a suitable 
personalised activity level that does not lead to excessive fatigue. The moment the patient 
has set his base level, the physical activity programs start. The patient selects a simple 
physical activity that can be performed every day (e.g. walking or cycling). The aim is to have 
the patient gradually and systematically increase the frequency or duration of this particular 
activity. The inactive patient starts immediately with the physical activity program. Intensifying 
or curbing specific activities will also raise the patient’s (perceptions of his) capabilities in 
other areas. In subsequent stages the feasibility of a resumption of (paid) work and other 
desired activities should be considered for both patient types. To this end, the discrepancy 
between the patient’s daily activity pattern and his preferred level needs to be established, 
after which activity-regulating schemes to reach the new goals are jointly set. If needs be, 
separate goals may be formulated to modify mental and social activity patterns. The patient 
thus learns to balance his activities, allowing him to perform his daily tasks and routines in an 
appropriate way, paving the way for a phased return to work. 
Case example 
T is an example of an inactive patient. T. needs to plan all her activities well ahead and 
reserves ample time to recover from them. She tries to prevent herself from becoming 
excessively fatigued because this will lead to failure in all other areas.  
T: “I have many interests, but I restrain myself because if I don’t, the fatigue will only get 
worse. If I need to be somewhere, for instance, I take extra time out to rest before I go, just to 
help me manage to get through it. That’s also why I spend so much time lying on the settee. 
It is about the only thing that helps me to do the little I can, really. ” 
  
O. is an example of an overactive patient. O has periods that he tries to do everything. He 
brings his son to football and stays to view the match. He visits with his wife his daughter’s 
dance performance. During and afterwards he feels awfully and exhausted. Sometimes if a 
friend asks him to play tennis, he does not want to say  no. The next day he is not able to go 
to his work . But he says to himself “before I could do that, so now I also should be able to do 
that”.   
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Module: low social support and negative interactions 
Rationale 
The extent of the social support disease-free cancer patients enjoy is positively related to 
their perceptions of quality of life.31  Research of our group has shown that fatigued cancer 
survivors report more incidences of negative social interactions and that the discrepancy 
between the self-reported extent of their social interactions and the preferred level is larger 
than it is for their non-fatigued cancer survivors: most indicate needing more support than 
they currently receive.13 Sometimes they crave the same attention and recognition they 
received while undergoing treatment even though for most people in their immediate vicinity 
these events are no longer relevant, which makes the fatigued former cancer patient feel 
neglected and ignored.  
Assessment 
We have gauged the patients’ dimensions of social support with the 34-item Discrepancies 
subscale of the Sonderen Social Support Inventory (SSL-D).32 The SSL-D measures the 
perceived discrepancy in actual and desired support, also denoted as insufficiency in 
supportive interactions. Total scores for the SSL-D range from 34 to 136. Scores exceeding 
50 are seen as indicative of the current treatment module.13,33  
Procedure 
The module is directed at modifying the patients’ excessive expectations regarding their 
social environment by promoting more realistic expectations, which are expected to reduce 
their negative cognitions and feelings vis-à-vis their social contacts. The patient’s perceived 
insufficiency in supportive interactions is discussed. The patient is encouraged to adopt a 
different attitude towards his environment, abandoning any expectations of empathy and 
support where these are no longer relevant or reasonable. If these also pertain to the 
patient’s spouse, inviting him or her to participate in this part of the programme is 
recommended. If indicated, time may be dedicated to enhancing the patient’s capacity to 
assert himself. 
Case example 
O.: “At work they never talk about it anymore; it’s as if it’s never happened. They don’t even 
know about my feeling so damned tired. They also act as if things are all back to normal 
even though they know full well why I’m working fewer hours. They expect me to attend each 
meeting, just like they do of the others. They obviously have no idea of what I’ve been 
through. They could ask me how I’m doing every once in a while, now couldn’t they?!”. 
 
 
Treatment content and module frequency   
The mean treatment duration for the 65 patients who completed the above-described CBT in 
our controlled trial was 11.8 (sd=4.4) hours divided over 12 sessions.20 On average, three 
and a half hours were spent on general topics such as the session’s introduction, discussion 
of the assessment outcomes, fine-tuning of expectations and joint goal setting.  
In Table 1 we have listed per module the extent to which they contributed to the actual 
treatment of our sample of cancer survivors, i.e. the time (in terms of the percentage of total 
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treatment time) dedicated to the relevant module, the number of patients for whom the 
module had indeed become part of their tailored treatment and the percentage of sessions in 
which the topic of the module was raised. 
Example how to read the table: 25% of total treatment time was spent on the module 
challenging the patient’s cognitions, which was part of the final treatment protocols for all 65 
patients, and this topic was raised in 49% of the total number of sessions. 
 
Table 1 
 
Module frequency of 65 patient who completed the treatment for postcancer fatigue 
 
Modules  
 
Time spent on the 
module  (% of total 
treatment time)
Patients for whom 
the module was part 
of the treatment 
protocol (% / n)
 
% of sessions in 
which  the module  
was raised
Poor coping with cancer    5%   63% (n=41) 12%
Fear of disease recurrence   3%   45% (n=29)   8%
Dysfunctional cognitions  25%  100% (n=65) 49%
Dysregulation of sleep   6%   86% (n=56) 36%
Dysregulation of activity  49%  100% (n=65) 71%
low social support   12%   86% (n=56) 25%
 
 
 
 
Treatment efficacy and relevance 
As mentioned earlier, the efficacy of the proposed CBT was demonstrated in a randomised 
controlled trial in which we tested the programme in fatigued patients that had successfully 
completed curative treatment for various types of cancer: 76% of the patients no longer 
reported to be (severely) fatigued after CBT completion.20  
The CBT is especially designed for fatigued cancer survivors for whom at least one year has 
elapsed since their clinical treatment and that patients presenting or diagnosed with 
comorbid psychological or psychiatric symptoms are excluded.  
It is, of course, even more desirable to prevent people from developing post-cancer fatigue. 
Additional investigations are underway to explore the usefulness of the current CBT in 
preventing persistent fatigue in this population by offering the programme to patients 
immediately following or even during their curative clinical treatment. 
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ABSTRACT 
Persistent fatigue is a long term adverse effect experienced by 30% to 40% of patients cured 
of cancer. The main objective of this randomised controlled trial was to show the 
effectiveness of cognitive behaviour therapy (CBT) especially designed for fatigue in cancer 
survivors. 
A total of 112 cancer survivors with somatically unexplained fatigue were allocated randomly 
to immediate cognitive behaviour therapy or to a waiting list condition for therapy. Both 
conditions were assessed two times, at baseline and 6 months later. The primary outcome 
variables were fatigue severity (Checklist Individual Strength) and functional impairment 
(Sickness Impact Profile).  Data were analyzed by intention to treat. 
Analyses were based on 50 patients in the intervention condition and 48 patients in the 
waiting list condition. Patients in the intervention condition reported a significantly greater 
decrease than patients in the waiting list condition in fatigue severity (difference, 13.3; 95% 
CI, 8.6 to 18.1) and in functional impairment (difference, 383.2; 95% CI, 197.1 to 569.2). 
Clinically significant improvement for the CBT group compared with the waiting list group was 
seen in fatigue severity (54% vs. 4% of the patients, respectively). 
Cognitive behaviour therapy has a clinically relevant effect in reducing fatigue and functional 
impairments in cancer survivors.  
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INTRODUCTION 
Current cancer treatments are increasingly effective in improving survival. However, with 
larger numbers of survivors a variety of long term adverse side effects have emerged. One of 
these adverse effects is persistent fatigue, which occurs in at least 30% to 40% of the cancer 
survivors, with profound effects on quality of life.1-6
The etiology of postcancer fatigue is unknown. Fatigue seems to be elicited during the 
treatment phase, but later there is no clear relationship between persistent fatigue and initial 
disease and cancer treatment variables.1-3,7-8 Hypotheses have been proposed about 
increased proinflammatory cytokine activity and dysregulation in hypothalamic-pituitary-
adrenal axis responsiveness9-11; however, contradictory findings exist.2 At present, there is no 
somatic strategy in managing fatigue in cancer survivors.  
We believe it is useful to make a distinction between precipitating factors and perpetuating 
factors of fatigue after cancer. The assumption is that cancer itself and/or cancer treatment 
may have triggered fatigue (precipitating factors), but other factors are responsible for 
persistence of fatigue complaints (perpetuating factors); for example, physical activity,1,2,7 
sleep quality,1,2 cognitions related to fatigue,4 the use of catastrophizing as coping strategy,12 
and fear of disease recurrence.7,13
Exercise is one of the few interventions suggested to decrease fatigue among cancer 
survivors,14,15 but randomised controlled trials (RCTs) supporting this are absent.16,17 The 
main objective of this RCT was to study the effectiveness of cognitive behaviour therapy 
(CBT), directed at perpetuating factors of postcancer fatigue. Our hypothesis is that fatigue 
severity and functional impairment will decrease significantly more in a group of patients 
assigned to CBT than in patients waiting for the therapy. 
 
 
PATIENTS AND METHOD 
Sample 
Between December 2001 and September 2004, disease-free cancer patients with severe 
fatigue (score of 35 or higher on the Checklist Individual Strength [CIS], fatigue subscale) 
were recruited from outpatient clinics of medical oncology, urology, surgery, orthopedics, 
hematology and gynecology. Patients were screened by their physician on clinically relevant 
systematic diseases (eg, malnutrition, hemoglobin level, presence of hypothyroidism, and 
other physical co morbidities). If a physician was certain that the fatigue had no somatic 
cause, the patient was invited to participate. Patients completed curative treatment for cancer 
at least 1 year previously and had no evidence of disease recurrence at the time of 
participation. The minimum age at disease onset was 18 years, patients were no older than 
65 years and had no current psychological or psychiatric treatment when participating in the 
study. The ethics committee of the hospital approved the study.  
 
Design and procedure  
We gave patients verbal and written information about the study and obtained informed 
consent before randomly assigning them to either the intervention condition (CBT) or the 
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waiting list condition. Random assignment was done by means of a sequence of labelled 
cards contained in sealed, numbered envelopes prepared by a statistical adviser. The 
envelopes were opened by the researcher (M.G.) in the presence of the patient. Both 
conditions were assessed two times, at baseline and six months later. Patients in the waiting 
list condition were informed beforehand that, if desired, they could start therapy after the 
second assessment.  
 
Intervention  
The rationale of the intervention was based on the model of precipitating and perpetuating 
factors. CBT was focused on six perpetuating factors (six modules) of postcancer fatigue, 
which were based on existing literature and experience in clinical practice. They involve 
insufficient coping with the experience of cancer, fear of disease recurrence,7,13 dysfunctional 
cognitions concerning fatigue,4,12 dysregulation of sleep,1,2 dysregulation of activity,1,2,7 low 
social support and negative social interactions.4
Because of the existence of large differences within the group of fatigued cancer survivors,18 
therapy was adapted to each individual. To determine which modules were necessary, each 
perpetuating factor was measured with specific questionnaires. If a patient had a score on 
one of these questionnaires indicating problems, the accessory module became part of the 
treatment, resulting in an individualized treatment protocol per patient. Notably, the therapy 
only varied in number of modules, but within each module the therapy is standardized. The 
number of sessions was determined by the number of modules used and whether the goal of 
the therapy was reached. Therapy sessions varied between 5 and 26 sessions (mean, 12.5 
sessions; standard deviation [s.d.], 4.7 sessions) with a duration of 1 hour during a 6-month 
period. Patients were offered a maximum of two sessions during a 6-month follow-up period. 
Three therapists with previous CBT experience with patients with chronic fatigue  (eg, 
patients with chronic fatigue syndrome [CFS], neuromuscular diseases, and other chronic 
diseases) treated the patients. The therapists were trained in the use of instruments to 
determine which module should be included in the therapy. Therapists were also trained in 
instrument application. Role-playing was an important part of this training. The therapists 
were supervised throughout the study by one author (G.B.). During supervision, it was 
discussed how the relevant module should be applied to a particular patient.  
To give some insight into cognitive and behavioural techniques used in the therapy, we 
illustrate briefly how the six perpetuating factors were challenged during CBT.19
 
Insufficient coping with the experience of cancer 
A patient can continue to be occupied with the period of being diagnosed or treated for 
cancer (similar to a patient with a post traumatic stress disorder). By means of talking, or 
writing about this experience (which we would refer to as exposure), the patient will acquire 
better coping skills.  
Fear of disease recurrence 
The therapist helps the patient to formulate explicit words to describe the thoughts of fear of 
disease recurrence. These thoughts are challenged against reality (reality testing). In this 
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way, daily unhelpful thoughts about the possibility of a recurrence are reduced and put into 
perspective. 
Dysfunctional cognitions concerning fatigue 
Dysfunctional cognitions relate to a variety of ideas, including a patient’s idea of lack of 
control over symptoms (“I cannot do anything about it, I am helpless”), unhelpful attributions 
(“The chemotherapy caused the fatigue”), and dysfunctional cognitions about fatigue, such 
as catastrophizing (“This fatigue is awful, I can’t stand it”). These cognitions are disputed and 
more helpful ways of thinking are taught. Explaining the distinction between precipitating and 
perpetuating factors can also help reduce dysfunctional cognitions.  
Dysregulation of sleep 
An irregular sleep-wake rhythm can perpetuate fatigue. To restore the biologic rhythm, 
patients are encouraged to adhere to fixed bedtimes and wake-up times and are discouraged 
from sleeping during the day.  
Dysregulation of activity 
Some patients experience fluctuating periods of activity with subsequent periods of rest 
during a longer period. Others avoid activity because they are concerned that activity 
increases fatigue; consequently, they are physically inactive. For patients with fluctuating 
activity levels,  a base level should be established by alternating rest and activities to prevent 
bursts of activity. Once the patient has set a base level, the physical activity program started, 
usually twice a day, starting with 5 to 10 minutes of an activity such as walking or cycling. 
The activity is increased by 1 minute a day each time the activity is performed (ending at a 
maximum of 120 minutes per day). The inactive patient will start the activity program 
immediately. Gradually, physical activities are replaced by other activities.  
Low social support and negative social interactions.  
If a patient still has unrealistic expectations of others (eg, expecting that others still recognize 
him or her as a patient who has experienced something terrible) or perceives a discrepancy 
between actual support and desired support, the therapist helps to instil more realistic 
expectations toward the patient’s social support group.  
 
Assessment 
Primary outcome variables 
Fatigue severity was measured by the fatigue severity subscale of the CIS.20-22 The subscale 
consists of eight items, each scored on a 7-point Likert scale (range, 8 to 56 points), in which 
the patient is asked about fatigue in the 2 weeks preceding the assessment. Based on 
research with CFS patients, a score of 35 or higher indicates severe fatigue.20 The 
questionnaire has been used in cancer survivors,4,13,18 and showed good reliability, 
discriminative validity, and sensitivity to change.21,23-24  
Functional impairment was measured by the Sickness Impact Profile-8 (SIP-8). The SIP-8 
consists of eight subscales: home management, mobility, alertness behaviour, sleep/rest, 
ambulation, social interactions, work, recreation and pastimes. A total score was calculated 
by addition of the weights of items (range, 0 to 5.799). This widely used measure has good 
reliability and content validity.25  
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Secondary outcome variable 
Psychological distress was measured by the Symptom Check List 90 (SCL-90). The scale 
consists of 90 items scored on a 5-point Likert scale. The total score ranges from 90 to 450. 
The SCL-90 has good reliability and discriminating validity.26 
 
Clinically Significant Improvement 
There has been growing recognition that the clinical importance of a treatment effect is not 
equivalent to the statistical effect. The following questions can be addressed regarding this 
issue. First, is the amount of change in fatigue that has occurred after CBT large enough to 
be considered meaningful? Second, are patients comparable with a normative group with 
respect to their fatigue after CBT? A patient was classified as showing clinically significant 
improvement if both criteria were met. A meaningful change was calculated with the reliable 
change index.27 The method of normative comparison was used in answering the second 
question.28  
A patient’s own opinion about improvement is another possible approach in investigating the 
clinical importance of a treatment effect. Self-rated improvement was measured on the 
second assessment by one specific question: patients indicated whether they had completely 
recovered, felt much better, had the same complaints or had become worse compared with 
the baseline assessment.23-24,29 
 
Statistical analysis 
Power calculations showed that 49 patients were needed in each condition assuming a 
significance of 5% (two-tailed), power of 85%, and a dropout rate of 20%, in detecting a 
clinically relevant change of 8 points on the primary outcome variable (CIS-fatigue).4,18, 20 
Data analyses were performed using SPSS, version 12.1 (SPSS Inc, Chicago, IL). Analyses 
were conducted on an intention-to-treat basis and the last observation was carried forward if 
data were missing. Independent samples t test and χ2 tests were performed testing baseline 
differences between the two conditions. If a significant difference was present, the baseline 
assessment was used as a covariate in additional analyses.  
Differences between the two conditions on the amount of change in the outcome variables 
were calculated with analyses of variance on change from baseline to 6 months, with 95% 
CIs. A patient was defined as having a clinically significant improvement if he or she had a 
reliable change index more than 1.96 and decreased to a normal range (defined as any 
score < 1 s.d. above the mean of a normative group).23-24,27-28 The normative group consisted 
of 93 nonfatigued breast cancer survivors (mean age, 46.4 years; s.d.= 6.34). Normal range 
was defined as less than 30.4 on CIS-fatigue and less than 643 on SIP-8-total. Patients who 
reported “I have completely recovered” or “I feel much better” on self-rated improvement 
were also seen as clinically significant improved. χ2 tests were used to analyze the 
differences between the proportions of patients meeting these criteria for clinically significant 
improvement. 
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Figure 1 
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RESULTS 
 
Trial profile 
Figure 1 shows the trial profile. Of the 145 patients who met the eligibility criteria, 33 refused 
to take part (23%). There were no differences on baseline characteristics (demographic 
characteristics, disease and cancer treatment characteristics, or fatigue severity) between 
participants and nonparticipants (data not shown). 
Fifty-six patients were allocated to both conditions. After random assignment, 14 ineligible 
patients were excluded from the trial.30 Intention-to-treat analyses were based on 50 patients 
in the intervention condition and 48 patients in the waiting list condition. Five patients did not 
start treatment and seven patients dropped out of treatment. In the intervention condition, 47 
patients had a complete second assessment. After baseline assessment, four patients in the 
waiting list condition withdrew from the study. For these missing data, the last observation 
was carried forward (7%; n=7). No differences in baseline characteristics (demographical 
characteristics, disease and cancer treatment characteristics, and the outcome variables) 
were found among those who completed treatment (n=82) and the total number of patients 
who did not start treatment, who dropped out of treatment or withdrew from the study (n=16; 
data not shown). 
 
Baseline comparison 
Table 1 demonstrates baseline demographic, disease and cancer treatment characteristics, 
and the outcome variables in both conditions. Compared with the intervention condition, 
patients in the waiting list condition underwent chemotherapy more often and had less 
psychological distress.  
 
Effect of intervention  
Patients in the intervention condition reported a significantly greater decrease in fatigue 
severity (difference, 13.3; 95% CI, 8.6 to 18.1), in functional impairment (difference, 383.2; 
95% CI, 197.1 to 569.2), and in psychological distress (difference, 21.6; 95% CI, 12.7 to 
30.4) than patients in the waiting list (Table 2).   
 
Clinically significant improvement 
The proportion of patients with clinically significant improvement on fatigue severity, 
functional impairment, and self-rated improvement was significantly higher in the intervention 
condition than in the waiting list condition (Table 3). 
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Table 1 
 
Baseline characteristics of study participants. Values are means (sd) unless stated otherwise 
 
Characteristics  Cognitive behaviour 
therapy (n=50)
Waiting list
(n=48)
Age: years 44.6 (9.9) 45.3 (10.3)
Male / Female : n 27 / 23 23 / 25
Education: (1=low to 7=high)  4.4 (1.6)  4.3 (1.7)
Marital status : % (n) 
     married / cohabiting 
     unmarried 
     divorced 
     widowed 
82% (41)
12% (  6)
 4%  (  2)
 2%  (  1)
86% (41)
  8% (  4)
  6% (  3)
              - 
Employment : % (n)* 
     work outside home 
     voluntary work 
     full disablement insurance act 
     partial disablement insurance act 
     sick leave 
     school 
54% (27)
14% (  7)
28% (14)
24% (12) 
10% (  5) 
  4% (  2) 
56% (27) 
  8% (  4)
29% (14)
33% (16)
  4% (  2)
  6% (  3)
Cancer diagnosis : % (n) 
     mamma carcinoma 30% (15) 31% (15)
     testicular cancer 24% (12) 27% (13)
     haematological cancer  20% (10) 13% (  6)
     other solid tumors 26% (13) 29% (14)
Treatment type : % (n)* 
     surgery 78% (39) 88% (42)
     chemotherapy  60% (30) 85% (41)**
     radiotherapy 54% (27) 48% (23)
Duration of cancer treatment : months   6.5 (6.8)   7.1 (6.0)
Time since cancer treatment : years    5.5 (4.3)   4.6 (3.4)
Primary outcome variables*** 
     fatigue severity     47.6 (6.5)   47.3 (6.9)
     functional impairment  1029.6 (504.9) 860.7 (485.5)
Secondary outcome variable*** 
     psychological distress   143.6 (39.9) 130.1 (23.5)**
    
  *  percentages do not add up to 100% because more options are possible 
 **  the difference is significant at P <.05 level between the two conditions 
*** high scores reflects a high level of fatigue, more functional impairments, and high   
     psychological distress 
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Table 2 
 
Effect of cognitive behaviour therapy on fatigue severity, functional impairment and psychological 
distress analyzed on the basis of intention-to-treat  
 
Condition * 
 
 
0 months 6 months Treatment effect 
(95% CI)** 
p-value 
Fatigue severity      
CBT      47.6 (    6.5)     29.0 (  14.9)
WL      47.3 (    6.9)     42.1 (    9.6)
13.3 (8.6 to 18.1) .000 
Functional impairment   
CBT  1029.6 (504.9) 607.4 (578.9)
WL    860.7 (485.5) 821.7 (524.3)
383.2 (197.1 to 569.2) .000 
Psychological distress   
CBT  143.6 (39.9) 123.2 (36.3)
WL  130.1 (23.5) 131.2 (28.9) 21.6 (12.7 to 30.4) .001 
  * cognitive behaviour therapy (CBT), n=50; waiting list condtion (WL), n=48 (n=46 for functional   
     impairment and psychological distress).  
 ** difference in improvement between intervention and control group. In analyzing differences,  
     baseline psychological distress and chemotherapy were used as covariates. 
 
Table 3 
 
Clinically significant improvement at 6 months in fatigue severity, functional impairment, and self 
rated improvement by treatment group 
 
 
6 months
% (n) improved
Treatment effect 
(95% CI)** 
p-value 
Fatigue severity*    
CBT  54% (27) 
WL    4% (  2)
0.50 (0.34 to 0.65) .000 
Functional Impairment**   
CBT 50% (25)
WL  18% (18)
0.32 (0.14 to 0.51) .001 
Self rated improvement***   
CBT  66% (33)
WL  21% (10)
0.45 (0.27 to 0.63) .000 
  * reliable change index > 1.96 and cutoff score of Checklist Individual Strength-fatigue < 30.4 
 ** reliable change index > 1.96 and cutoff score of the Sickness Impact Profile-8 total < 643 
*** answer of ‘yes’ to statement, ‘I have completely recovered’ or ‘I feel much better but still  
     experience some symptoms’ 
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DISCUSSION 
This study is the first RCT in managing postcancer fatigue. The results show that CBT is 
successful in treating fatigue in cancer survivors. CBT was more effective than remaining on 
a waiting list in reducing fatigue severity, functional impairment, and psychological distress. 
Moreover, treatment resulted in a greater proportion of patients with clinically significant 
improvement in these variables and self-reported improvement.   
The model of precipitating and perpetuating factors is also used in patients with CFS.23-24,31 
However, it is important to note that there are differences between patients with CFS and 
cancer survivors with fatigue.18 Therefore, CBT for fatigue also is different for both patient 
groups. For cancer survivors, there is a distinct starting point of fatigue complaints, namely 
the period in which they were diagnosed and treated for cancer. For patients with CFS, the 
onset differs per patient and often is unknown. This suggests automatically that the 
attributions relating to the cause of the fatigue are different for both groups. In addition, there 
is a difference in perpetuating factors. Dealing with fear of disease recurrence and coping 
with the experience of cancer are important factors in CBT of fatigued cancer survivors and 
are not present in CBT for CFS. Intraindividual differences are larger in fatigued cancer 
survivors than in CFS patients, especially for physical activity.18 Therefore, CBT for cancer 
survivors is tailored more to the individual, unlike CBT for CFS.   
The dropout rate in this study was slightly higher than assumed in the power calculation. In 
the CBT condition the dropout rate was 24%; in the waiting list condition, the dropout rate 
was only 8%. However, many patients who dropped out were willing to attend for the 
assessment. At the second assessment only 7% of the total group had missing data. 
Because analyses were conducted on an intention-to-treat basis and the last observation 
was carried forward if data were missing, the dropout rate will not weaken our findings. 
Although the normative group used in analyzing clinically significant improvement were all 
female cancer survivors and were slightly older than the patients in the present study, it is a 
more adequate control group than healthy controls. Servaes et al4 demonstrated that in 
general, these breast cancer survivors with non-severe fatigue were comparable to a healthy 
control group, with the exception of functional impairment. The cancer and/or the cancer 
treatment seem to be responsible for permanent impairments and therefore comparison with 
nonfatigued cancer survivors is more appropriate. 
Our study was limited to patients no older than age 65 years, whereas almost 50% of the 
cancer will be diagnosed after this age. Furthermore, the study was performed with 
frequently diagnosed tumours. Replication of this study is necessary for older cancer 
survivors and survivors with other diagnoses.   
Controlled follow-up was not possible in this RCT because patients in the waiting list were 
offered CBT immediately after the second assessment. Therefore, future research should 
give more insight into the long-term effects of CBT. Another limitation of this study is the 
omission of an attention placebo control group. Previous studies showed no effect of an 
attention placebo group on fatigue in CFS patients.24,32 However, as described herein, there 
are differences between CFS patients and fatigued cancer survivors. Therefore, we can not 
rule out that mere attention for the patient has contributed to the outcome. 
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For a medical specialist it is difficult to treat postcancer fatigue when a somatic explanation is 
excluded. However, with a growing number of cancer survivors and given the substantial 
adverse physical, psychosocial, and economic consequences of postcancer fatigue, 
rehabilitation is critical. Even more desirable would be to prevent postcancer fatigue by 
intervening during cancer treatment. Additional investigation is needed to demonstrate the 
usefulness of CBT just after or during cancer treatment in preventing persistent fatigue.  
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ABSTRACT 
An earlier randomised controlled trial demonstrated the positive effects of cognitive 
behaviour therapy (CBT), especially designed for fatigued cancer survivors in reducing 
fatigue, functional impairments and psychological distress. In the current prospective study, 
we were able to examine the long term effect of CBT in patients who completed the therapy. 
Predictors of fatigue severity at follow-up were exploratory investigated. 
Sixty-eight patients who completed CBT were assessed at pretreatment, post-treatment and 
at follow-up (mean follow-up 1.9 years (s.d.=1.0), range 0.5 – 4 years). To analyse possible 
predictors of treatment outcome a linear regression (enter) was carried out. 
Improvements on fatigue severity, functional impairment and psychological distress after 
CBT appeared to remain stable during the follow-up period. Patients who were not fatigued 
anymore at follow-up were not different from a reference group of non-fatigued cancer 
survivors. The explorative regression analysis showed that fatigue severity, psychological 
distress and somatic attributions at pretreatment contributed to persistent fatigue severity at 
follow-up. 
CBT especially designed for postcancer fatigue, is successful in reducing fatigue and 
functional impairment in cancer survivors. Moreover, these positive effects were maintained 
at about 2 years after finishing CBT.  
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INTRODUCTION 
Fatigue is a common and distressing side effect of cancer treatment.1,2 Unfortunately, fatigue 
persists in patients for even years after completion of curative treatment. At least a quarter of 
the cancer survivors suffer from postcancer fatigue, with profound effects on quality of life.1-6  
Although research on postcancer fatigue has increased in the last decennia, there are only a 
few randomised controlled trials (RCTs) investigating the management of postcancer fatigue. 
Until now, 6 RCT’s  have investigated the effect of an intervention on fatigue, measured as a 
primary or secondary outcome. Two were pilot studies and found no effect on fatigue.7,8 No 
effect was found investigating a lifestyle physical activity intervention,7 and the second study 
found no effect of yoga.8 Two studies investigated the effect of exercise in cancer survivors. 
Both studies used fatigue as a secondary outcome and showed beneficial effects.9-10 The 
fifth study found that acupuncture was a more effective method to improve fatigue compared 
with acupressure or sham acupressure.11 None of these RCTs includes follow-up 
assessments. In the last RCT cognitive behaviour therapy (CBT), especially designed for 
postcancer fatigue, appeared to be highly effective.12 The rationale of this intervention was 
based on the model of precipitating and perpetuating factors. Fatigue seems to be elicited 
during the treatment phase, but later on there is no clear relationship between persistent 
fatigue and initial disease and cancer treatment variables.1-3,13,14 The assumption is that the 
cancer itself and/or the cancer treatment may have triggered fatigue (precipitating factors), 
but other factors are responsible for persistence of fatigue complaints (perpetuating factors). 
Cognitive behaviour therapy for postcancer fatigue is focused on these perpetuating factors. 
The RCT consisted of two conditions, the intervention condition (6 months of CBT) and 
waiting list condition (6 months). Patients in the intervention condition reported a clinically 
relevant decrease compared to patients in the waiting list condition in fatigue severity, 
functional impairment and psychological distress. Patients in the waiting list condition were 
informed beforehand that, if desired, they could start therapy directly after the waiting period 
of 6 months. 
In this current study, the long-term effect of CBT will be investigated in patients who were 
involved in this former study and received CBT, including patients in the intervention 
condition and patients who had been treated after the 6-month waiting list. Furthermore, we 
will exploratory investigate predictors of fatigue severity at follow-up. 
 
METHODS 
Sample 
Between December 2001 and September 2004, six departments of the Radboud University 
Nijmegen Medical Centre participated in the recruitment of patients for this study. Cancer 
survivors who experienced severe fatigue (score of 35 or higher on the Checklist Individual 
Strength, fatigue subscale), were recruited from the outpatient clinics of medical oncology, 
urology, surgery, orthopaedic, haematology and gynaecology. During follow-up visits in the 
hospital fatigued survivors were screened by their physician on clinically relevant systematic 
diseases (eg, malnutrition, haemoglobin level, presence of hypothyroidism, and other 
physical comorbidities). If a physician was certain that the fatigue had no somatic cause, the 
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patient was invited to participate. Patients completed curative treatment for cancer at least 1 
year ago and had a minimal age at disease onset of 18 years. At time of participation 
patients had no evidence of disease recurrence and patients were not older than 65 years. 
Patients with current psychological or psychiatric treatment were excluded. The ethics 
committee of the hospital approved the study.    
 
Intervention 
Cognitive behaviour therapy was focused on six perpetuating factors of postcancer fatigue, 
which were based on existing literature and experience in clinical practice. They involve (1) 
insufficient coping with the experience of cancer, (2) fear of disease recurrence,13,15 (3) 
dysfunctional cognitions concerning fatigue,16,17  (4) dysregulation of sleep,1,2 (5) 
dysregulation of activity,1,2,13 (6) low social support and negative social interactions.16  
Each perpetuating factor became a module in the therapy protocol. Because of the existence 
of large differences within the group of fatigued cancer survivors,18 therapy was adapted to 
each individual. To determine which modules were necessary, each perpetuating factor was 
measured with specific questionnaires. If a patient scored problematic on one of these 
questionnaire, the accessory module became part of the treatment, resulting in an 
individualized treatment protocol per patient. It is important to realise that the therapy only 
varied in number of modules, but within each module the therapy is standardised. The 
number of sessions was determined by the number of used modules and by reaching the 
goal of the therapy.  
Three therapists with previous CBT experience in patients with chronic fatigue treated 
patients who started directly with CBT as well as patients who started CBT after the waiting 
list period. For a more detailed description of the intervention see Gielissen et al.12
 
Assessment (Appendix A) 
Patients were asked to complete questionnaires at the Expert Centre Chronic Fatigue of the 
Radboud University Nijmegen Medical Centre, pretreatment and post-treatment. Additionally, 
a package of questionnaires was sent by mail to all patients 6 months after the last patient 
finished CBT.    
 
Outcome measures 
Fatigue severity was measured by the fatigue severity subscale of the Checklist Individual 
Strength (CIS).19-21 The questionnaire has been used in cancer survivors,4,12,15,16,18 showed 
good reliability, discriminative validity and sensitivity to change.12,20,22,23  
Functional impairment was measured by the Sickness Impact Profile-8 (SIP-8). This widely 
used measure has good reliability and content validity.24,25  
Psychological distress was measured by the Symptom Check List 90 (SCL-90), which has 
good reliability and discriminating validity.26,27
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Perpetuating factors  
Coping with the experience of cancer was measured with the Dutch version of the Impact of 
Event Scale (IES), which measures the extent to which a subject is currently occupied with 
the coping process after a major event (in this study the diagnose and treatment for 
cancer).28-30
Fear of disease recurrence was measured by two items of the Cancer Acceptance Scale 
(CAS).15   
Cognitions related to fatigue. Self-efficacy was measured with the Self-Efficacy Scale 
(SES)15,16,23,31 and somatic related attributions with regard to fatigue complaints were 
measured with the Causal Attribution List (CAL).16  
Sleep disturbances was measured with the sleep/rest subscale of the SIP-8 ,and the 
insomnia subscale of the Quality of Life Questionnaire-C30 (QLQ-C30).32  
Physical activity was measured with the physical functioning and role functioning subscale of 
the QLQ-C30. Furthermore, physical activity was measured with the subscales home 
management, work, and recreation / pastimes from the SIP.  
Social functioning was measured with the van Sonderen Social Support Inventory (SSL).33  
 
Statistical analysis  
Data analyses were performed using SPSS (version 12.1). Independent samples t-test and 
Chi-squared tests were performed testing differences between the intervention condition and 
the waiting list condition.  
In the current study, the data collected at the end of the 6-month waiting period were used as 
pretreatment measurements. Comparison of the results of the pretreatment, post-treatment 
and follow-up assessments were carried out by GLM repeated measures analysis. 
Furthermore, GLM multivariate analysis was performed testing the differences between 
different follow-up periods and with a reference group. In a previous study of our research 
group 93 non-fatigued breast cancer patients were identified and used in this study as 
reference group (CIS-fatigue < 35; mean age, 46.4 years; s.d.=6.3).16  
Mann-Whitney U-tests were used testing the differences between patient who did not accept 
CBT after the 6-month waiting list period and patients who completed CBT. 
McNemar tests were used to analyse the differences between the proportions of patients 
who did not meet the criteria for severe fatigue (CIS-fatigue < 35) anymore at post-treatment 
and follow-up.  
To analyse possible predictors of treatment effects a linear regression (enter) was carried 
out, with fatigue severity at the last follow-up assessment as dependent variable. Pearson 
correlations between fatigue severity at follow-up and the six perpetuating factors were used 
as preparatory analyses to examine the contribution of these factors to fatigue severity. 
Those measures that correlated significant with the fatigue severity at follow-up were used as 
independent variables in the logistic regression analyses. Correlations between the six 
perpetuating factors were tested on multicollinearity (r < 0.9 ). 
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RESULTS 
Sample 
Figure 1 shows the trial profile. The controlled data are described in Gielissen et al.12  In this 
current study, we used the pooled data of both conditions. In the intervention condition, 38 
patients completed CBT of whom 36 had a follow-up assessment. Forty-four patients 
completed the 6-month waiting list period and were offered CBT. Thirty-two patients 
accepted and completed the therapy and the follow-up assessment. There were no 
significant differences between patients in the intervention condition and waiting list condition 
on demographic and medical characteristics (Table 1). In addition, no significant differences 
were found on the outcome variables at pretreatment (fatigue severity P =0.052; functional 
impairment P =0.210; psychological distress P = 0.300) and post-treatment (fatigue severity 
P =0.582; functional impairment P =0.118; psychological distress P =0.346). Furthermore, 
the number of CBT sessions in both conditions were equal (12.5 (s.d.=4.7) vs 12.4 
(s.d.=4.6), P =0.853).  Because no differences were found, the data of both conditions were 
pooled (Table 1).  Furthermore, we compared patients who did not accepted CBT after the 6-
month waiting list period (n=12) with patients who completed CBT (n=68). There were no 
differences in the pretreatment assessment on fatigue severity (P =0.205), functional 
impairment (P =0.925) and psychological distress (P =0.671). Seven of the 12 patients who 
did not accept CBT after the waiting list period, completed the follow-up assessment 
 
Long-term effect 
The mean length of time between completion of therapy and follow-up assessment was 1.9 
years (s.d.=1.0) with a range of 6 months to 4 years. The median was 2.0 years. The time 
interval between completion of therapy and follow-up assessment varied because patients 
entered the study at various times and started treatment at different moments. 
Information about the outcome variables at the three assessments are listed in Table 2. 
Scores of fatigue severity, functional impairment and psychological distress significantly 
decreased at post-treatment and follow-up assessment compared with the pretreatment 
assessment. Additionally, the means on all outcome measures remained stable between 
post-treatment and follow-up. Compared with the reference group, patients in this study were 
significantly more fatigued at follow-up assessment, but had the same level of functional 
impairment and psychological distress. The follow-up period of patients who did not accept 
CBT (n=7) was comparable with the follow-up period of patients who completed CBT (1.5 
years (s.d.=0.8), P =0.145). Patients who did not accept CBT were significantly more 
fatigued, had more functional impairments and higher psychological distress at follow-up 
compared to patients who accepted CBT (Table 2). 
Eighty-one percent (n=55) of the patients did not meet the criteria of severe fatigue at post-
treatment (CIS-fatigue < 35). At follow-up this percentage of non-fatigued patients was 71% 
(n=48, P =0.118).  Compared with the non-fatigued reference group (Table 2), the patients 
who were not fatigued after CBT (n=48) had the same level of fatigue (19.9; s.d.=8.4,  
P =0.842), the same level of functional impairment (271.0; s.d.=292.7, P =0.476) and a 
significantly lower level of psychological distress (106.3; s.d.=14.4, P  =0.042). 
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Figure 1 
 
Trial profile 
Intervention 
condition 
n = 56 
Waiting list 
condition 
n = 56 
Eligible to enter trial 
N=145 
refused participation   n=33  
Takes to much time   n=9 
Did not feel like taking part   n=5 
Study site too far from home   n=6 
Too tired to participate   n=4 
Wanted to move on with their lives   n=3 
Did not believe CBT would help them   n=3 
Did not want to risk allocation to waiting list 
condition   n=1 
Reason unknown   n=2
Random assignment
n = 112
Entered study  
n = 50 
Entered study 
n = 48 
Excluded from trial    n=6 
Disease recurrence  n=3 
Failed to fill out questionnaires n=2
Excluded from trial    n=8  
Disease recurrence n=7 
Failed to fill out questionnaires n=1 
medical explanation for fatigue  
n=1
 
Not starting therapy   n=5
Therapy takes too much time  n=2 
Priority to other health issues  n=2 
Reason unknown  n=1 
 
Drop out   n=7  
Therapy takes too much time  n=3 
did not want to change their lives 
n=2 
Too emotional  n=1 
Moved to S
Withdrew from study   n=4 
 
Study takes too much time  n=2 
 
Refused further participation after
random assignment to the waiting
list condition  n=2 
pain  n=1 
complete 2n
Did not accept CBT   n=12 
 
Therapy takes to much time n=6 
Did not want to change live n=2 
Not fatigued anymore n=2 
Traveling to expert centre for
therapy too expensive n=2 
No follow-up assesment   n=2
 
Assessment and traveling to Expert
Centre takes too much time n=2 
Complete follow-
up assessment 
n=36 
Accepted CBT and 
completed follow-
up assessment 
n=32
Pooled follow-up 
assessment  
N=68 
d 
assessment    
n = 44; CBT was offered
Completers CBT  
n = 38 
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Table 1 
 
Characteristics of study participants. Values are means (s.d.) unless stated otherwise 
 CBT
(n=36)
Waiting list 
(n=32) 
Pooled group 
(n=68)
Age : years 43.8 (10.3) 43.9 (10.3) 43.8 (10.2)
Male / Female : n 19 / 17 16 / 16  35 / 33
Cancer diagnosis : % (n)  
     mamma carcinoma 36% (13) 25% (  8) 31% (21)
     testicular cancer 33% (12) 25% (  8) 29% (20)
     haematological cancer  17% (  6) 16% (  5) 16% (11) 
     other solid tumors 14% (  5) 34% (11) 24% (16) 
Treatment type : % (n)*  
     surgery 75% (27) 81% (26) 78% (53)
     chemotherapy  70% (24) 84% (27) 75% (51)
     radiotherapy 53% (19) 44% (14) 49% (33)
Duration of cancer treatment: months   6.6 (7.1)   7.3 (6.3)   6.9 (6.7)
Time since cancer treatment : years    5.2 (4.0)   5.1 (3.6)   5.1 (3.8) 
 
*   percentages do not add up to 100% because more options are possible 
 
There were no significant differences between the cognitive behaviour therapy (CBT) and waiting list 
condition. 
 
 
Table 2 
 
Means (s.d) of CBT-completers (n=68) at pretreatment, post-treatment and follow-up, a reference 
group of non-fatigued cancer survivors and non-accepters of CBT at follow-up assessment 
 
 A 
pre-treatment 
B 
post-treatment 
C 
follow-up 
D 
reference 
values 
(n=98) 
 
non-accepters 
CBT at 
follow-up 
(n=7) 
Fatigue 
Severity 
45.3 
(7.7)b,c,d
24.3 
(10.9)a,d,
26.9 
(13.1)a,d,e
19.6 
(8.4) a,b,c
40.3 
(14.8)* 
Functional 
impairment 
937.1 
(530.4)b,c,d
415.1 
(438.6)a,
429.8 
(483.2)a,e
309.5 
(333.4)a
842.9 
(302.2)* 
Psychological 
well-being 
138.5 
(35.6)b,c,d
113.6 
(25.5) a,
119.3 
(37.1)a
113.2 
(20.3)a
138.6 
(39.8) 
 
a: significantly different from pretreatment assessment (p <0.05) 
b: significantly different from post-treatment assessment (p <0.05) 
c: significantly different from the follow-up assessment (p <0.05) 
d: significantly different from the reference group (p < 0.05) 
* significantly different from follow-up assessment of CBT-completers 
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Short versus Long-term follow-up 
As there is a considerable range in the duration of the follow-up, we investigated whether the 
treatment outcome differed between patients with a shorter and a longer follow-up period. 
Patients were divided into four groups: patients who completed CBT between 6 months and 
1 year ago (n=15), between 1 and 2 years ago (n=21), between 2 and 3 years ago (n=20), 
between 3 and 4 years ago (n=12). Post hoc analyses showed no significant differences on 
change scores (pretreatment scores - / -  follow-up scores) between the four-follow-up period 
on fatigue severity, functional impairment and psychological distress (Table 3).  Furthermore, 
correlations between time since CBT and fatigue severity (r = - 0.067, P =0.585), functional 
impairment (r =0.216, P =0.077) and psychological distress (r = 0.141, P =0.251) were low 
and nonsignificant. 
 
 
 
 
Predictors 
Results of the preparatory analyses indicated that fatigue at follow-up was significantly 
correlated with fatigue severity (CIS-fatigue, r = 0.354, P =0.003), psychological distress 
(SCL90-total, r = 0.398, P =0.001), somatic related attributions (CAL, r = 0.293, P =0.015) 
and insufficiency in social interactions (SSL-D, r = 0.316, P =0.009) at pretreatment. These 
variables were used as independent variables in the linear regression analysis. Table 4 
summarise the regression analysis. Somatic attributions contributed almost significantly (P = 
0.050) to fatigue severity at follow-up. Furthermore, a trend was seen for pretreatment 
fatigue severity (P =0.064) and psychological distress (P =0.074). 
 
 
 
Table 3 
 
Change scores (pretreatment scores - / - follow-up scores) at different follow-up points 
 A 
6 months – 1 year 
(n=15) 
B 
1 year – 2 years 
(n=21) 
C 
2 years – 3 years 
(n=20) 
D 
3 years – 4 years 
(n=12) 
Fatigue 
severity 
16.3 (13.0) 20.4 (13.1) 15.8 (12.2) 21.8 (11.9) 
Functional 
impairment 
507.1 (358.3) 557.2 (473.5) 473.5 (501.5) 476.3 (351.1) 
Psychological 
well-being 
26.0 (19.5) 18.9 (21.0) 11.3 (38.7) 24.3 (14.4) 
 
There were no significant differences on change scores between the four-follow-up periods 
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DISCUSSION 
The results of the present study indicate that the positive results of CBT especially designed 
for fatigued cancer survivors were maintained at follow-up. Fatigue severity, functional 
impairment and psychological distress remained stable in patients who completed CBT after 
almost a mean follow-up period of 2 years. Furthermore, we could not find any difference 
between patients with a short- and a long-term follow-up. Therefore, even after 4 years the 
positive effect of CBT remained.    
Patients who were allocated to the 6-month waiting list, were offered CBT directly after the 
second assessment. Therefore, the long-term effect was investigated with an uncontrolled 
design. Nevertheless, patients who were recovered at follow-up were comparable with a 
reference group of non-fatigued cancer survivors. Additionally, we investigated a small group 
of patients who did not accept CBT after the waiting list period. These patient did not improve 
over time on fatigue severity, functional impairment and psychological distress. Because of 
the small sample size, we should be careful in interpreting these results. Patients could have 
improved regardless of the followed treatment. It would increase the impact of our findings if 
future studies could prove the long-term superiority of CBT over natural course in fatigued 
cancer survivors. Another reason why it is difficult to draw firm conclusions is that follow-up 
data were not available of all patients who participated in the previous RCT.  
The explorative regression analysis showed a trend that patients with more fatigue, higher 
psychological distress and stronger somatic attributions at pretreatment were more fatigued 
at the follow-up assessment. Fatigued cancer survivors have the tendency to attribute their 
fatigue complaints to the cancer itself and/or cancer treatment.16  However, research on 
postcancer fatigue fails to show such relationship, which makes this a false attribution.1-3,13,14 
In the current model of postcancer fatigue, we assume that fatigue originates in the 
Table 4 
 
Linear Regression (enter) to predict fatigue severity at follow-up (n=68) 
 
           Dependent variable 
            CIS-fatigue at follow-up 
Independent variables  
(pretreatment measurements) 
Beta p-value
 
Fatigue (CIS-fatigue) .373 .064
Psychological distress (SCL90-total) .087 .074
Dysfunctional cognitions (somatic-CAL) 1.803 .050
Social insufficiency (SSL-D) .086 .422
 
CAL=Causal Attribution List; CIS=Checklist Individual Strength; SCL=Symptom CheckList; 
SSI=Social Support Inventory. Adjusted R2 = 0.222 
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diagnostic and treatment stage; however, there is no clear relationship between fatigue long 
after curative treatment and the initial disease and cancer treatment characteristics. Because 
somatic attributions still proved to contribute to fatigue at follow-up in this study, it seems that 
this aspect has received not enough attention during the CBT. If a patients continues to think 
that the cancer itself and/or cancer treatment is responsible for the experienced fatigue, the 
chance on recovery is lowered. It is possible that (further) education on postcancer fatigue 
for professionals working in cancer care, can increase the chance of improvement with CBT. 
Somatic attributions in fatigued cancer survivors can be reinforced by inaccurate information 
delivery about the cause of postcancer fatigue. Therefore, education should be aimed 
particularly on the model of precipitating and perpetuating factors.  
Furthermore, indications were found that patients with high psychological distress, had a  
worse treatment outcome. Extreme high scores on the SCL90 total score (>200) are 
indicative for psychiatric comorbidity.27 Five patients in our sample met this criterion. All five 
patients remained fatigued after CBT. When deleting these cases, the trend of psychological 
distress as contributor to fatigue at follow-up disappeared in the regression analysis (P = 
0.776). Therefore, fatigued cancer survivors with high scores on psychological distress 
(probably indicative of psychiatric comorbidity) proved to have hardly any chance to improve 
with CBT for postcancer fatigue. However, results from the regression analyses should be 
regarded as exploratory and interpreted with caution.  
Most studies on postcancer fatigue do not find an association between fatigue and cancer 
type.1,2,34  In the current study we did not find a significant difference in fatigue severity at 
baseline between the different types of cancer (P =0.821). There was also no difference in 
effect of CBT on fatigue severity (P =0.983). However, our study was limited to patients with 
rather frequently diagnosed tumours. Therefore, replication is necessary in survivors with 
other cancer types.    
The long term follow results of our study shows that the positive effects of CBT especially  
designed for postcancer fatigue are maintained even years after treatment. Until now, no 
other interventions have been published with comparable good results on postcancer fatigue 
on the long term. 
 
ACKNOWLEDGEMENTS 
Current Controlled Trials: ISRCTN: 44562532. Funding for this study was provided by the 
Dutch Cancer Society (KUN 2001-2378). 
 
 
 
 
 
 
 
 
 
 Appendix A    
 
Patients were asked to complete questionnaires at the Expert Centre Chronic Fatigue of the Radboud University Nijmegen Medical Centre, pre-treatment and post-
treatment 
Questionnaires 
 
 Response format Example questions 
Fatigue Severity Checklist Individual strength –  
Subscale Fatigue Severity (8 items) 
7 point Likert scale 
* range 8 – 56  
* a score of 35 indicates   
  severe fatigue 
 
* I feel tired 
* I am rested 
* Physically I feel exhausted 
Functional 
impairment 
Sickness Impact Profile – 8 
• Home management (10 items) 
• Mobility  (10 items) 
• Alertness behaviour (10 items) 
• Sleep/ Rest (7 items) 
• Ambulation (12 items) 
• Social interactions (20 items) 
• Work (8 items) 
• Recreation and pastimes (8 items)  
 
patients can mark a box behind 
each statement. 
* a total score is calculated   
  by addition the weights of    
   items 
* range 0 - 5799 
* I am not doing any of the house cleaning     
  that I would usually do (hm) 
* I am not going out to visit people at all (si) 
* I walk shorter distances or stop to rest often  
  (amb) 
* I react slowly to thing that are said (alert) 
* I have difficulty doing activities involving  
 concentration and thinking (alert) 
Psychological 
distress 
Symptom Check List 90 (90 items) 
• Anxiety (10 items) 
• Agoraphobia (7 items) 
• Depression (16 items) 
• Somatisation (12 items) 
• Obsessive-compulsive behaviour (9 items) 
• Interpersonal sensitivity (18 items) 
• Hostility (6 items) 
• Sleep  (3 items) 
5 point Likert scale  
* range 90 – 450  
During the past 7 days about how much were 
you distressed or bothered by: 
* Feeling fearful (anx) 
* Feeling of worthlessness (depr) 
* Numbness or tingling in parts of your body  
  (som) 
* Feeling that people are unfriendly or dislike  
  you (int.sens) 
* Nervousness or shakiness inside (anx) 
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 Appendix A. continued   
Questionnaires 
 
 Response format Example  
Coping with the 
experience of cancer 
Impact of Event Scale  
• Intrusion (7 items) 
• Avoidance (8 items) 
 
6-point Likert Scale 
* range 13 – 52  
 
* I had dreams about it  (intr) 
* I tried not to think about it (avoid) 
* I tried not to talk about it  (avoid) 
Fear of disease 
recurrence 
Cancer Acceptance Scale 
 
4-point Likert Scale 
* range 2 – 8   
 
* I am worried about a tumour relapse 
* I am anxious about my health 
Cognitions related to 
fatigue 
Self Efficacy Scale (7 items) 4-point Likert Scale 
* range 7 – 28  
*  Whatever I do, I cannot change my      
   complaints 
*  I think I could positively influence my fatigue 
 
 Causal Attribution List – subscale somatic 
attribution  (4 items) 
4-point Likert Scale 
* range 4 – 16  
*  Do you think your complaints have to do   
   with the anti-cancer treatment? 
 
Sleep disturbance SIP-8 – subscale Sleep / Rest   * I sleep more during the day 
 EORTC QLQ-C30 – subscale Insomnia (1 item) 
 
4-point Likert Scale * Have you had trouble sleeping? 
Physical activity EORTC QLQ-C30 – subscale physical functioning  
(5 items) 
EORTC QLQ-C30 – subscale role functioning  
(2 items) 
Yes / No;  range 5 – 10  
 
4-point Likert; range 2 - 8 
* Do you have trouble waling a long walk? 
 
* Has your physical condition interfered with   
  your family life? 
 SIP-8 – Home management 
SIP-8 – Work 
SIP-8 – Recreation and Pastimes  
 
patients can mark a box behind 
each statement. 
* I am not doing any of the clothes washing 
* At work, I make more mistakes than usually  
* I am doing fewer community activities 
Social functioning Van Sonderen Social Support Inventory  
• SSL-I: amount of social support (34 items) 
• SSL-D: insufficiency of supporting 
interactions   (34 items) 
• SSL-N: amount of negative interactions        
(7 items) 
4-point Likert Scale 
* range 34 – 136  
* range 34 – 135  
 
* range 7 - 28 
* Do you experience friendliness and   
  sympathy in your contacts with other   
   people? 
* Do you talk problems over with other  
  people? 
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ABSTRACT 
Literature suggests that cancer survivors with more aggressive treatments are more at risk 
for postcancer fatigue. In this study, we investigated the prevalence of fatigue after 
completion of  stem cell transplantation (SCT). Furthermore, we studied if medical variables 
are associated with fatigue and if the model of perpetuating factors of postcancer fatigue 
derived from previous studies in cancer survivors, without SCT, is applicable in SCT 
survivors. 
Ninety-eight patients treated with autologous or allogeneic SCT filled out several 
questionnaires. Medical characteristics were obtained from the medical charts. All patients 
had to be in persistent complete remission for at least 1 year. 
Thirty-five per cent of the patients experienced severe fatigue. The percentage of patients 
with severe fatigue remained stable during the years after transplantation. Several 
psychosocial factors, but no medical factors, were associated with fatigue. The model of 
perpetuating factors appeared to be applicable. 
Contrary to cancer survivors without SCT, we found no decrease in fatigue complaints during 
the first years after SCT. Cognitive behaviour therapy (CBT) is a general form of 
psychotherapy directed at changing condition-related cognitions and behaviours. CBT 
especially designed for postcancer fatigue, aimed at perpetuating factors, can also be used 
to manage fatigue in cancer survivors treated with SCT. 
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INTRODUCTION 
Stem cell transplantation (SCT) is a potentially curative treatment for various malignant 
diseases. Results are improving in the course of time and this has led to reduced morbidity 
and an increased life expectancy. Therefore, the number of patients surviving a SCT is 
growing during the last decennia. Because SCT is a highly aggressive and demanding 
medical intervention, significant concerns related to the long-term well-being of SCT 
survivors have been voiced. Generally speaking, most patients seemed to have reached an 
acceptable level of functioning during the first year after transplant.1-5 However, there seems 
to be a subgroup of patients who experience ongoing problems following transplantation.6 
One of these problems is persistent fatigue.3,4,7-9
More research has been done in the field of postcancer fatigue in cancer survivors who were 
not treated with a SCT. Fatigue seems to be a problem for about a quarter of these patients 
long after curative treatment for cancer, with profound effects on quality of life.10,11 
Furthermore, it seems that patients with more aggressive treatments are more at risk for 
persistent fatigue.12-14 However, little is known about the aetiology of persistent fatigue and at 
this moment, persistent fatigue is unexplainable by somatic factors. Fatigue seems to be 
elicited during the treatment phase, but later on there is no clear relationship between 
persistent fatigue and initial disease and cancer treatment variables.10,11,15-17 Therefore, we 
think it is useful to make a distinction between precipitating factors and perpetuating factors 
of fatigue after cancer. The assumption is that cancer itself and/or cancer treatment may 
have triggered fatigue (precipitating factors), but other factors are responsible for the 
persistence of fatigue complaints (perpetuating factors).13,18,19
In a previous study we found cognitive behaviour therapy (CBT) especially designed for 
fatigued cancer survivors effective in reducing fatigue and impairment.18 The rationale of this 
intervention was based on the model of precipitating and perpetuating factors. The 
intervention was focused on six perpetuating factors of post-cancer fatigue: (1) insufficient 
coping with the experience of cancer, (2) fear of disease recurrence,13,16 (3) dysfunctional 
cognitions concerning fatigue,19,20 (4) dysregulation of sleep,10,11 (5) dysregulation of 
activity,10,11,16 (6) low social support and negative social interactions.19
However, in this last study none of the patients included were treated with a SCT. Therefore 
we conducted this study, to answer to following research questions: 
1. What is the prevalence of severe fatigue in patients after successful SCT? 
2. Is the model of precipitating and perpetuating factors found in other cancer survivors 
also applicable in cancer survivors treated with a SCT? 
(a) Is there a relationship between past and/or current medical characteristics and 
     fatigue severity? 
        (b) Are the same perpetuating factors, that play a role in persistent fatigue after 
     curation for solid tumours, involved in fatigue after successful SCT? 
 
 
 
 
84      Chapter 6 
METHODS 
Patients 
This study involved all patients who were treated at the age of eighteen or older with an 
autologous or an allogeneic SCT between 1981 and 2003 at the Department of Haematology 
of the Radboud University Nijmegen Medical Centre. Diagnoses included were acute myeloid 
or lymphatic leukaemia in first complete remission (CR1), chronic myeloid leukaemia in first 
chronic phase (CP1), non-Hodgkin’s lymphoma in CR1. The conditioning regime included 
total body irradiation. All patients had to be in persistent complete remission for at least 1 
year after SCT. 
Graft versus host disease (GVHD) is a frequent complication of an allogeneic SCT in which 
the engrafted donor cells attack the patient's organs and tissue. Acute GVHD was classified 
as grade I-IV according to Glucksberg et al.21 and chronic GVHD as limited or extensive 
following the Shulman criteria.22 Patients with severe GVHD after allogeneic SCT (i.e. grade 
III and IV, acute GVHD or extensive chronic GVHD) may experience many acute and chronic 
medical problems, are treated with several drugs and other therapies, which may influence 
an unstable clinical balance and may provoke fatigue. Therefore, these patients were 
excluded from this study. 
Anaemia is a well known physical factor that can cause fatigue. Therefore, all patients with a 
haemoglobin (Hb) concentration of 10 g/dl and lower were not eligible for this study. 
 
Recruitment procedure 
All patients that underwent SCT since 1981 could be identified by a database that was set up 
at the research centre of the Department of Haematology. Inclusion and exclusion criteria 
were checked according to the data of the most recent clinical check-up. All patients were 
sent a package of questionnaires and an informed consent form, together with a letter of their 
physician, explaining the purpose of the study. Patients were asked to fill out and send back 
the questionnaires together with the informed consent to the Expert Centre Chronic Fatigue. 
The ethics committee of the hospital approved the study. 
 
Demographic and medical characteristics 
The demographic characteristics like age, gender, marital status, education and employment 
were gathered by self-report. 
Characteristics of the medical history of patients were obtained from the medical chart and 
consisted of type of diagnosis, type of transplantation, time since transplantation, grade of 
GVHD, duration of hospitalization during SCT and number of hospitalizations for 
complications after SCT. Additionally, we acquired information about current medical 
characteristics from the medical chart, like comorbidity, medication use, Hb concentration 
and body mass index (BMI) at time of participation in the study. 
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Questionnaires 
Fatigue severity was measured by the ‘fatigue severity’ subscale (CIS-fatigue) of the 
Checklist Individual Strength (CIS),23-26 consisting of 8 items designed to measure fatigue 
severity during the previous 2 weeks. Each item was scored on a 7-point Likert scale. High 
scores indicated a high level of fatigue. A CIS-fatigue score equal or higher 35 was used to 
identify severe fatigue.19,23 The questionnaire has been used in cancer survivors,13,18,19,27,28 
showed good reliability, discriminative validity and sensitivity to change.18,22,29,30
Coping with the experience of cancer was measured with the Dutch version of the Impact of 
Event Scale. This 15 item scale consists of two subscales  (intrusion: 7 items and avoidance: 
8 items) on a 6-point Likert Scale and measures the extent to which a subject is currently 
occupied with the coping process after a major event (in this study the diagnose and 
treatment for cancer). High scores are indicative for intrusively experienced ideas, images, 
feelings or bad dreams about the event and avoidance of unpleasant feelings or memories of 
the event.31-33
Fear of disease recurrence was measured by two items of the Cancer Acceptance Scale 
(CAS) scored on a 4-point Likert Scale.13 The items are (1) I am worried about a tumour 
relapse, (2) I am anxious about my health. High scores are indicative of a high level of fear. 
Cognitions related to fatigue. Self-efficacy was measured with the Self-Efficacy Scale (SES), 
consisting of five questions, which measured sense of control in relation to fatigue 
complaints.13,19,30,34 Cancer-related attributions with regard to fatigue complaints were 
measured with the Causal Attribution List (CAL),19 consisting of 4 items (cancer, SCT, 
radiation therapy, chemotherapy). For each item, patients were asked to indicate their 
opinion regarding the cause of their fatigue complaints on a 4-point scale (1 = not at all 
applicable to 4 = very applicable). Internal reliability of this questionnaire was good, with a 
Cronbach’s alpha coefficient 0.95. 
Sleep disturbances was measured with the sleep/rest subscale of the Sickness Impact 
Profile (SIP-8),35,36 and the insomnia subscale of the Quality of Life Questionnaire-C30 (QLQ-
C30),37 with higher values reflecting an increased presence of symptoms. 
Physical activity was measured with the physical functioning and role functioning subscale of 
the QLQ-C30, with higher scores representing a better level of physical/role functioning. 
Furthermore, physical activity was measured with the subscales home management, work, 
and recreation and pastimes from the SIP, with high scores reflecting more functional 
impairments 
Social functioning was measured with the social functioning subscale of the QLQ-C30 and 
the social interaction subscale of the SIP. 
 
Statistical analysis 
Data analyses were performed using Statistical Package for Social Science (SPSS; version 
12.1). Descriptive statistics were used for description of the sample. Chi-square, independent 
samples t-tests and analyses of variance general linear model (GLM) have been performed 
to test differences between groups. Pearson correlations were used to investigate the 
association between fatigue severity (CIS-fatigue) and medical characteristics. Furthermore, 
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Pearson correlations between fatigue severity and the six perpetuating factors were used as 
preparatory analyses to examine the contribution of these factors to fatigue severity. Those 
measures that correlated highest with the fatigue severity score were used as independent 
variables in a linear regression analyses (enter-method). Correlations between the six 
perpetuating factors were tested on multicollinearity (r < 0.9 ). 
 
 
 
Table 1 
 
Demographic and medical characteristics (n=98) 
 
cancer survivors  
treated with a SCT 
Age  45.3 (10.9) 
range 19.0 – 67.3 
Gender  
     male 
     female 
 
 57  (58%) 
 41  (42%) 
Marital status 
     married / cohabiting 
     unmarried 
     divorced 
     widowed            
 
 77  (79%) 
 17  (17%) 
   2  (  2%) 
   2  (  2%) 
Higher education ( ≥ 12 years)  34  (35%) 
Employment 
     work outside home 
     study 
     disablement insurance act 
     partial disablement insurance act 
     sick leave 
     no work 
 
54  (54%) 
   6  (  6%) 
 26  (26%) 
   7  (  7%) 
   3  (  3%) 
        4  ( 4%) 
Primary diagnosis 
     acute leukaemia 
     chronic leukaemia 
     lymphoma  
 
 70  (72%) 
 21  (21%) 
  7   (  7%) 
Transplantation 
     allogeneic 
     autologous  
 
79   (81%) 
19   (19%) 
Time since transplantation (years)   9.3 (  5.5) 
range 1.0 – 21.5  
Abbreviation: SCT = stem cell transplantation 
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RESULTS 
Response 
Hundred twenty-four patients met the eligibility criteria and were asked to participate in this 
study. Ultimately, the questionnaires were filled out and returned by 98 patients (79%). 
Reasons for non-participation (n=26) were: too emotional to participate (n=6), did not feel like 
taking part because they had no complaints at the moment (n=3), bad concentration and 
therefore not able to fill out the questionnaires (n=1) and unknown (n=16). Non-participants 
did not differ from the participants with regard to demographic characteristics (data not 
shown), except for age. Non-participants were significant younger compared with the 
participants (40.5 (s.d.=8.9) vs 45.3 (s.d.=10.8); P =0.038). Information about demographic, 
disease and treatment characteristics of the participants are listed in Table 1. 
 
Research questions 
What is the prevalence of severe fatigue in patients after successful SCT? 
The mean CIS-fatigue severity score of the total sample was 26.9 (s.d.=14.0). Thirty-four 
patients (35%) met the cutoff criteria for severe fatigue (CIS-fatigue ≥ 35), whereas an 
additional 12 patients (12%) had heightened fatigue scores (CIS-fatigue between 27 and 35). 
There were no differences in fatigue severity between male (27.6, s.d.=14.0) and female 
cancer survivors (25.9, s.d.=14.2, P =0.558), younger (24.7, s.d.=12.6) and older survivors 
(29.0, s.d.=15.1, P =0.125) (median 45.7 years), married/cohabiting (27.0, s.d.=14.0) and 
unmarried/divorced/widowed survivors (26.5, s.d.=14.3, P =0.880) and survivors with lower 
and higher education, respectively 27.7 (s.d.=14.9) and 26.0 (s.d.=12.2)  (P =0.552) 
 
Is there a relationship between past and/or current medical characteristics and fatigue 
severity? 
Medical History 
Diagnose and transplantation: No significant difference was seen in mean fatigue score 
between patients who were diagnosed with acute leukaemia, chronic leukaemia or 
lymphoma and between patients who were treated with allogeneic transplantation or 
autologous transplantation (Table 2).  
Time since transplantation: To investigate the relationship between fatigue severity and time 
since transplantation, the total sample has been divided into four groups: patients who were 
treated with a SCT between 1 and 5 years ago (n=32), between 5 and 10 years ago (n=19), 
between 10 and 15 years ago (n=30) and more than 15 years ago (n=17). Mean fatigue 
scores and percentages of severe fatigue for these four groups are shown in Table 3. No 
statistically significant differences were found in mean fatigue scores and in percentages of 
severe fatigue. In addition, the correlation between the CIS-fatigue score and time since 
transplantation proved to be very low and non-significant  (Figure 1). 
GVHD: From the medical charts, we obtained for each patient the maximum GVHD grade 
after transplantation. As described in the Methods section, patients with severe GVHD were 
excluded. There were no differences in the mean fatigue score between patients who 
experienced no GVHD after transplantation, or who suffered from grade I or grade II. 
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Table 2 
 
The association of fatigue with medical characteristics (medical charts) 
 
n Mean CIS-fatigue (s.d.) P-value
Diagnosis  
     acute leukaemia   70 27.3 (13.9) 
     chronic leukaemia  21 27.8 (14.2) 
     lymphoma     7 22.9 (16.0) 
0.733
Transplantation  
     allogeneic 79 27.6 (13.9) 
     autologous 19 23.8 (14.4) 
0.285
Graft vs Host Disease  
     absent 36 26.8 (13.8) 
     grade I 34 29.4 (14.5) 
     grade II   9 24.4 (12.4) 
0.562
Duration of hospitalization SCT  
     ≤ 5 weeks 51 27.3 (13.4) 
     >   5 weeks 47 26.5 (14.8) 
0.471
Hospitalizations after SCT for complications  
     0 hospitalizations 55 24.7 (12.5) 
     1 hospitalization  26 28.9 (15.9) 
     > 1 hospitalization (range 2 – 7) 17 31.1 (15.2) 
0.181
Co morbidity at the time of participation  
     (7 missings) 
 
     yes  38 31.7 (14.9) 
     no  53 24.7 (12.7) 
0.018
Medication at the time of participation  
     no medication 51 25.8 (13.5) 
     medication but no antibiotics and/or beta blocker 17 29.9 (14.8) 0.174
     antibiotics 11 35.8 (14.9) 
     beta blocker   9 26.6 (13.7) 
Hb concentration at the time of participation  
     =  normal concentration 78 26.7 (14.1) 
     <  normal concentration     20 27.6 (14.0) 
0.814
BMI at the time of participation  
      normal BMI 53 25.0 (12.6) 
      > or <  normal BMI 45 29.1 (15.4) 
0.156
Abbreviations: BMI = body mass index; CIS= Checklist Individual Strength; SCT= stem cell transplantation 
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Table 3 
 
Mean CIS-fatigue scores and percentages of fatigue for patients who finished SCT within a different 
time period 
 
 
 
n Mean CIS-fatigue (s.d.)* % of severe fatigue **
Time since transplantation 
between   1 and   5 years ago 32 27.5 (12.3) 41
between   5 and 10 years ago 19 28.4 (14.2) 32
between 10 and 15 years ago 30 25.4 (14.5) 30
    more than 15 years ago 17 26.7 (16.9) 35
 
total 98
Abbreviations: CIS = Checklist Individual Strength; GLM = general linear model; SCT = stem cell 
transplantation.  
 * analyses of variance (GLM), P=0..901 
** chi-square, P =0.832 
 
Figure 1 
 
The association of time since treatment with fatigue severity (CIS-fatigue); r  = - 0.080, P = 0.434
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Hospitalization and complications: To analyse the association between post-cancer fatigue 
and the duration of hospitalization during the transplantation, the group was divided into two 
groups based on the median time of hospitalization (5 weeks). No difference in mean fatigue 
scores of the two groups was found. Furthermore, the correlation between the fatigue score 
and total days of hospitalization was nonsignificant (r = 0.046, P =0.652). 
Owing to complications, 44% of the patients (n=43) had been re-admitted after the SCT (n=5 
abdominal pain; n=9 nausea/vomiting/diarrhoea; n=21 fever; n=9 respiratory insufficiency/ 
failure, n=7 Herpes Zoster; n=11 other complications). No difference was found between the 
mean fatigue score of patients who had no complications after transplantation, patient who 
had been hospitalized once, and patients who had been hospitalized more than one time. 
Additionally, post-treatment fatigue was not related to the number of hospitalizations and to 
the number of days of hospitalization due to complications (respectively, r = 0.128, P = 
0.208; r = 0.043  P =0.676). 
 
Current medical characteristics  
Comorbidity: Patients with comorbidity at the time of participation (n=38) were significantly 
more fatigued than patients without comorbidity (n=53; P = 0.018) (Table 2). The group of 
patients with comorbidity was divided in three subgroups: 
(a) comorbidity that possibly can cause fatigue (n=10; four hepatitis C, four hypertension 
with use of a beta blocker, two recurrent respiratory infections); 
(b) comorbidity possibly caused by the SCT (n=13, six iron overload, five good controlled 
hypothyroidism (normal levels of thyroid stimulating hormone (TSH) and Free T4 at 
the time of participation in the study) , two postherpetic neuralgia); 
(c) remaining comorbidities (n=15, five diabetes mellitus, six hypercholesterolemia, two 
epilepsy, one haematuria,  one gout). 
Within these three groups, mean fatigue scores were, respectively, 33.9 (s.d.=14.7), 33.2 
(s.d.=15.0) and 28.9 (s.d.=15.5) and were not significantly different (P  =0.662). 
Medication use: We investigated medication use by patients at the moment of participation in 
the study. There was no significant difference between postcancer fatigue in patients 
(a) without medication  (n=51) 
(b) with antibiotics (n=11), 
(c) with beta blocker (n=9), 
(d) with other medication (n=17). 
Hb concentration: To test the association between postcancer fatigue and the Hb 
concentration at the moment of participation, two subgroups were identified based on the 
normal distribution of Hb concentration of the WHO.38,39 No difference was seen in the mean 
fatigue score between patients with a normal Hb concentration (n=78: men 13.6 – 17.2 g/dl ; 
women 12 – 15 g/dl) and patients with a low Hb concentration (n=20: men < 13.6 g/dl ; 
women < 12 g/dl). Additionally, the correlation between fatigue severity and Hb concentration 
was non-significant (r = -0.024, P =0.813) 
BMI: Based on WHO standards, BMI was categorized as underweight (BMI < 18.5), normal 
weight (BMI = 18.5-24.9), overweight (BMI = 25-29.9) and obese (BMI ≥ 30).40 To analyse 
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the association between post-cancer fatigue and the weight of patients at the time of 
participation, the total group was divided into two groups. Patients with a normal weight 
(n=53) and patients with underweight, overweight and obese patients (n=43).There was no 
difference in fatigue severity between these two groups. Additionally, the correlation between 
fatigue severity and BMI was low and non-significant (r = 0.098, P =0.338). 
 
Are the same perpetuating factors, that play a role in persistent fatigue after curation for solid 
tumours, involved in fatigue after successful SCT? 
In Table 4, comparisons have been made between fatigued cancer survivors (CIS ≥ 35) and 
non-fatigued cancer survivors (CIS < 35) with regard to the six perpetuating factors.  
 
 
Table 4 
 
Comparisons between severely fatigued cancer survivors (CIS-fatigue ≥ 35) and non-fatigued 
cancer survivors (CIS-fatigue < 35) long after SCT 
 
 Nonfatigued
n=64 
    Severe    
        fatigued 
     n=34 
p-value Correlation: 
CIS_fatigue
Coping with the experience of cancer 
     Impact of event scale 
7.6 (10.6) 16.5 (16.1) 0.004 0.380**
Fear of disease recurrence 
     Cancer Acceptance Scale 12.7 (3.3) 16.8 (4.9)
 
0.000 0 .454**
Dysfunctional cognitions    
     Self-Efficacy  (SEQ) 22.3 (3.6) 17.4 (3.3) 0.000 - 0.639**
     Cancer related attributions (CAL) 11.1 (4.0) 14.7 (1.9) 0.000   0.599**
Sleep disturbances   
     Sleep / Rest (SIP) 20.5 (36.9) 85.1 (76.4) 0.000  0.550**
     Insomnia (QLQ-C30) 13.0 (21.1) 29.4 (35.5) 0.021  0.407**
Dysregulation of physical activity  
     Home management (SIP) 32.0 (66.9) 93.3 (70.6) 0.000   0.514**
     Recreation and pastimes (SIP) 30.1 (53.6) 91.7 (71.7) 0.000   0.518**
     Work (SIP)  61.7 (125.0) 149.5 (157.0) 0.001  0.358**
     Physical functioning (QLQ-C30) 91.8 (13.7) 71.8 (13.7) 0.000 - 0.614**
     Role functioning (QLQ-C30)  94.5 (11.2) 57.8 (30.5) 0.000 - 0.675**
Social functioning  
     Social functioning (QLQ-C30) 90.4 (18.3) 71.1 (25.4) 0.000 - 0.472**
     Social interactions (SIP) 52.1 (92.7) 150.3 (136.1) 0.000  0.544**
 
Abbreviations: CAL = Causal Attribution List; CIS = Checklist Individual Strength; QLQ-C30 = Quality of Life 
Questionnaire-C30; SES = Self-Efficacy Scale ; SIP = Sickness Impact Profile. 
** p < 0.01 
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Results were consistent; patients experiencing severe fatigue had more difficulties in coping 
with the experience of cancer, more fear of disease recurrence, more dysfunctional 
cognitions, sleep disturbances, less physical activity and low social functioning. Furthermore, 
all measurements correlated significantly with the fatigue severity score. 
The highest correlations were used as independent variables in a linear regression analyses. 
There was no multicollinearity between the six perpetuating factors entered in the regression 
analyses. Results of the regression analyses (Table 5) indicated that insufficient coping with 
the experience of cancer, fear of disease recurrence, low self-efficacy, sleep disturbances 
and low role functioning contributed significantly to fatigue severity. In total, 68% of the 
variance of fatigue severity was explained by the six perpetuating factors. 
 
 
Table 5 
 
Linear Regression (enter) to predict fatigue severity 
 
Independent variables      Dependent variable: 
     CIS-fatigue severity 
 Beta  P-value
Coping with the experience of cancer (IES)   0.172 0.016
Fear of disease recurrence (CAS)   0.175 0.034
Dysfunctional cognitions (SES) - 0.243 0.002
Sleep disturbances (SIP- sleep / rest)   0.215 0.007
Dysregulation of physical activity (QLQ-C30- role functioning) - 0.376 0.000
Social functioning (SIP – social interactions)   0.005 0.958
  
Total R2 (adjusted)   0.679 
 
Abbreviations: CIS = Checklist Individual Strength; IES = Impact of Event Scale; CAS = Cancer Acceptance 
Scale; SES = Self-Efficacy Scale; SIP = Sickness Impact Profile; QLQ-C30 = Quality of Life Questionnaire-
C30;  
 
 
 
DISCUSSION 
In this study, 35% of  a group of patients experienced severe fatigue long after finishing SCT 
(mean = 9.3 years). The percentage cancer survivors with severe fatigue remained stable 
during the years after transplantation, even after more than 15 years. 
Cross-sectional studies investigating the prevalence of fatigue (all not including patients who 
were treated with a SCT) showed that the percentage of cancer survivors with severe fatigue 
decreases during the years after treatment: this was 38% after 2.5 years,19  30% after 3 
year,41 37% after 4 years,42  26% after 12 years,43 16% after 12 years.44 The course of 
fatigue was also investigated in four longitudinal studies, measuring the prevalence of fatigue 
in cancer survivors two times at different time points. Bower et al.12  found a decrease of 35% 
(3.5 years after treatment) to 21% (6.3 years after treatment) and Servaes et al.27 found a 
decrease of 38% (2.5 years after treatment) to 23% (4.5 years after treatment). In the two 
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other longitudinal studies the percentage of patients with severe fatigue remained equal, 
28% (6 years after treatment) to 26% (8 years after treatment).12 Hjermstad et al.15 
investigated disease-free cancer patients 16 years and 24 years after treatment for cancer. 
In this longitudinal study the percentage of fatigued cancer survivors was respectively, 25% 
to 28%. These results seem to suggest that fatigue complaints continue to decrease during 
the first 3–4 years after curative treatment and remains a persistent problem for about a 
quarter of the cancer survivors. However, in the current study we investigated the course of 
fatigue, and we found no decrease of fatigue even up to 15 years after completing SCT. So it 
seems that in patients after a SCT the percentage of fatigue remains high. This finding is in 
agreement with the assumption that patients with more aggressive treatments are more at 
risk for persistent fatigue.12-14, 45
The respondent sample consist of almost 80% of the patients who were treated for acute 
leukemia in CR1, non-Hodgkin lymphoma in CR1 and chronic leukemia’s in CP1. The 
population of (A)SCT patients from the Department of Haematology of the Radboud 
University Nijmegen Medical Centre does not differ from other Dutch and European centres 
for (A)SCT.46 Our study involved patients who were 18 years or older at the time of (A)SCT 
and who had to be in persistent CR for at least 1 year after (A)SCT. Patients with acute 
GVHD grade III or IV and/or extensive GVHD were excluded and this was also true for 
patients with a Hb concentration of 10 g/dl at the time of inclusion. This is given in the 
Methods section. The exclusion of patients with severe acute or sever chronic GVHD and the 
exclusion of patients with a haemoglobin level of less than 10.0 g/dl may result in a 
respondent sample with relatively more patients who are less prone to fatigue than the 
general population after (A)SCT. This means that the impressive number of patients that 
experienced severe fatigue will be even higher in a general (A)SCT population. 
We found no associations with fatigue severity and characteristics of the medical history. 
Owing to shorter time in protective isolation, fewer treatment-related side effects and no risk 
of GVHD, the assumption has been uttered that patients with allogeneic SCT have more late 
effects than patients with a autologous SCT. However, the literature is ambiguous on this 
point.1, 47-50  Concerning fatigue, Hjermstad et al.1 also found no differences between the two 
types of transplantation. However, similar to their studies, the small number of patients in our 
autologous group implies that chance findings cannot be ruled out. 
Because in this study the focus was on fatigue with no somatic cause, we excluded 
beforehand patients with medical problems that could possible cause fatigue, like GVHD-
grade of III and IV and Hb concentration of 10 g/dl and lower. This could be the reason why 
no relation between fatigue severity and somatic characteristics were found. 
Thirty-eight of the 98 patients (39%) had a medical comorbidity besides persistent fatigue. 
Patients with a medical comorbidity scored higher on fatigue severity compared with patients 
without a medical comorbidity. However, no differences were found in fatigue severity 
between the different kinds of medical comorbidity (comorbidity that possibly can cause 
fatigue, comorbidity possibly caused by the SCT and the remaining comorbidities). Because 
of the relatively small numbers of patients in the different groups, an actual difference cannot 
be ruled out fully. 
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The model of perpetuating factors derived from previous studies in cancer survivors, not 
undergoing transplantation, appears to be applicable in SCT cancer survivors as well. 
Persistent fatigue was well predicted by the supposed perpetuating factors: insufficient 
coping with the experience of cancer, fear of disease recurrence, dysfunctional cognitions 
concerning fatigue, dysregulation of sleep and dysregulation of activity. In total, 68% of the 
variance of fatigue severity was explained by the six factors. Only impairment in social 
functioning did not contribute significantly to fatigue severity.  Servaes et al.19 demonstrated 
that severely fatigued cancer survivors experienced more negative interactions and 
insufficiency of supporting interactions than those who were not fatigued. No significant 
difference was found in the frequency of supporting interactions. So, it seems that the 
experienced insufficiency and negative interactions have more influence on fatigue severity 
than impairment in social functioning as measured in this study.  Additionally, these results 
suggests that in the absence of clear medical causes, the CBT especially designed for 
fatigued cancer survivors after conservative treatment, can also be used in the management 
of fatigue after SCT. 
The strength of this paper is characterized by an underlying theoretical perspective of 
postcancer fatigue, the model of precipitating and perpetuating factors. However, it could be 
argued that the factors do not perpetuate fatigue, but represent, for example, psychosocial 
consequences of stress. Furthermore, the study is cross-sectional and limits our ability to 
draw conclusions about the course of post-cancer fatigue in patients following a SCT. For 
definitive conclusions, a longitudinal design would be more appropriate. 
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ABSTRACT 
In this study we want to get a better understanding of suffering associated with fatigue by 
using a simple, graphic instrument: the Pictorial Representation of Illness Measure (PRISM). 
In this study four research questions were investigated:  
(1) Is suffering, as measured with the PRISM, a separate dimension of chronic fatigue?  
(2) Is there a difference in suffering between patient groups experiencing chronic 
fatigue?  
(3) Is it possible to discriminate within a patient between the suffering due to an illness 
and the suffering due to fatigue?  
(4) Does suffering diminish following a treatment for chronic fatigue? 
Three samples, 60 chronic fatigue syndrome patients, 82 cancer survivors experiencing 
severe fatigue complaints and 68 fatigued patients with various neuromuscular disorders 
were assessed on dimensions of fatigue, disease specific characteristics and with the 
PRISM. 
Correlations found with dimensions of fatigue were not to the extent that the PRISM could be 
seen as a parallel test. Furthermore, the three patient groups displayed different profiles in 
the correlations of the PRISM with the dimensions of fatigue. Discrimination of suffering due 
to fatigue or due to cancer was possible in the sample of the fatigued cancer survivors. 
Finally, suffering diminished following successful therapy of chronic fatigue. 
The present study offers encouraging data for the use of the PRISM as a tool in fatigue 
research and clinical practice. 
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INTRODUCTION 
Fatigue is a complaint experienced differently among persons and occurs both in health and 
in illness. In healthy individuals fatigue seems to be a protective, sometimes even a pleasant 
regulatory response to physical or psychological stress. For people with a disease chronic 
fatigue becomes a disabling and life- and activity limiting experience.1-5 Therefore, fatigue is 
a concept with several modes of expression. Our research group has focused on the study of 
chronic fatigue for years now and has identified nine dimensions of chronic fatigue, namely 
fatigue severity, functional impairment associated with the fatigue, the level of physical 
activity, psychological distress, sleep disturbances, concentration problems, social 
functioning and social support, self-efficacy and causal attributions.1,2 These dimensions 
appear to be relatively independent, meaning that each dimension uniquely contributes to the 
experience of fatigue. Based on these dimensions a multidimensional assessment method 
has been developed. However, since fatigue has such a profound effect on many aspects of 
quality of life, it would also be valuable to know which impact fatigue has in a patients’ life,  
the suffering due to fatigue. This is a concept that is not included in the present 
multidimensional assessment method.  
Suffering is a multi-faceted experience which reflects the patients’ perception and appraisal 
of his illness in everyday life.6 It implies that what causes suffering in one patient may not do 
so in another, whereas they have symptoms in the same degree. For one patient an illness 
may not be seen as the most important aspect of his life. If there are other aspects in his life 
which are more important to him than his illness, these are likely to moderate the impact of 
the illness, and so the suffering. Because suffering is a complex and elusive symptom 
without a precise definition, it is difficult to assess. 
However, recently a novel instrument was developed by Büchi et al. that aims to assess the 
perception of suffering caused by an illness.7 This instrument is called the Pictorial 
Representation of Illness Measure (PRISM). It measures in a simple, graphic way  the 
burden of suffering due to illness or due to a symptom. To date five studies have been 
carried out supporting validity and reliability of the PRISM.7-10 The first study showed that the 
PRISM task was simple to administer and well accepted by patients. Furthermore, significant 
correlations were found with a variety of physical and psychological measurements.7 The 
usefulness of the PRISM in the clinical practice was demonstrated by discussing three case 
vignettes.8 The third study presented supporting evidence of reliability, validity and sensitivity 
to change in 714 patients with a variety of chronic physical illnesses.9 Furthermore, validity 
aspects were provided of the PRISM used in a self-administered paper-pencil format within a 
sample of 333 patients suffering from vitiligo.10
In this study we want to get a better understanding of suffering associated with fatigue, in 
three different patients groups; patients with chronic fatigue syndrome, fatigued cancer 
survivors and fatigued and non-fatigued patients with a neuromuscular disorder. Four 
specific research questions were investigated: 
1. Is suffering, as measured with the PRISM, a separate dimension of chronic fatigue? 
2. Is there a difference in suffering between the three patient groups experiencing 
chronic fatigue? 
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3. Is it possible to discriminate within a patient between the suffering due to an illness 
and the suffering due to fatigue? 
4. Does suffering diminish following the treatment of chronic fatigue? 
 
METHODS 
Patients 
Patients in this study were all patients participating in scientific studies conducted by the 
Expert Centre Chronic Fatigue of the Radboud University Nijmegen Medical Centre. For a 
more detail description of the patients groups we refer to the original studies  
Sixty patients with chronic fatigue syndrome (CFS) were included in this study (mean age 
36.1 (s.d.=12.1); female 67%). Chronic fatigue syndrome is characterised by persistent or 
relapsing unexplained fatigue, of new or definite onset and lasting for at least six months. 
The fatigue is not the result of an organic disease or ongoing exertion, rest does not alleviate 
it, and there is substantial limitation of occupational, educational, social and personal 
activities as a result of the fatigue.11 All 60 patients were treated with cognitive behaviour 
therapy (CBT) at our department.12 Multidimensional assessments at pre- and post treatment 
were available (a period of 6 months).  
The second patient group consisted of 82 fatigued cancer survivors (mean age 44.7 
(s.d.=10.2; female 48%). Fatigue is a problem for many cancer patients during the active 
phase of their disease. After successful treatment of the cancer fatigue complaints return to a 
normal level in most patients within several months. However, in at least 30-40% of the 
survivors severe fatigue persists even years after successful cancer treatment has ended 
and has profound negative effects on self-care abilities and quality of life.3,13 The 82 patients 
described in this paper participated in a randomised controlled trial studying the effectiveness 
of CBT especially designed to reduce chronic fatigue in cancer survivors.14 Patients were 
randomly allocated to the intervention condition (n=41) and the waiting list condition (n=41). 
Multidimensional assessments were made pre- and post treatment (a period of 6 months).   
The third sample consisted of 68 fatigued patients who participated in a study assessing the 
prevalence of fatigue in various neuromuscular disorders (mean age 42.7 (s.d.=10.0); female 
43%), namely: facioscapulohumeral muscular dystrophy (FSHD), a myogenic disorder; adult-
onset myotonic dystrophy (MD), a multisystem disorder; and hereditary motor and sensory 
neuropathy type I (HMSN), a neurogenic disorder.15 Multidimensional assessments were 
made, at baseline and after a period of 18 months.5
 
Materials  
The PRISM task7: Patients were shown a A4 shaped paper with a yellow fixed disk at the 
bottom-right hand corner (diameter 6 cm) and were asked to imagine that the paper 
represents his/her life as it is at the moment. The disk represents the subjects’ self. A red 
detachable disk (diameter 4 cm) was used to represent the fatigue. Subjects were asked : 
‘where would you put fatigue to reflect its importance in your life at this moment?’. In the 
sample of the fatigued cancer survivors and the patients with a neuromuscular disorder the 
PRISM+ was used, meaning that a second blue detachable disk (diameter 4 cm) was used to 
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represent the illness. Subjects were asked: ‘where would you put cancer/neuromuscular 
disorder to reflect its importance in your life at the moment?’. The PRISM was quantified in 
measuring the distance between the disks centres and the centre of the self disk, called the 
Self-Illness Separation (SIS). A smaller distance indicates a greater burden of suffering. The 
SIS values, called SIS-fatigue and SIS-Illness, ranged from 0 to 27 cm. In the sample of the 
fatigued cancer survivors the PRISM+ was also used in a qualitative way. After putting the 
disks on the paper patients were asked to explain why they put the ‘fatigue disk’ and ‘cancer 
disk’ at the position where they had done. A note of these comments was made by the 
researcher (MG).  
 
Questionnaires: Elements of eight dimensions of fatigue were measured with valid and 
reliable measures. The dimension ‘causal attribution’ was omitted in this study because 
different questionnaires were used in the three samples, making comparisons between the 
three groups impossible. 
Fatigue severity was measured by a subscale of the Checklist Individual Strength (CIS-
fatigue) consisting of 8 items. Each item was scored on a 7-point Likert scale. High scores 
indicated a high level of fatigue severity. Based on research with CFS patients, a score of 35 
or higher on the subscale fatigue severity indicated severe feelings of fatigue.1,16-18 The 
questionnaire has also been used in cancer survivors3,13,14 and patients with chronic 
diseases.2,5
Functional impairment was measured with the ‘physical functioning’ subscale of the SF-36, 
consisting of 10 items. Each item was scored on a 3-point Likert scale. High scores indicated 
good physical functioning.19-21
Physical activity  was measured with the subscale ambulation from the Sickness Impact 
Profile-8 (SIP-8), consisting of 12 items. High scores indicated more limitations in the domain 
of ambulation.22-24
Psychological distress  was measured with the total score of the Symptom Checklist (SCL-
90), consisting of 90 items. Each item was scored on a 5-point Likert scale. High scores 
indicated a high level of psychological distress.25
Sleep disturbance was measured with the sleep-rest subscale of the SIP-8, consisting of  7 
items. High scores indicated more sleep disturbances.  
Experienced concentration problems were measured with the concentration subscale of the 
CIS, consisting of 5 items. A high score indicated a high level of problems with regard to 
concentration. 
Impairment of social functioning was measured with the social interaction subscale of the 
SIP-8, consisting of 20 items. High scores indicated more problems in social functioning.  
Self Efficacy was measured with the Self Efficacy Scale (SES). The SES consisted of 7 
questions that measure sense of control with respect to fatigue complaints. High scores 
reflected more sense of control.4
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Disease specific measures for fatigued cancer survivors  
Stress response symptoms were measured with the Dutch version of the Impact of Event 
Scale. This 15 item scale consists of two subscales  (intrusion; 7 items and avoidance: 8 
items) on a 6-point Likert Scale and measures the extent to which a subject is currently 
occupied with the coping process after a major event (in this study the diagnose and 
treatment for cancer). High scores are indicative for intrusively experienced ideas, images, 
feelings or bad dreams about the event and avoidance of unpleasant feelings or memories of 
the event.26-28
Acceptance of the experience of cancer is measured by the Cancer Acceptance Scale 
(CAS), a questionnaire of 7 statements on a 4-point Likert Scale (range; not at all applicable 
to very applicable). High scores indicated low acceptance.29
Furthermore two treatment characteristics were defined; time since cancer treatment has 
ended and duration of treatment. 
Disease specific measures for patients with neuromuscular disorders 
Disease severity / muscle strength: Disease severity was determined using the Medical 
Research Council (MRC) grading scale (MRC; 0 – 5) investigating the muscle strength of the 
shoulder abductors, grip force, foot extensors and knee extensors.30 In order to characterise 
the patients, these eight values (both left and right) were averaged. High scores indicated 
muscle strength. 
 
Statistical analysis  
Data analysis was performed using SPSS (version 12.1). Because data were not normally 
distributed non-parametric analyses were used. Spearman rho’s correlations were used to 
assess bivariate correlations with the SIS fatigue / illness. Kruskal Wallis Test, Mann-Whitney 
U-test and Chi-square were performed testing the differences between the samples. 
Wilcoxon Signed Ranks Test for matched pairs was used in comparing values of the SIS 
fatigue and SIS illness within the three samples at T1 and T2. All analysis were tested two-
tailed. 
 
RESULTS  
Is suffering, as measured with the PRISM, a separate dimension of chronic fatigue?  
Table 1 shows negative significant correlations of the SIS fatigue and the severity of fatigue 
(CIS-fatigue). Patients who experienced less fatigue, positioned the fatigue disk further away 
of the self disk. For the other eight dimensions overall low and moderate correlations were 
found with the SIS fatigue. Furthermore, significant correlations were found in investigating 
the SIS illness and disease specific measures in fatigued cancer survivors and patients with 
a neuromuscular disorder (Table 2). None of the correlations were to the extent that the 
PRISM could be seen as a parallel test. 
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Table 1 
 
Bivariate spearman’s rho correlations at T1 between the SIS fatigue and eight dimensions of 
fatigue. 
 
 
 
Dimensions of fatigue 
Chronic fatigue 
syndrome (n=60) 
Fatigued cancer 
survivors  (n=82) 
Fatigued patients 
with neuromuscular 
disorders (n=68) 
 Rho p-value* Rho p-value* Rho p-value*
experienced fatigue  - 0.324 0.012 - 0.319 0.003 - 0.422 0.000
functional impairment    0.174 ns 0.149 ns   0.119 ns
physical activity    0.050 ns - 0.095 ns - 0.274 0.033
psychological distress  - 0.240 ns - 0.170 ns - 0.300 0.016
sleep disturbances  - 0.163 ns  - 0.008 ns - 0.133 ns
concentration problems  - 0.267 0.039 - 0.166 ns - 0.337 0.001
impairment of social functioning  - 0.023 ns - 0.216 ns - 0.340 0.002
self-efficacy    0.215 ns   0.103 ns  0.171 ns
 
* P > 0.05 are not displayed 
 
 
 
 
Table 2 
 
Bivariate spearman’s rho correlations at T1 between the  SIS Illness and disease specific 
measures. 
 
 Rho p-value*
Fatigued cancer survivors (n=82) 
Cancer Acceptance Scale  - 0.425 0.000
Impact of Event Scale  
• intrusion 
• avoidance 
- 0.459
- 0.351
0.000
0.001
Time since cancer treatment ended  0.338 0.002
Duration of treatment - 0.118 ns
 
Neuromuscular disorder (n=68) 
Muscle strength (MRC)  0.312 0.014
 
* P > 0.05 are not displayed 
 
 
 
106      Chapter 7 
Is there a difference in suffering between the three patient groups experiencing chronic 
fatigue? 
The three samples significantly differ in the mean level of fatigue severity (Table 3), CFS 
patients demonstrating the most fatigue, followed by the cancer survivors and the patients 
with various neuromuscular disorders. In accordance with the fatigue scores, we found that 
patients with CFS situated the fatigue disk in the closest distance of the self disk, followed by 
the cancer survivors and the patients with various neuromuscular disorders. These values 
were statistically significantly different. Investigating the SIS illness, data showed that the 
patients with various neuromuscular disorders positioned the illness disk significantly closer 
to the self disk than the cancer survivors. Furthermore, the correlations of the SIS fatigue and 
the variables of the eight dimensions showed a different profile in the three samples, finding 
the most significant correlations in the sample of the patients with various neuromuscular 
disorders (Table 1). 
 
 
Table 3 
 
Comparison of the mean and sd of fatigue severity, SIS fatigue, SIS illness between three samples 
(Mann-Whitney U test) 
 
 Chronic fatigue 
syndrome patients 
(n=60) 
Fatigued cancer 
survivors 
(n=82) 
Fatigued patients with 
neuromuscular 
disorders (n=68) 
fatigue severity (CIS-fatigue) 49.8 (  5.1)b,c 47.3 (  6.7)a,c 43.3 (5.9)a,b
mean SIS fatigue (sd)   4.8 (  4.0) b,c   7.1 (  5.2) a,c    9.3 (6.6) a,b
mean SIS illness (sd) -     18.0 (  8.4)c 9.8 (7.5)b
 
 
a: significantly different from chronic fatigue syndrome patients (p <0.05) 
b: significantly different from fatigued cancer survivors (p <0.05) 
c: significantly different from fatigued patients with neuromuscular disorders (p <0.05) 
 
 
 
Is it possible to discriminate within a patient between the suffering due to an illness and the 
suffering due to fatigue? 
In investigating this research question the sample of the fatigued cancer survivors was 
divided into two separate groups. The first group (n=67) positioned the fatigue disk closer to 
the self disk than the cancer disk. The second group (n=15) positioned the cancer disk closer 
to the self disk than the fatigue disk. Data showed (Table 4) that the first group revealed 
higher fatigue severity in contrast with the second group. The second group demonstrated 
less acceptance and higher intrusion and avoidance scores on the IES compared to the first 
group. In addition, comments of fatigue cancer survivors when performing the PRISM task at 
pretreatment were evaluated. Table 5 shows examples of comments of fatigued cancer 
survivors when performing the PRISM task at pretreatment. These comments revealed that 
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the suffering of two symptoms can be different. Patients who felt that fatigue was an 
overruling complaint affecting their total life placed the fatigue disk in closer distance of the 
self disk, in contrast to patients who had come to terms with the fatigue. Additionally, patients 
with a short SIS cancer seemed not have dealt enough with the fact that they had cancer. 
For patients with a large SIS cancer, the disease was no issue more. These kind of 
comments came up consistently in the other cancer survivors. 
 
 
Table 4 
 
Position of the two disks with respect to each other (Mann-Whitney U test) 
 
Cancer survivors SIS fatigue < 
SIS cancer  
(n=67) 
SIS fatigue > 
SIS cancer  
(n=15) 
 
MWU 
 
Z 
 
p-value 
CIS fatigue * 48.1 (6.7) 44.3 (5.8) 325.5 -2.127 0.033 
Cancer Acceptance Scale** 14.3 (3.5) 16.3 (3.1) 338.5 -.1977 0.044 
Impact of Event Scale *** 
• intrusion 
• avoidance 
 
 4.7 (5.1) 
 4.6 (6.5) 
 
10.8 (6.5) 
10.5 (6.6) 
 
234.0 
243.5 
 
-3.246 
-.3173 
 
0.001 
0.002 
      
   * high scores are indicative of a high level of fatigue 
  ** high scores are indicative of low acceptance 
*** high scores are indicative of a high stress response 
 
 
 
Does suffering diminish following treatment of chronic fatigue? 
We investigated the change of the SIS fatigue and SIS illness at T1 and T2 within the three 
samples (Table 6). The CFS patients and the cancer survivors who were allocated to the 
CBT condition were divided into two groups: patients who were completely recovered after 
CBT and had no severe fatigue complaints (CIS-fatigue < 35) and patients who still remained 
fatigue after CBT (CIS-fatigue ≥ 35). Patients with various neuromuscular disorders did not 
get any treatment for their fatigue complaints but followed their natural course. CFS patients 
(n=32) and cancer survivors (n=27) who recovered after CBT showed a significant increase 
on the SIS fatigue at T1 versus T2. Additionally, the recovered cancer survivors showed a 
significant increase in SIS illness after CBT. CFS patients (n=28) and cancer survivors 
(n=14) who still remained severely fatigued after CBT displayed no change of the SIS fatigue 
at T1 with respect to T2 and the fatigued cancer survivors showed no change on the SIS 
illness. The patients with various neuromuscular disorders showed stable values of the SIS 
fatigue and SIS illness at T1 versus T2. 
The comments of cancer survivors when performing the PRISM task at pre- and post 
treatment were examined (Table 7). These comments showed that patients who were 
recovered after CBT and were less fatigued expressed more positive and in the line of 
recovery comments at post treatment with respect of pretreatment comments. These kind of 
comments came up consistently in the other cancer survivors.  
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Table 5 
 
Examples of comments of four fatigued cancer survivors when performing the PRISM task at T1. 
 
 SIS fatigue < SIS cancer 
SIS-fatigue Fatigue that’s me, that’s my life. I always have to take fatigue into 
consideration when planning my activities. Fatigue has changed my life 
enormously. 
3.6 cm
SIS-cancer I have no fear for cancer. I don’t see it as a threat anymore. If the cancer 
would recur, I will deal with it than. I’m not worried about that now. 
27.0 cm
SIS-fatigue The fatigue complaints are always present and affect my whole life. 4.9 cm
SIS-cancer Cancer is not an important part of my life. I’m not afraid of disease 
recurrence. I have dealt with it. 
26.7 cm
  
 SIS fatigue > SIS cancer 
SIS-fatigue The fatigue has its influence on my life, but it makes me not desperate. It 
is just there and I have to deal with it. 
17.4 cm
SIS-cancer 14 days ago my sister has been diagnosed with breast cancer. By that a 
lot of memories of my treatment period returned. Also the thought that my 
two daughters can be a victim of hereditary haunts me. 
5.3 cm
SIS-fatigue I have learned to accept the fatigue complaints. 12.5 cm
SIS-cancer The experience with cancer is always present. I do not plan anything in 
the future. When I feel fine it remains in the background. But at moments I 
feel sick, have a little pain etc it becomes prominent. It alarms me. 
  8.5 cm
  
 
Table 6 
 
SIS fatigue and SIS illness at T1 and T2  (Wilcoxon signed ranks test for matched pairs). 
 
Group SIS fatigue         Z p-value* SIS illness      Z p-value*
A T1   5.3 (4.1)  
 T2 16.5 (6.8) 
-.4937 0.000
 
B T1   4.2 (3.9)  
 T2   5.5 (5.6) 
-1.430 ns
 
C T1   8.6 (6.8) 17.1 (9.5)
 T2 17.1 (9.5) 
-.3592 0.000
23.3 (6.5)
-.2399 0.017
D T1   5.9 (4.3) 16.6 (7.1)
 T2   6.0 (5.8) 
-.454 ns
14.7 (8.6)
-.847 ns
E T1   9.3 (6.6)   9.8 (7.5)
 T2 11.4 (7.8) 
-1.321 ns
11.4 (7.8)
- 1.705 ns
 
*  P > 0.05 are not displayed 
 
A: CFS non-fatigued after CBT (n=32); B: CFS still fatigued after CBT (n=28); C: Cancer survivors 
non-fatigued after CBT (n=27);  D: Cancer survivors still fatigued after CBT (n=14); E: Natural 
course neuromuscular disorders (n=68) 
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Table 7 
 
Examples of comments of two cancer survivors when performing the PRISM task at pre-treatment 
and post-treatment 
 
Comment SIS fatigue patient 1 SIS Fatigue CIS_fat
Pre-treatment: Fatigue has a daily impact and restricts me in 
functioning the way I want. Fatigue dominates my life 
13.8 cm 46
Post-treatment:  Fatigue is not anymore an disturbing factor in my life 
and it does not disable me, in contrast to the period before the 
cognitive behaviour therapy. I still experience fatigue, but only after 
physical exertion or stress, and it is gone after a good night rest. 
23.1 cm 12
  
Comment SIS fatigue patient 2  SIS Fatigue CIS_fat
Pre-treatment: Fatigue is something that is present every hour of the 
day and forced me to adjust my life. Because of the fatigue I had to 
change my goals in life. 
  2.9 cm 46
Post-treatment: I have much more energy now and build up my 
activities. I demand less of myself. 
17.0 cm 16
 
 
 
DISCUSSION 
The present study offers encouraging data for the use of the PRISM as a tool in fatigue 
research and clinical practice. 
Is suffering, as measured with the PRISM, a separate dimension of chronic fatigue? 
We did not find extreme high correlations indicative for a parallel test ( r >.90 = parallel test) 
with one of the measurements. Overall moderate correlations were found between the SIS 
fatigue and the values of the eight dimensions of fatigue and also between the SIS illness 
and the disease specific measurements. Therefore, it seems that the PRISM contributes 
uniquely to the dimensions of fatigue and therefore gives us additional information aside from 
what we already know based on our multidimensional assessment method. Additionally, it 
seems to measure something different than acceptance, stress symptoms or disease 
severity (=disease specific measurements). However, is it suffering the PRISM measures? 
The most important aspects of suffering is the patient’s perception of the intrusiveness and 
controllability of the illness or its symptoms, the ‘threat to the self’.7-9 These aspects are 
nicely demonstrated investigating the correlations and the qualitative data of the fatigued 
cancer survivors (Table 2 and 5). Cancer survivors who positioned the cancer disk further 
away of the self disk were less occupied with the fact that they had cancer and revealed 
more acceptance. Quite the contrary, if a patient is really occupied with the disease cancer, 
the influence of this on his life can be enormous. Furthermore, the positive significant 
correlation of  SIS-cancer and the time since cancer treatment can be explained by the fact 
that intrusion due to illness is fading away with time.9
110      Chapter 7 
 
Is there a difference in suffering between the three patient groups experiencing chronic 
fatigue? 
The differences between the samples in the position of the fatigue disk at baseline, were in 
agreement with the severity of the experienced fatigue measured with the fatigue 
questionnaire (CIS-fatigue). So fatigue severity seems to be an aspect of suffering in these 
patient groups. Investigating the positioning of the illness, we found that patients with various 
neuromuscular disorders positioned the illness disk in closer distance to the self disk than the 
fatigued cancer survivors. Patients with neuromuscular disorders have a chronic progressive 
disorder and are confronted with this everyday. The intrusiveness of the disease is present 
everyday and the controllability low. The significant positive correlation of the SIS illness and 
the muscle strength supports this explanation. On the other hand, the cancer survivors had 
an acute disease in the past but were disease-free at the moment of participation in this 
study. Therefore most of them are not daily confronted with their past disease. Most patients 
will have accepted their experience with cancer and the treatment for cancer with time and 
by doing so the suffering will also diminish. This is also represented with the correlation of 
the SIS illness and the time since treatment.  
One would expect that the contributions of different variables to suffering would be different 
between illnesses, therefore one should expect that the correlations between the PRISM and 
the other variables would differ from one illness to another.  A different pattern of correlations 
was actually seen within the three samples, with the most significant correlations in the group 
of patients with a neuromuscular disorder. A neuromuscular disorder is a complex illness 
with many symptoms besides fatigue. It is possible that  for patients with a neuromuscular 
disorder the fatigue is entangled with all the other symptoms making it difficult for patients to 
separate. Therefore, fatigue seems to be a symptom of their overall state rather than a 
predominant focus of their attention, as is likely the case in the other two groups. For that 
reason the SIS-fatigue is significantly correlated with many dimensions of fatigue. For the 
fatigued cancer survivors the ‘threat to the self’ is largely in the past, so the suffering in this 
group appears mainly related to the adjustment to the cancer and previous memories of it. 
For patients with CFS, fatigue is the main symptom without the experience of a current or 
past severe illness. These patients can not attribute their fatigue to a distinct cause and 
therefore, it’s possible that they are more focussed on their fatigue.  
 
Is it possible to discriminate within a patient between the suffering due to an illness and the 
suffering due to fatigue? 
Fatigue is a symptom which frequently occurs in combination with physical illnesses and it’s 
difficult to determine when fatigue leads to suffering or when another symptom is more 
important to a patient. However, this aspect can be of great importance in the clinical 
practice.  
In this study suffering of fatigue and the suffering of a past disease (cancer) was compared in 
fatigued disease-free cancer patients. We found that fatigued cancer survivors who suffer 
more due to the fact that they have had cancer compared to the fact that they were severe 
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fatigued, also revealed less fatigue complaints, more difficulty in coping with their cancer past 
and were more anxious of disease recurrence (assessed with the IES). Also the qualitative 
data demonstrated the possibility to separate two kinds of suffering. The comments made by 
fatigued cancer survivors when performing the PRISM task were in agreement with the 
aspect that causes the patient the most suffering. By using the PRISM a clinician can 
observe in a quick and easy way which symptom (of course this not only applies for fatigue) 
gives the most suffering to the patient and thereby choose the main focus of attention in a 
treatment. For example, in the fatigued cancer survivors who positioned the cancer disk 
closer to the self disk than the fatigue disk, the focus of any treatment should be first on 
handling the experience of cancer before fatigue can be an issue in the treatment. 
 
Does suffering diminish following the treatment of chronic fatigue? 
Patients who were recovered and experienced no fatigue after CBT positioned at post-
treatment not only the fatigue disk significant further away of the self disk than at pre-
treatment, but also the illness disk. Patients who did not recover after CBT or patients with 
various neuromuscular disorders during natural course did not show a change in the position 
of the fatigue disk or the illness disk. Comments made when performing the PRISM task at 
pre- and post treatment were also supporting the change in suffering. Therefore, the PRISM 
can be a valuable tool in the clinical practice is to assess suffering at pre- and post treatment. 
In comparing these two assessments the treatment effect can be demonstrated instantly to 
the clinician as well as the patient.  
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ABSTRACT 
The primary objective was to develop an adjective checklist, the Fatigue Quality List (FQL), 
aimed at assessing different perceptions of fatigue. 
Nine hundred sixty-one participants filled out the FQL (28 adjectives). A component and 
confirmatory factor analyses were performed and psychometric properties were evaluated. 
Differences on factor scores between different patients’ groups were investigated and pre- 
and posttreatment scores were compared in demonstrating change of perceptions after 
treatment of fatigue. 
Four independent factors were found with adequate psychometric properties. Different 
perceptions were found between the patients’ groups. Patients who were recovered after 
treatment for fatigue showed similar scores on the factors as healthy controls. 
The FQL appears to be a promising tool in measuring different perceptions of fatigue, which 
can be especially interesting for clinical practice. 
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INTRODUCTION 
What is meant by fatigue? Most people are familiar with the experience of fatigue, but the 
meaning of this sensation can differ between people and even within one person the 
meaning of fatigue can change. Therefore, fatigue can be defined in different ways and there 
is no ‘gold standard’. Healthy people would characterise fatigue as a pleasant, acute, normal 
and regulating phenomenon after exercise or a busy day, disappearing after a good night’s 
sleep or a period of rest. However, fatigue can also have a more negative connotation as in 
fatigue experienced by patients with a health problem. To them fatigue can be a chronic, 
disabling and life- and activity-limiting experience.1-6  
There are also differences in the factors underlying fatigue severity between patients with 
different somatic conditions. Processes involved in the experience of fatigue in patients with 
chronic fatigue syndrome (CFS) are clearly different from processes related to the 
experience of fatigue in patients with multiple sclerosis (MS)2 and there are many differences 
between severely fatigued breast cancer survivors and females with CFS.7  
Because fatigue is not clearly defined, poor communication regarding fatigue exist in the 
clinical practice.8 Additionally, health care professionals find consultations on fatigue difficult 
and are often dissatisfied with or uncertain about the care they provide to patients with 
fatigue complaints.9,10 Without appropriate assessment, recognition and providing the proper 
management to patients with chronic fatigue is difficult. The first necessary step towards 
improving recognition and management is a thorough understanding of the symptom. 
Until now fatigue scales are mostly used to measure fatigue severity.11 However, fatigue 
severity does not reflect a persons’ perception and appraisal of the fatigue. Therefore, the 
quantitative way of assessing fatigue fails to capture the nuances and differences in the 
experience of fatigue. In pain research assessment methods already exists in determining 
the quality of pain in a patient by using adjectives.12,13
In this study an adjective checklist, the Fatigue Quality List (FQL), was constructed aimed at 
assessing different perceptions of fatigue. The development of the FQL was described and 
additionally three research questions were investigated: 
1. Is the FQL a reliable and valid instrument to assess different perceptions of fatigue? 
2. Are perceptions of fatigue different between several patient groups with and without 
chronic fatigue complaints and healthy controls? 
3. Do perceptions of fatigue change in patients who recover after treatment for fatigue? 
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METHODS 
Materials 
The Fatigue Quality List: Researchers and clinicians working at the Expert Centre Chronic 
Fatigue of the Radboud University Nijmegen Medical Centre made a large list of all possible 
adjectives that can be used to characterize the feeling of fatigue. The FQL was developed by 
asking researchers and health care professionals working with patients with unexplained 
fatigue complaints to indicate on this large list which of the adjectives best fitted with the 
experience of the fatigue described by their patients. The final list consisted of 28 adjectives 
most frequently mentioned by the raters.   
In filling out the FQL, subjects are instructed to mark with a cross which of the 28 adjectives 
fit their experienced fatigue. Multiple answers are possible. In this study the Dutch version of 
the FQL was used. However, the adjectives were translated into English by a back-
translation procedure. 
Fatigue severity was measured by a subscale of the Checklist Individual Strength (CIS-
fatigue) consisting of 8 items.14 Each item was scored on a 7-point Likert scale. High scores 
indicated a high level of fatigue severity. Based on research with CFS patients, a score of 35 
or higher on the subscale fatigue severity indicated severe feelings of fatigue. Furthermore, 
the CIS has excellent psychometric properties.1,11
 
Patients 
Nine hundred-sixty-one participants with a mean age of 43.6 years (s.d.=10.2, range 18-79) 
predominantly female (65%) filled out the FQL. All were either patients or healthy controls 
participating in scientific studies conducted by the Expert Centre Chronic Fatigue. The total 
group consisted of: 
- 219 cancer survivors. Hundred-twenty-eight (mean age 44.8 (s.d.=8.9); female 72%) 
experienced severe chronic fatigue and 91 (mean age 46.5 (s.d.=6.3); female 100%) 
were not fatigued.3 Forty-one of these cancer survivors were participating in a 
randomised controlled trial about the effectiveness of cognitive behaviour therapy 
(CBT) especially designed to reduce chronic fatigue in cancer survivors.15 These 
patients filled out the FQL at pre- and post treatment. 
- 160 patients who were diagnosed with CFS, according to the CDC criteria (mean age 
38.0 (s.d.=10.7); female 69%).4,16 Eighty-two CFS patients who were included in this 
study were treated for their chronic fatigue complaints with CBT.4 These patients filled 
out the FQL two times, at pre- and post treatment.  
- 151 employees on sick leave with unexplained fatigue complaints (mean age 44.0 
(s.d.=8.4); female 55%).17 Sixty-six (44%) of these met research criteria for CFS 
(mean age 42.9 (s.d.=8.6); female 61%). 
- 276 patients with various neuromuscular disorders. Hundred-sixty-five experienced 
severe fatigue (mean age 42.2 (s.d.=10.6); female 48%) and 120 experienced no 
fatigue complaints (mean age 42.2 (s.d.=11.3); female 48%).5,18 
- 77 patients who were diagnosed with pancreatitis. Fifty-three experienced severe 
fatigue (mean age 49.3 (s.d.=10.0); female 47%) and 24 were not fatigued (mean age 
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50.2 (s.d.=15.5); female 58%). 
- 78 healthy persons who experienced no fatigue complaints (mean age 48.2 
(s.d.=6.2); female 100%).3 
 
Statistical analysis  
Data analysis was performed using SPSS (version 12.0.1). The total participant group was 
randomly divided into two groups. A principal component factor analysis was performed in 
the first group to identify independent factors. A varimax rotation was used to facilitate the 
interpretation. Furthermore, factor loadings had to be above 0.40 with a 0.10 or greater 
difference in loadings with the other factors. The scree test and the eigenvalues (above 1) 
were used to identify the number of factors. The factor model was then tested in the second 
group by using confirmatory factor analyses / AMOS 5.0 (Comparative Fit Index, Goodness 
of Fit Index, Adjusted Goodness of Fit Index19,20).  
The internal consistency reliability for each factor was calculated using Cronbach’s alpha. 
Spearman’s rho correlations were used to evaluate psychometric properties of the FQL. To 
investigate the differences between the groups of patients Kruskal-Wallis tests were 
performed. When the Kruskal-Wallis test was significant, Mann-Whitney-U tests between the 
groups followed. The sensitivity to change of the FQL was demonstrated by comparing 
cancer survivors and CFS patients at pre- and post treatment assessment, using the 
Wilcoxon Signed Ranks Test of matched pairs. To correct for the multiple comparisons, P-
value was set on < 0.01.  
 
RESULTS 
Factor solution 
Three of the 28 adjectives were marked with a cross for less than 10% and therefore 
excluded from further analyses. Final analyses were done with the remaining 25 adjectives. 
Table 1 presents the final factor solution in the first group (n=476). Seven adjectives were 
excluded of factor analysis because factor loadings were < 0.40 and/or < 0.10 difference in 
loadings with the other factors. Both the scree test and eigenvalues indicated a 4-factor 
solution (Table 2). Factor 1 consisted of 5 adjectives, factor 2 of 4 adjectives, factor 3 of 5 
adjectives and factor 4 of 4 adjectives, explaining respectively, 24%, 9%, 6%, 5% of the 
variance prior to rotation. After rotation the four factors explained respectively, 13%, 12%, 
10% and 9% of the variance. Factor 1 was labelled as ‘Frustrating’, Factor 2 as ‘Exhausting’, 
Factor 3 as ‘Pleasant’ and Factor 4 as ‘Frightening’. This four factor model was then tested in 
the second group (n=485) by using confirmatory factor analysis. The fit indices indicated an 
adequate fit. Chi-square (129, n=485) = 364.5, P < 0.001; Comparative Fit Index = 0.87; 
Goodness of Fit Index = 0.92; Adjusted Goodness of Fit Index = 0.90.  
The four factors were recoded on a 0 to 100 scale, facilitating comparisons between the 
factors. Higher scores indicate a higher appraisal of the fatigue experience as frustrating, 
exhausting, pleasant and frightening. The final version of the FQL and the criteria for scoring 
are presented in appendix A.   
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Table 1 
 
Final factor solution: principal-components analysis with varimax-rotation in the first group. 
Cronbach’s Alpha of the four factors 
 
 Frustrating
 
Exhausting Pleasant Frightening
discouraging .735  
incessant .585  
annoying .680  
persistent .559  
frustrating  .704  
  
exhausting .690  
wearisome  .537  
extreme  .724  
unbearable .509  
  
temporary .400 
relaxing .661 
fulfilling .713 
normal .522 
pleasant  .792 
  
upsetting  .727
frightening  .618
inexplicable  .490
insuperable   .444
  
Cronbach’s Alpha .79 .68 .61 .57
  
Three adjectives were excluded of factor analysis because they were marked with a cross for less than 10%: 
Protective, Soothing, Threatening. 
 
Seven adjectives were excluded of factor analysis because factor loadings < 0.40 and/or < 0.10 difference in 
loadings with the other factors: Demanding, Paralysing, Aggravating, Compelling, Treacherous, Insoluble, 
Acceptable 
 
 
 
Is the FQL a reliable and valid instrument to assess different perceptions of fatigue? 
For each factor the internal consistency reliability was calculated in the entire sample of 961 
participants, which demonstrated moderate to adequate internal consistencies for all four 
factors, ranging from 0.57 to 0.79 (Table 1).  
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Supporting convergent validity we found that all four factors were statistically significant 
related to fatigue severity (CIS-fatigue) (Table 3). In calculating general psychometric 
properties statistically significant intercorrelations between the four factors were found (Table 
3). Additionally, low correlations were found between the four factors and age and gender, 
explaining less than 3% of the variance. 
 
Table 2 
 
Principal-components analysis with varimax-rotation, initial eigenvalues 
 
Component 
 
Eigenvalues 
1 4.788 
2 1.906 
3 1.285 
4 1.176 
5 0.984 
6 0.875 
7 0.813 
8 0.742 
9 0.714 
10 0.664 
11 0.623 
12 0.593 
13 0.568 
14 0.514 
15 0.503 
16 0.445 
17 0.428 
18 0.380 
 
 
Table 3 
 
Convergent validity of the 4 factors. Spearman’s rho correlation in total group (N=961) 
 
Factor  Frustrating Exhausting Pleasant Frightening
Fatigue severity 0.66* 0.58* -0.54* 0.43*
Exhausting 0.54*  
Pleasant -0.48* -0.35*  
Frightening 0.49* 0.42* -0.25* 
Age -0.16* -0.14*                0.05               -0.03 
Gender (1=M, 2=F) -0.09*                0.03  0.11* -0.10*
* p < 0.01   
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Are the perceptions of fatigue different between several patient groups with and without 
chronic fatigue complaints and healthy controls?  
The non-fatigued groups scored significantly lower on Frustrating, Exhausting and 
Frightening and significantly higher on Pleasant compared with the fatigued groups (Table 4). 
The following analyses were performed separately in the fatigued groups and the non-
fatigued groups. 
Tabel 4 
 
Mean score on 4 factors: comparisons between fatigued disease-free cancer patients, CFS patients, 
employees with unexplained fatigue, fatigued patients with neuromuscular disease, fatigued 
patients with pancreatitis, non-fatigued disease-free cancer patients, non-fatigued patients with 
neuromuscular disease, non-fatigued patients with pancreatitis and healthy persons 
 
  Frustrating 
 
Exhausting Pleasant Frightening 
 
A. 
 
Fatigued disease-free 
cancer patients 
 
48.6 (30.9)b,c
 
29.3 (28.6)b,d
 
11.7 (17.7)b,c
 
22.7 (24.2)d,e
B. Chronic fatigue 
syndrome patients 
58.5 (32.2)a,d,e 37.8 (31.5)a,c,d,e 6.6 (13.0)a,c,d 25.2 (25.9)d,e
C. Employees with 
unexplained fatigue 
63.7 (29.2)a,d,e 29.5 (28.1)b,d 4.3 (11.2)a,b,d,e 26.0 (26.6)d,e
D. Fatigued patients with   
neuromuscular disease 
41.8 (32.6)b,c 17.8 (24.8)a,b,c 13.6 (18.5)b,c 13.8 (20.1)a,b,c
E. Fatigued patients with  
pancreatitis 
41.1 (33.1)b,c 25.9 (29.8)b 9.1 (13.9)c 14.2 (22.7)a,b,c
F. Non fatigued disease-
free cancer patients 
8.1 (16.3) 6.6 (14.4)g 38.9 (28.3)g 7.7 (17.0)
G. Non fatigued patients 
with neuromuscular 
disease 
9.0 (16.2) 1.7 (7.1)f,h 24.7 (21.3)f,I 5.6 (13.9)
H. Non fatigued patients 
with pancreatitis 
13.3 (28.1) 9.4 (17.8)g 29.2(23.6) 5.2 (12.7)
I.  I. Healthy persons 7.7 (18.3) 3.9 (13.4) 36.2 (23.3)g 3.2 (10.2)
 
 
a. significantly different from group A, Mann-Whitney test p< 0.01 
b. significantly different from group B, Mann-Whitney test p< 0.01 
c. significantly different from group C, Mann-Whitney test p< 0.01 
d. significantly different from group D, Mann-Whitney test p< 0.01 
e. significantly different from group E, Mann-Whitney test p< 0.01 
f. significantly different from group F, Mann-Whitney test p< 0.01 
g. significantly different from group G, Mann-Whitney test p< 0.01 
h. significantly different from group H, Mann-Whitney test p< 0.01 
i. significantly different from group I, Mann-Whitney test p< 0.01 
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Frustrating 
The non-fatigued groups were similar with respect to the mean scores on Frustrating (P = 
0.757). Patients with chronic fatigue syndrome and employees with unexplained fatigue 
scored significantly higher on Frustrating with respect to the other fatigued groups. 
Exhausting 
The non-fatigued patients with various neuromuscular disorders scored significantly lower on 
Exhausting than the non-fatigued cancer survivors and the non-fatigued patients with 
pancreatitis. Between the fatigued groups, CFS patients scored significantly higher on 
Exhausting than the other groups. Furthermore, fatigued patients with pancreatitis scored 
significantly lower with respect to fatigued cancer survivors and employees with unexplained 
fatigue. Additionally, patients with neuromuscular disorders scored significantly lower than 
employees with unexplained fatigue. 
Pleasant 
In the non-fatigued group patients with various neuromuscular disorders scored significantly 
lower on Pleasant than non-fatigued cancer survivors and healthy persons. In the fatigued 
group employees with unexplained fatigue scored significantly lower on Pleasant than the 
other groups. CFS patients scored significantly lower than cancer survivors and patients with 
neuromuscular disorders. 
Frightening 
The scores on Frightening in the non-fatigued groups were similar. In the fatigued groups a 
dichotomy was found between the patients with unexplained fatigue with and without a 
chronic disease. Fatigued patients without a chronic disease (cancer survivors, CFS patients 
and employees) scored significantly higher on Frightening than fatigued patients with a 
chronic disease (patients with a neuromuscular disorder or pancreatitis). 
 
Do perceptions of fatigue change in patients who recover after treatment for fatigue? 
Forty-one fatigued cancer survivors and eighty-two CFS patients were treated for their 
fatigue complaints with CBT at our department and filled out the FQL at pre- and post 
treatment. Sensitivity to change of the FQL was demonstrated by dividing the CFS patients 
and the cancer survivors into two groups: patients who were completely recovered after CBT 
(CIS-fatigue < 35) and patients who remained fatigued after CBT (CIS-fatigue ≥ 35). Baseline 
scores on the four factors were not significantly different between patient who recovered and 
patients who remained fatigued. The scores on the four factors at pre- and post treatment 
were compared. Additionally, we compared the post treatment scores on the four factors with 
the scores of healthy individuals (Table 5). Cancer survivors who were completely recovered 
after CBT (n=27) showed a significant decrease on the factors Frustrating, Exhausting and 
Frightening and a significant increase on the factor Pleasant. The post-treatment scores 
were not significantly different from those of healthy individuals. In contrast, the cancer 
survivors who still remained fatigued after CBT (n=14) did not show a change in the scores 
on the four factors from pre- to post treatment. Furthermore, their scores at post treatment 
were significantly different from the scores of healthy individuals. In investigating CFS 
patients who recovered after CBT (n=47) the same pattern was found. They also decreased 
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significantly on the factors Frustrating, Exhausting and Frightening and increased 
significantly on the factor Pleasant. The scores at post treatment were not significantly 
different from those of healthy individuals. CFS patients who were not recovered after CBT 
(n=35) showed no change between pre- and post treatment scores on the factors Frustrating, 
Exhausting and Pleasant. Although a significant decrease was seen on the factor 
Frightening, the posttreatment scores of the four factors were significantly different form 
those of healthy individuals. 
 
 
 
DISCUSSION 
The present study shows that the FQL provides a self report instrument that assesses the 
perceptions of fatigue. The FQL consists of four coherent factors, namely Frustrating, 
Exhausting, Pleasant and Frightening. The stable pattern of these factors was indicated with 
a confirmatory factor analyses, revealing an invariant internal structure in a second group of 
Table 5 
 
Comparison of pre- and post treatment scores on the four factors. Comparison of the post 
treatment scores with those of healthy individuals 
 
 Frustrating 
 
Exhausting Pleasant Frightening 
 Cancer survivors  
pre-treatment 52.6 (27.8) 27.8 (24.4) 11.1 (14.0) 22.2 (23.3) A non fatigued after 
CBT (n=27) post-treatment 11.9 (23.0)*   5.6 (20.0)* 36.3 (25.4)*   6.5 (11.2)* 
pre-treatment 67.1 (27.9) 46.4 (30.8)   8.6 (17.0) 19.6 (24.4) B still fatigued after 
CBT (n=14) post-treatment 58.6 (34.6) 33.9 (38.7)   7.1 (12.7) 12.5 (19.0) 
 
 
Chronic fatigue syndrome patients  
pre-treatment 60.4 (26.5) 42.0 (31.8)    4.7 (  8.6) 20.2 (22.5) C non fatigued after 
CBT (n=47) post-treatment 11.1 (18.1)*   3.2 ( 8.4)* 32.3 (30.5)*   5.9 (11.9)* 
pre-treatment 57.7 (30.6) 44.3 (35.9)    5.1 (11.2) 24.3 (24.6) D still fatigued after 
CBT (n=35) post-treatment 45.1 (31.2) 30.0 (33.1)    9.1 (17.0) 12.9 (15.3)* 
  
 Healthy individuals  7.7 (18.3)b,d 3.9 (13.4)b,d 36.2 (23.3)b,d 3.2 (10.2)b,d
 
 
CBT = cognitive behaviour therapy 
* significant difference between pre- and post treatment scores, Wilcoxon signed rank test p< 0.01 
a. significantly different from post treatment scores of group A, Mann-Whitney-U test p< 0.01 
b. significantly different from post treatment scores of group B, Mann-Whitney-U test p< 0.01 
c. significantly different from post treatment scores of group C, Mann-Whitney-U test p< 0.01 
d. significantly different from post treatment scores of group D, Mann-Whitney-U test p< 0.01 
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patients. Furthermore, the data of this study show that the FQL has adequate psychometric 
properties. Both the intercorrelations and the correlations of the four factors with the subscale 
CIS-fatigue were not to the extent that the factors could be seen as a parallel test, thus 
supporting the relative uniqueness of each factor. 
The assumption that fatigue is experienced differently by everybody is confirmed with the 
data of this study. Severely fatigued patients had different perceptions of fatigue compared to 
healthy individuals. The healthy persons described fatigue as temporary, relaxing, fulfilling, 
normal and pleasant. None of these adjectives were chosen by 70% of the severely fatigued 
patients. Even patients with similar fatigue severity, appreciated fatigued differently. Different 
patterns were seen on the four factors of the FQL between the different populations of 
patients experiencing fatigue. CFS patients and severely fatigued employees had the highest 
score on the factors Frustrating, Exhausting and Frightening and also the lowest score on the 
factor Pleasant in contrast with the other fatigued groups. Until now the underlying aetiology 
of CFS still remains unclear.21,22 Because the patients can not attribute their fatigue to a 
distinct cause, it’s possible that they are more focussed on their fatigue and perceive their 
fatigue in a more negative way, than the other groups. In agreement with this finding, Moss-
Morris et al.23 found that CFS patients had a more negative view about their symptoms than 
patients with Rheumatoid arthritis (RA). Additionally, Taillefer et al.24 found higher levels of 
illness worry in CFS patients than MS patients who were fatigued. Results of the FQL also 
showed that patients with a current chronic disease experience their fatigue as less 
frightening than patients with no current or a past disease. It is possible that these patients 
attribute their fatigue to their illness and therefore perceive it as less frightening. Cancer 
survivors may experience fatigue as highly anxiety provoking because they can see fatigue 
as a symptom for disease-recurrence. Therefore fatigue can be labelled as frightening.25 
Future research is necessary to examine if the FQL is applicable for individual assessment 
and furthermore investigate what the effect of these different perceptions is on the 
management of fatigue complaints in the clinical practice. 
To reach recovery not only a decrease in fatigue severity is important, it is also important that 
a change in the evaluation of fatigue in the patient occurs. As fatigue is also a part of normal 
health, being recovered also includes feeling tired sometimes. This makes it difficult to 
decide where experiencing fatigue as a sign of illness ends and the experience of normal 
health surfaces. During CBT patients learn that fatigue may occur as part of normal healthy 
life. When a decrease is seen in the fatigue severity of a patient and the evaluation of the 
fatigue stays negative, it implicates that a patients still suffers and is disabled due to the 
fatigue. The patient cannot be seen as fully recovered.26 The results of this study showed 
that the FQL can demonstrate change in fatigue perceptions following treatment of fatigue. 
Patients who were recovered after CBT had the same scores on all four factors compared to 
healthy persons. So, not only the fatigue severity changed after therapy but also the 
evaluation of fatigue. The FQL can therefore be a helpful tool to define full recovery in the 
clinical practice. 
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Appendix A  
 
 
Fatigue Quality List (FQL) 
 
 
 
Fatigue can be described in different ways. The adjectives below can be seen as 
descriptions of fatigue.  
 
Please indicate which adjectives accurately describe the fatigue you experienced during the 
last two weeks by marking them with a cross.   
 
 
 
 
   upsetting      persistent 
   discouraging     frustrating 
   temporary      relaxing 
  exhausting      inexplicable 
   incessant      fulfilling 
   wearisome      insuperable 
   frightening      unbearable 
   annoying      normal 
  extreme      pleasant 
  
 
 
 
 
 
 
 
 
 
FQL: differences in the experience of fatigue      127 
Appendix A continued 
 
 
Scoring Fatigue Quality List (FQL) 
 
 
 
Subsequently the four factors are calculated by summing the respective items (0 – 100): 
 
Factor 1: Frustrating 
Score of each item: 20 
Adjectives: discouraging, incessant, annoying, persistent, frustrating 
 
Factor 2: Exhausting 
Score of each item: 25 
Adjectives: exhausting, wearisome, extreme, unbearable 
 
Factor 3: Pleasant 
Score of each item: 20 
Adjectives: temporary, relaxing, fulfilling, normal, pleasant 
 
Factor 4: Frightening 
Score of each item: 25 
Adjectives: upsetting, frightening, inexplicable, insuperable 
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GENERAL DISCUSSION 
In this final chapter the results of the studies presented in the preceding chapters will be 
placed into the perspective of the existing literature of postcancer fatigue. The literature 
presented is based on two previously written review articles in which postcancer fatigue was 
discussed.1,2 These reviews are updated with manuscripts that appeared since 2005 till May 
2007. The following topics will be discussed:  
1. Fatigue measurements;  
2. The prevalence and course of post-cancer fatigue;  
3. Predisposing, precipitating and perpetuating factors of postcancer fatigue; 
4. Interventions on postcancer fatigue.  
  
1.  Fatigue measurements 
The assessment of fatigue in cancer survivors is beset by a number of methodological 
challenges. Whilst the studies on postcancer fatigue are growing, there is still no universally 
accepted definition of postcancer fatigue. This lack of a commonly agreed on definition of 
fatigue is perhaps the greatest challenge. In the absence of such a definition, it is not 
surprising that there is a lack of consensus about the optimal approach to assessing fatigue. 
As a result, a great variety of self-report techniques are used. To give an indication, in 
studies on postcancer fatigue alone 15 different fatigue questionnaires are used, all 
developed in a time period of about 7 years. Furthermore, fatigue can be assessed in 
different ways. It is possible to use single-item measures, asses fatigue as a general concept 
in multi-item unidimensional measures (sometimes incorporated in other instruments) and in 
a more comprehensive approach in multi-item multi-dimensional measures. 
The purpose of this paragraph is to report on psychometric characteristics of fatigue 
instruments used in studies on postcancer fatigue.3-55 The majority of the information is 
based on three previously written review articles in which assessment measures of  fatigue 
were discussed.56-58 Table 1 gives an overview of a single item fatigue measure, 
unidimensional fatigue measures and multidimensional fatigue measures. Information is 
provided on the characteristics of each fatigue scale, describing the subscales, number of 
items, response format, time frame, the reliability and validity. With regard to the validity, 
questionnaires are mentioned that are associated with the fatigue questionnaire as proof of 
concurrent validity. Good discriminative and sensitivity to change is indicated with a plus (+).  
A minus ( - ) indicates that there is no information available on the validity. In addition, the 
number of studies on postcancer fatigue in which the instrument is used are mentioned.  
 
1.a. Single item measurement 
The Visual Analog Scale-Fatigue (VAS-F) is a single item measurement.59 Very simple and 
quick to complete with minimal burden for the patients and therefore especially useful in the 
clinical setting. Although a commonly agreed on definition of fatigue is lacking, more 
consensus has been derived at the multidimensional concept of fatigue and a single item 
measure does not differentiate between different aspects of fatigue. Furthermore, it cannot 
be evaluated for many forms of statistical reliability.  
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1.b. Multi-item unidimensional measures 
Multi-item unidimensional measures have better psychometric properties than single-item 
measures and provide information about patients’ general level of fatigue severity. In studies 
on postcancer fatigue 5 unidimensional measures are used of which 4 are incorporated in 
other questionnaires.  
The Fatigue subscale of the EORTC QLQ-C30 is used to measure postcancer fatigue  
Although, the EORTC QLQ-C30 is translated in 42 languages and therefore quite 
appropriate for use in multicultural clinical settings,60 the questionnaire is not developed to 
measure fatigue, but to measure quality of life.  
The Short Form-36 (SF-36) is developed for measuring general health status.61 Five studies 
used the subscale Vitality as a measure for postcancer fatigue.7,8,23,45,50 With the SF-36 
Vitality it is possible to identify cases with severe fatigue. In three studies the prevalence of 
fatigue was measured, two studies used the cutoff point of 50 or less as fatigue caseness8,45 
and one used a score of 40 or less.23 You could wonder if the concept of Vitality is the same 
as the concept of fatigue. In our own data we found a correlation between the CIS-fatigue 
and SF-36 Vitality, however not to the extent that the scales could be seen as a parallel test 
(r = -.562, unpublished data). Furthermore, the SF-36 has a very long reference period (4 
weeks), which makes it less appropriate to measure fatigue fluctuations.   
The Profile of Mood State (POMS)62 is developed to measure change in mood states in 
psychiatric outpatients. The subscale Fatigue (POMS-F) is used as an additional 
questionnaire in 3 studies on postcancer fatigue, but not as a primary outcome 
measure.51,52,55 Although the POMS-F is short and easy to use, the questionnaire is less 
adequate because the psychometric properties are untested.58
The Functional Assessment of Cancer Therapy-Fatigue (FACT-F)63 is developed specifically 
in the cancer population. To asses fatigue alone, the brief subscale Fatigue (13 items) may 
be used in isolation of the full FACT-F scale (the subscale is validated independently). To 
assess both fatigue and its consequences the total FACT-F must be used. The Brief Fatigue 
Inventory (BFI)64 is also developed in the area of cancer research. The scale is virtually 
interchangeable with the FACT-F, but the authors claim to use a simpler language and is 
therefore easier to understand and to translate. Also the BFI measures fatigue severity and  
the impact of fatigue. 
 
1.c. Multi-item multidimensional measures 
In measuring only severity or intensity of the fatigue, unidimensional fatigue measures fail to 
capture the full spectrum of the fatigue complaint. To assess fatigue in a more 
comprehensive way, measuring different aspects of fatigue, a multi-item multi-dimensional 
questionnaires is the most appropriate. Most studies assess postcancer fatigue with a 
multidimensional measure. In total 9 different questionnaires are used. In Table 1 the 
dimensions measured by each instrument has been summarized in column two.
  
Table 1 
 
Characteristics and properties of fatigue questionnaires used in studies on postcancer fatigue 
 
Fatigue 
questionnaire 
Fatigue- scale 
(no. items) 
Response 
format 
Time frame Reliability Validity  Used in 
postcancer 
fatigue studies 
 
Single item   
VAS-Fatigue 59 Fatigue severity (1) 10 cm line  Present  0.91 Concurrent validity
Discriminative validity 
Sensitivity to change
: SSS, POMS-F 
:  - 
: + 
One  24
 
Multi-item, incorporated in other instruments 
  
EORTC-QLQ 
C30 60
Fatigue subscale (3) 4-point 
scale 
Past week Fatigue 
subscale: 
0.80-0.85 
Concurrent validity
Discriminative validity 
Sensitivity to change
: + 
: + 
: + 
Two  10,14
SF-36 Vitality 61 Vitality subscale (4) 6-point 
scale 
During the 
past 4 weeks 
 Concurrent validity
Discriminative validity 
Sensitivity to change
: FSI, MFSI 
: + 
: + 
Five  7,8,23,45,50
POMS-F 62 Fatigue-inertia subscale 
(7) 
5-point 
scale 
Past week 
including today
Psychometric properties of  
POMS-F are untested 
Three  52,55 
FACT-F 63 41 items 
General (28)  
Fatigue (13) 
5-point 
scale 
Past 7 days 0.95 Concurrent validity
Discriminative validity 
Sensitivity to change
: POMS-F,  PFS 
:  - 
:  - 
Four  16,22,28,33
 
Unidimensional     
BFI 64 Fatigue Severity  (3) 
Impact of Fatigue (6) 
0-10 scale  Now / Past 24 
hours 
0.96 Concurrent validity
Discriminative validity 
Sensitivity to change
: FACT,   POMS 
: + 
:  -  
Four  9,12,17,31
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 Table 1 continued   
Fatigue 
questionnaire 
Fatigue- scale  
(no. items) 
Response 
format 
Time frame Reliability Validity  Used in 
postcancer 
fatigue studies  
 
Multidimensional    
CIS 66 Experienced fatigue (8) 
Concentration (5) 
Motivation (4) 
Activity (3) 
7-point 
scale 
Past 2 weeks 0.90 Concurrent validity 
Discriminative validity
Sensitivity to change 
: MBI-GS 
: + 
: +  
Nine  3,5,6,11,37,40-
42,44  
MFI 65 General fatigue (4) 
Physical fatigue (4) 
Concentration (4) 
Motivation (4) 
Activity (4)  
5-point 
scale 
Lately /  
previous days 
average 
0.84 
Concurrent validity 
Discriminative validity  
Sensitivity to change
: VAS-F 
: + 
: + 
Seven  5,18,30,32, 
36,46,53
PFS 70 40 items, 7 subscales:  
Temporal, Intensity, 
Affective, Sensory,  
Evaluative, Associated 
symptoms, Relief 
components 
Visual 
analogue 
scale 
0 – 100  
present / today 0.85 Concurrent validity 
Discriminative validity
Sensitivity to change: 
: POMS 
:  -  
:  -  
One  50
R-PFS 72 Behavioural/severity (6) 
Affective meaning (5) 
Sensory (5) 
Cognitive/mood (6) 
10 point 
Likert Scale 
present / today 0. 92 Concurrent validitiy 
Discriminative validity 
Sensitivity to change 
: FQ 
:  -  
:  -  
Four  25,29,38,54
FQ (FRS, CFS, 
FS)73
Physical fatigue (7) 
Mental fatigue (4) 
yes/no & 
4-point 
scale 
Last month 0.85 
0.82 
total : 0.89 
Concurrent validity 
Discriminative validity
Sensitivity to change
: interview :R-CIS 
: +  
: +  
Nine  13,20,21,34,35, 
43,47, 48,49  
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Table 1 continued   
Fatigue 
questionnaire 
Fatigue- scale  
(no. items) 
Response 
format 
Time frame Reliability Validity  Used in 
postcancer 
fatigue studies  
Multidimensional continued   
FSI 74 Fatigue (5) 
Frequency (2) 
Interference (6) 
11-point 
scale  
Past week > 0.94 
 
 
Concurrent validity
Discriminative validity 
Sensitivity to change
: POMS-F,   
SF-36 Vitality 
: +  
: +  
Five  16,26,51,52,55
RSCFS 75 6 items 
Physical  
Perceptual  
5-point 
scale  
In the past 2 to 
3 days 
0.88 
0.81 
total : 0.90 
Concurrent validity
Discriminative validity 
Sensitivity to change
: +  
:  - 
:  -  
One  4
MFSI 76 83 items (SF=30 items) 
General, Emotional, 
Physical, Mental, 
Vigour 
 
5-point 
scale 
In the past 7 
days 
Subscales: 
0.87-0.92 
Concurrent validity
Discriminative validity 
Sensitivity to change
: POMS-F,  
SF-36 Vitality 
: + 
:  -  
Two  19,51
CaFS 77 15 items: 
Physical 
Affective 
Cognitive  
5-point 
scale 
Right now 0.79-0.89 Concurrent validity
Discriminative validity 
Sensitivity to change
: VAS 
:  -  
:  -  
One  39
Other instruments used in this dissertation    
PRISM 79
 
A4 shaped paper 
(=patients’ life) with a 
yellow fixed disk at the 
bottom (=patient), 2 
detachable disks 
(=cancer, fatigue)  
where would you put fatigue / 
cancer to reflect its 
importance in your life at the 
moment 
At this moment 
 Concurrent validity
Discriminative validity 
Sensitivity to change
: Dimensions of 
fatigue 
: + 
: + 
Chapter 7 
evaluates use of 
PRISM in 
fatigue 
research. 
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 Table 1 continued   
Fatigue 
questionnaire 
Fatigue- scale  
(no. items) 
Response 
format 
Time frame Reliability Validity  Used in 
postcancer 
fatigue studies  
Other instruments used in this dissertation   
FQL 80
 
18 adjectives 
characterizing   
fatigue experience 
4 subscales: 
Frustrating 
Exhausting 
Pleasant 
Frightening 
Mark with a 
cross the 
adjectives 
that fit 
fatigue 
experience 
Last two 
weeks 
0.57-0.79 Concurrent validity
Discriminative validity 
Sensitivity to change
: CIS 
: + 
: + 
Chapter 8 
reports about 
the development 
and 
psychometric 
testing of the 
FQL 
 
 
Fatigue questionnaires: VAS – Visual Analog Scale; EORTC QLQ-C30 - European Organization for Research and Treatment of Cancer Quality of Life 
Questionnare-C30; SF 36 – Short Form 36; POMS-F – Profile of Mood State Fatigue; FACT-F – Functional Assessment of Cancer Therapy Fatigue; BFI – Brief 
Fatigue Inventory; CIS – Checklist Individual Strenght; MFI – Multidimensional Fatigue Inventory; PFS – Piper Fatigue Scale; R-PFS – Revised Piper Fatigue Scale; 
FSI – Fatigue Symptom Inventory; RSCFS – Revised Schwartz Cancer Fatigue Scale; MFSI – Multi dimensional Fatigue Symptom Inventory; CaFS – Cancer 
Fatigue Scale; FQL – Fatigue Quality Scale; PRISM – Pictorial Representation of Self and Illness Measure; SSS – Stanford Sleepiness Scale; MBI-GS – Maslach 
Burnout Inventory General Survey; R-CIS – Revised  Clinical Interview Schedule 
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The Checklist Individual Strength (CIS) and the Multi-dimensional Fatigue Inventory (MFI) 
were developed together. However, the MFI is developed in the research area of cancer 
treatment65 and the CIS is developed and well validated amongst patients with chronic 
fatigue syndrome.66-69 The CIS and MFI closely resembles each other. Both questionnaires 
have 20 items and share 18 identical items. Subscales are comparable, however the MFI 
distinguishes the subscales ‘general fatigue’ and ‘physical fatigue’, whereas the CIS 
combines these into one subscale ‘fatigue severity’. The main difference between both 
instruments is the time frame covered. Compared to the CIS, the MFI assesses momentary 
fatigue (previous days). The CIS asks about the last two weeks. In the MFI a 5 point Likert 
scale is used, while the CIS uses a 7 point Likert scale. At this moment more norm data are 
available for the CIS than for the MFI, in chronic fatigue syndrome (CFS) as well as in 
postcancer fatigue. Furthermore, based on research of patients with CFS, cancer survivors 
and healthy controls, a cutoff of the CIS-fatigue is available to measure fatigue caseness 
(CIS-fatigue >= 35).  
The Piper Fatigue Scale (PFS) is developed for the use in research in cancer patients.70 The 
wording of the PFS assumes that the patient is already suffering from fatigue and therefore 
requiring initial screening before use. Besides shortcomings of psychometric qualities, the 
PFS was criticized for its lack of clarity and length, limiting its application with patients who 
are very ill or tired.71 The PFS was therefore revised in 1998.72 This Revised Piper Fatigue 
Scale (RPFS) is shorter and the response format was changed to a Likert scale, making it 
easier to score. Confusingly, this new version is often still referred to as the PFS.  
The Fatigue Questionnaire (FQ) is also referred to as the Fatigue Rating Scale (FRS), the 
Chalder Fatigue Scale (CFS) and the Fatigue Scale (FS). The FQ was developed to 
establish the prevalence of excessive fatigue in the general population or in primary care 
patients.73 The FQ is easily and quickly to complete. Another advantage is the presence of a 
cutoff point to assess fatigue caseness ( >= 4).  
The Fatigue Symptom Inventory (FSI) is developed by Hann et al52,74 in cancer research. 
Besides fatigue severity, the FSI also provides information about the fatigue intensity, 
duration and the interference with various aspects of quality of life.  
The Revised Schwartz Cancer Fatigue Scale (RSCFS)75 is the shortest (6 items) 
multidimensional measure specifically developed for fatigue in cancer patients. However, the 
psychometric properties need further examination. 
The Multidimensional Fatigue Questionnaire (MFSI)76 is based on literature of cancer related 
fatigue, discussions with cancer treatment providers and a survey of available measures of 
fatigue. Although, good psychometric properties, the questionnaire is limited by its length (83 
items) and therefore difficult to complete for already fatigued patients. In response to this 
limitation a short version is developed, the MFSI-Short Form (30 items). 
The Cancer Fatigue Scale (CaFs) is developed based on interviews with cancer patients.77 
The questionnaire can be easily completed in 2 minutes. A score of 18 or higher was found 
to be an optimal cutoff point for fatigue casesness.78 However, the psychometric properties 
need further examination. 
 
General discussion      139 
1.d. Other measures used in this dissertation 
Fatigue research is mostly done by measuring fatigue severity in a quantitative way. In 
Chapter 7 and Chapter 8 two different assessment methods for assessing fatigue were 
introduced.   
The Pictorial Representation of Self and Illness Measure (PRISM) is an instrument which 
assesses suffering caused by an illness.79 In Chapter 7 the use of the PRISM in fatigue 
research was investigated. The PRISM can also be used to investigate the difference 
between suffering of fatigue and suffering of the cancer experience. It may be helpful to 
differentiate between these two underlying causes when managing fatigue.  
Both healthy persons and patients experience fatigue. However, fatigue shows differences in 
the characteristics of the experience of fatigue between healthy persons and patients. In 
addition, the meaning of the fatigue experience may differ between persons. This makes it 
difficult to define fatigue. The Fatigue Quality List (FQL) is developed to investigate these 
different experiences of fatigue between healthy persons and patients, but also between 
different patients groups by use of adjectives80 (Chapter 8). Additionally, the FQL is a helpful 
tool to define recovery in the clinical practice after treatment for fatigue81.   
 
Conclusion 
Given the number and variety of instruments to measure fatigue currently used in studies on 
postcancer fatigue, selecting which tool to use can be a challenge. Clearly, researchers have 
made great efforts to develop fatigue instruments to diagnose or evaluate fatigue severity, 
however at this moment no gold standard is available. In the future fatigue researchers must 
try to reach such a gold standard and should agree about the use of common instruments. 
This would make it easier to compare results of different studies.  
In choosing a questionnaire, it is important to select one that is psychometrically sound and 
validated for the language and cultural setting of the study population. Furthermore, all efforts 
should be taken to ensure that the questionnaire is measuring the concept that the study 
intends to measure. For example, some fatigue measures state they asses fatigue severity, 
but in reality proves to assess the limitations caused by the fatigue. So, read carefully the 
items before selecting a questionnaire (for example “Because of my fatigue complaints, I am 
not able to keep my thoughts on it” compared to “When I am doing something, I can not keep 
my thoughts on it”). Furthermore, the choice of a questionnaire should be closely aligned with 
the goal of measurement, for example research versus clinical assessment. In clinical 
practice, it is important to unravel fatigue systematically rather than waiting until patients 
report the symptoms spontaneously. A cutoff point to differentiate between normal variations 
or a pathological level of fatigue is helping the clinician in his decisions. Also important to 
consider is the respondent burden and possible limitations in processing information. 
Therefore, a brief and simple measurement would be most appropriate to use in a clinical 
setting. In research other standards can apply. The fatigue questionnaire should match the 
research questions being asked. For example, a study focusing on possible cognitive 
manifestations of fatigue should consider use of a measure that includes a mental or 
cognitive scale. The amount of research on the management of postcancer fatigue is 
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growing in the last years. Instruments used in intervention studies must be sensitive enough 
to detect change over time and stable enough to be used repeatedly.  
The CIS, MFI, FQ and the FSI are most used in studies on postcancer fatigue. All these 
questionnaires have good psychometric qualities. The additional value of the CIS and the FQ 
is that these questionnaires have cutoff points to capture the presence of severe and 
clinically important cases of fatigue. These instruments can be used in the individual patient 
to identify severely fatigued patients and also for prevalence estimates in populations. 
 
2. What is known about prevalence and the course of postcancer fatigue? 
In this paragraph the following topics will be discussed:  
2.a. What is the prevalence of postcancer fatigue? (cross-sectional studies) 
2.b. What is the relationship between time since treatment and postcancer fatigue? 
2.c. What is the course of postcancer fatigue?  (longitudinal studies) 
At this moment 7 cross-sectional studies reported about the percentages of cancer survivors 
suffering postcancer fatigue.5,27,34,40,44,45,49 Five longitudinal studies investigated the course of 
postcancer fatigue.6,8,20,23,37  In Table 2 these studies are summarized, describing the mean 
time since treatment, study design, diagnosis and treatment characteristics, patients 
characteristics, prevalence of fatigue, fatigue instrument used and the cutoff point of the 
instrument representing fatigue caseness. The studies are classified in sequence of time 
since end of curative treatment. 
 
2.a. What is the prevalence of postcancer fatigue? 
The cross-sectional study of Servaes et al.40 investigated a sample of  breast cancer 
survivors, in which 38% experienced severe fatigue 2.5 years after cancer treatment. This 
percentage was significantly higher than the incidence of severe fatigue in matched healthy 
volunteers without a history of cancer (11%). Within a large sample of breast cancer 
survivors, 35% reported severe fatigue 2.9 years after treatment.45 In another study of 
Servaes et al. investigating a sample of patients who were treated a mean of 3 years earlier 
for various kind of cancers, 19% experienced persistent severe fatigue.44  Sugawara et al. 
investigated fatigue in breast cancer survivors without major depression.27 Thirty-seven 
percent of the patients exhibited fatigue 4 years after treatment. Thirty-five percent of cancer 
survivors experienced severe fatigue 9.3 years after finishing stem cell transplantation (SCT) 
for leukemia or malignant lymphoma.5 In a sample of Hodgkin’s survivors, with a mean of 12 
years after curative treatment, 26% had substantial fatigue. This percentage was significantly 
higher than the percentage among the general Norwegian population (11%).49  Sixteen 
percent of disease-free testicular cancer patients were identified as having chronic fatigue 12 
years after treatment. Fatigue was more prevalent than in males of the general population 
(10%).34  
In conclusion: The percentages of fatigued cancer survivors found in cross-sectional studies 
ranged from 16%-38%. Three studies demonstrated that the percentage of fatigued cancer 
survivors was significantly higher than the percentage in a control group of persons without 
cancer, which was about 10-11%.  
  
Table 2   
 
Cross-sectional (CS) and longitudinal studies (LS1,2,3,4,5) investigating prevalence of post-cancer fatigue: arranged on time since curative treatment 
 
Study Study 
design 
Time 
since 
treatment 
Diagnosis and treatment Patient characteristics prevalence of 
fatigue 
Measurement /  
Fatigue 
Casesness  (FC) 
Nieboer et al, 
2005 23
LS1 1   year  Breast cancer survivors treated with 
standard-dose chemotherapy or 
high-dose chemotherapy 
N=430, mean age around 45 19% SF 36 – Vitality  
FC ≤  46 
Nieboer et al, 
2005  
LS1 2   years   22%  
Servaes et al., 6 
Chapter 2 
LS2 2.4 years Breast cancer survivors treated with 
surgery and/or radiotherapy and/or 
chemotherapy 
 
N=121, mean age 47 (sd 6) 
subgroup Servaes et al., 2002 40
39% CIS-Fatigue 
FC ≥ 35 
Servaes et al., 
2002 40
CS 2.5 years Breast cancer survivors treated with 
surgery and/or radiotherapy and/or 
chemotherapy 
N=150, mean age 46 (sd 6) 
 
Reference group:  78 women 
without history of cancer, mean 
age 48 (sd 6) 
38% CIS-Fatigue 
FC ≥ 35 
Bower et al., 
2000 45
CS 2.9 years Breast cancer survivors treated with 
chemotherapy and/or radiotherapy 
 
N=1953, mean age 55  35% SF 36 – Vitality 
FC ≤ 50 
Servaes et al., 
2001 44
CS 3   years Cancer survivors with different 
cancer diagnosis treated with 
chemotherapy and/or radiotherapy 
N=85, mean age 48 (sd 14), 60% 
male 
 
19% CIS 
FC ≥ 35 
Bower et al., 
2006 8
LS3 3.5 years Breast cancer survivors treated with 
chemotherapy and/or radiotherapy. 
N=761, mean age around 59 
years  
Subgroup Bower et al., 2000 45
 
34% SF 36 – Vitality  
FC ≤ 50 
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Table 2 continued      
Study Study 
design 
Time 
since 
treatment 
Diagnosis and treatment Patient characteristics prevalence of 
fatigue 
Measurement /  
Fatigue 
Casesness  (FC) 
Sugawara et al., 
2005 27
CS 4    years Breast cancer survivors treated with 
surgery and/or radiotherapy and/or 
chemotherapy 
N=79, mean age 48 (sd 6) 37% CFS 
FC ≥ 18 
Servaes et al.   
Chapter 2 
 
LS2 4 .5 years   23%  
Servaes et al., 
2003 37
LS4 6    years Cancer survivors with bone and soft 
tissue tumours, (malignant and 
benign tumours) treated with surgery 
and/or radiotherapy and/or 
chemotherapy 
N= 71 malignant tumour, mean 
age 43 (sd15),  54% male 
 
N= 99 benign tumour, mean age 
34 (sd13), 53% male 
28% CIS-Fatigue 
FC ≥ 35 
Bower et al., 
2006  
 
LS3 6.3 years   21%  
 
Servaes et al., 
2003 
 
LS4 8    years   26%  
 
Hjermstad et al., 
2005 20
LS5 8    years Hogkin’s disease survivors treated 
with radiotherapy and/or 
chemotherapy. 15 patients 
underwent a SCT 
N=476, median age 46, 56% male 28% FQ 
FC ≥ 4  on 
dichotomized 
scale 
Hjermstad et al., 
2005 20
LS5 8    years Hogkin’s disease survivors treated 
with radiotherapy and/or 
chemotherapy. 15 patients 
underwent a SCT 
N=476, median age 46, 56% male 28% FQ 
FC ≥ 4  on 
dichotomized 
scale 
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Table 2 continued     
Study Study 
design 
Time 
since 
treatment 
Diagnosis and treatment Patient characteristics prevalence of 
fatigue 
Measurement /  
Fatigue 
Casesness  (FC) 
Gielissen et al., 
2007 5  
Chapter 6 
CS 9.3 years Cancer survivors diagnosed with 
acute/chronic leukaemia, lymphoma 
treated with a SCT 
 
N=98, mean age 45 (sd 11), 58% 
male 
  
35% CIS-Fatigue 
FC ≥ 35 
Loge et al., 
1999 49
CS 12 years Hodgkin’s disease survivors treated 
with radiotherapy and/or 
chemotherapy  
N=459, mean age 44 (sd 12),  
56% male  
 
Reference group: N=2214 general 
population, mean age 45 (sd 17), 
49% male 
 
26% FQ 
FC ≥ 4  on 
dichotomized 
scale 
Fosså et al., 
2003 34
CS 12 years Testicular cancer survivors, 
41% had postorchiectomy 
radiotherapy 
39% had postorchiectomy 
chemotherapy 
 
N=791, median age 44 
 
Reference group: 1112 males of 
general population 
 
16% FQ 
FC ≥ 4  on 
dichotomized 
scale 
Hjermstad et al., 
2005 
 
LS5 16 years 
 
  25%  
 
 
Fatigue questionnaires:  CIS-Fatigue - Checklist Individual Strength subscale Fatigue;    SF 36 Vitality –Short Form 36 Health Survey,subscale Vitality;    
CFS - Cancer Fatigue Scale;    FQ- Fatigue Questionnaire. 
SCT : stem cell transplantation 
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2.b. What is the relationship between time since treatment and postcancer fatigue? 
Seven studies found no association with postcancer fatigue and time since 
diagnosis.16,32,45,47,49,51,52  One study did report an association between the time since 
diagnosis of haematological malignancy and fatigue, with those more recently diagnosed 
experiencing more fatigue.38 Thirteen studies found no association with time since end of 
treatment.5,6,19,20,27,28,34,36,43,44,46,47,50 Hann et al. found that the longer the time elapsed since 
bone marrow transplantation in breast cancer survivors, the more severe fatigue occurred.55
In conclusion: Most studies did not find an association between postcancer fatigue and time 
since end of treatment or time since diagnosis.  
 
2.c. What is the course of postcancer fatigue? 
A longitudinal study of Nieboer et al. demonstrated that fatigue levels before cancer 
treatment were similar with those observed 1, 2 and 3 years after this baseline assessment.23 
All patients had completed chemotherapy at the 1 year time point. Approximately 20% of 
women were classified as fatigued at each assessment point. In a study of Servaes et al. 
39% of the breast cancer survivors experienced severe fatigue at 2.4 years post treatment.6 
After a follow-up period of 2 years 23% of the original group of patients were persistent 
severely fatigued, demonstrating a decrease of 16%.  Bower et al. showed that within a large 
sample of breast cancer patients 34% experienced fatigue at 3.5 years after cancer 
treatment, this percentage decreased to 21% six-and-a-half years after cancer treatment.8 In 
a sample survivors of bone and soft tissue tumors Servaes et al found that the percentage of 
severe fatigue remained about equal, 28% (6 years after treatment) to 26% (8 years after 
treatment).37 Hjermstad et al. found in a large study that 28% of Hodgkin’s survivors 
experienced fatigue 8 years after treatment. This percentage remained about equal after a 8 
year follow-up (16 years after treatment), namely 25%.20  
In conclusion: The percentages of fatigued cancer survivors found in longitudinal studies 
ranged from 19%-39%. A longitudinal design is the most methodologically sound approach to 
determine the temporal variability of postcancer fatigue; the same group of cancer survivors 
are measured with the same fatigue questionnaire at two different time points. Because 
costly in terms of both time and resources, most researchers use a cross-sectional design to 
determine the prevalence and/or course of postcancer fatigue. At this moment there are only 
5 longitudinal studies. 
 
Conclusion 
Postcancer fatigue is an important problem for a considerable subgroup of cancer survivors. 
The percentages of fatigued cancer survivors found in all studies ranged from 16%-39%. 
Setting these studies against time since end of curative treatment, demonstrates that there is 
a recovery of fatigue during the first 3 – 4 years after curative treatment after which it remains 
a persistent problem for about a quarter of the cancer survivors.  
There are three exceptions in this pattern. The first exception is found in the results of the 
study of Nieboer et al.23 Bower wrote an editorial as reaction on this paper.82 Besides the 
merits of the study, like the study design (before and yearly after randomisation), Bower also 
made some critical comments. The percentage of patients who were categorized as fatigued 
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was quite low, and the mean levels of fatigue were comparable with Dutch population norms. 
These results might lead one to conclude that fatigue is not a significant problem among 
cancer survivors. However, in other studies considerable higher percentages of cancer 
survivors with persistent fatigue were found (see Table 2). In addition, there are also studies 
that have shown that fatigue is more prevalent in cancer survivors than in persons without a 
history of cancer.34,40,49  Bower indicates that women in the study of Nieboer et al. were 
participants in a clinical trial and may not be representative of the broader population of 
cancer patients. In addition, the cutoff point used to classify fatigued patients in this study 
was more stringent than used in previous research (SF-36 Subscale Vitality < = 46, instead 
of < = 50), which may have restricted the size of the fatigued group. Servaes et al. found 3 
years after cancer treatment a lower percentage than expected, 19% of the cancer survivors 
experienced severe fatigue.44 Because this study has been conducted in our research centre 
we know the shortcomings of this study. The sample probably does not represent a well 
balanced cancer survivors population. It might be that patients without fatigue were more 
inclined to participate. In contrast, the results of Chapter 6 demonstrated that the percentage 
of patients with fatigue is higher than expected, 35% of the cancer survivors experience 
severe fatigue even 9 years after treatment.5 However, this result is in agreement with the 
assumption that patients with more aggressive treatments are more at risk for persistent 
fatigue.6,8,37,54 For more definitive conclusions, a longitudinal design in this particular group is 
necessary.  
In conducting research on postcancer fatigue the importance of a comparison group should 
be kept in mind. Since fatigue is a common symptom in the general population, some frame 
of reference is necessary in order to evaluate data on postcancer fatigue. Additionally, more 
longitudinal studies that assess patients before, during and after cancer treatment are 
necessary to determine more accurately the prevalence of fatigue in cancer patients and to 
identify the exact course of fatigue. This kind of research will enable us to calculate how 
many patients begin treatment with significant fatigue, how many develop fatigue during 
treatment and how many experience persistent fatigue long after cancer treatment 
completion. This kind of research will also enable us to identify those cancer patients most at 
risk for postcancer fatigue. 
 
3. Predisposing, Precipitating and Perpetuating factors of postcancer fatigue 
For a better understanding of postcancer fatigue we used the model of predisposing, 
precipitating and perpetuating factors. In this model particular factors in a patient’s life can 
lay the groundwork for, initiate or maintain the process of persistent fatigue. The 
predisposing factors are the characteristics of a patient that enhance the chance to develop 
fatigue as soon as a precipitating factor is present. Precipitating factors trigger the onset of 
fatigue in cancer patients. The perpetuating factors are factors that maintain the fatigue over 
time. In this paragraph the existing literature on the three factors of the model will be 
discussed. Because the focus of this dissertation is on postcancer fatigue, the emphasis in 
this paragraph will also be on the perpetuating factors of postcancer fatigue and therefore will 
be discussed more elaborately than the other two factors. 
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3.a. Predisposing factors 
Studies investigating predisposing factors of postcancer fatigue are difficult to conduct. In 
order to examine predisposing factors of postcancer fatigue, large prospective studies are 
needed investigating people in the general population, subsequently look into those patients 
who develop cancer. These patients need to be followed during and long after cancer 
treatment to explore which patients develop postcancer fatigue. These kind of studies are 
nearly impossible. Until now the well known large cohort studies never focused on fatigue. 
To our knowledge, there are only two prospective studies trying to examine predisposing 
factors of postcancer fatigue by investigating patients just before cancer treatment, just after 
cancer treatment and long after cancer treatment ended. Smets et al. investigated possible 
predictors of persistent fatigue by assessing patients before, within two weeks of completion 
of radiotherapy and 9 months after radiotherapy.53 The degree of fatigue, functional disability 
and pain before radiotherapy started were the best predictors of fatigue at 9 months follow-
up, explaining  30%, 3% and 4% of the variance respectively. Geinitz et al. evaluated fatigue 
8 days before radiotherapy, after radiotherapy, 2.5 years after treatment and found that 
patients who had elevated levels of fatigue, anxiety or depression at pre-treatment, were at 
risk for fatigue 2.5 years after radiotherapy, explaining 60% of its variance.83  
A cross-sectional study of Loge et al. found that retrospective self-reported psychiatric 
symptoms before and during cancer treatment were no predictors of postcancer fatigue.48  
Furthermore, two studies found that women were more prone to experience postcancer 
fatigue than men.47,53 However, in nine studies this relationship was not 
found.5,16,20,25,36,37,43,44,48  
In conclusion: There is some evidence that fatigue, functional disability, pain, anxiety and 
depression before cancer treatment are predictors of postcancer fatigue. However, we could 
wonder if the variables discussed (except for gender), are really predisposing factors of 
postcancer fatigue. The moment of assessment was just before treatment and the patients 
were already diagnosed with cancer. Therefore, it is impossible to differentiate if the studies 
are measuring predisposing factors or already disease related variables.  
 
3.b Precipitating factors 
Fatigue is one of the most common complaints of people with cancer. It affects the majority 
of patients actively undergoing cancer treatment, with proportions of as high as 99% having 
been reported.1,2 It is generally accepted in clinical practice that fatigue complaints during 
cancer treatment are a result of the cancer and/or its treatment. However, the studies on this 
topic do not easily identify fatigue-related factors and contradictory results exists on each 
factor.1,2 Factors thought to be involved among others are: the anti-cancer treatment, 
anaemia, cancer treatment side effects like nausea and vomiting, metabolic and endocrine 
alterations, emotional distress, sleep disturbances, prolonged inactivity, pain and infections.  
In conclusion: It is clear that fatigue originates in the time period of diagnosis and anti-cancer 
treatment. Though the exact determinants of the onset of the fatigue is still poorly 
understood, its multifactorial nature seems to be generally acknowledged. There is the 
primary influence of the tumour on the organs involved. Second, secondary effects of the 
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tumour, like anemia, can play a role. Third, the anti-cancer treatment can be an important 
cause of fatigue, and finally, psychological factors like anxiety, emotional distress, 
depression can lead to complaints of fatigue.1,2,84-86   
 
3.c Perpetuating factors 
Are disease and/or treatment characteristics related to postcancer fatigue? 
Once fatigue has developed, several maintaining factors can impede recovery. Starting from 
the hypothesis that postcancer fatigue is initially caused by the cancer itself and/or cancer 
treatment, many studies investigated the association between postcancer fatigue and initial 
disease and treatment characteristics. The majority of the studies found no association 
between postcancer fatigue and cancer type (head and neck, gastrointestinal, 
gynaecological, lung, breast, prostate, testis, Hodgkin’s disease, Non-Hodgkin’s lymphoma, 
acute leukaemia, bone and soft tissue tumours),5,28,32,37,44,46,53  disease stage at time of 
diagnosis,20,39,47-53  size of original tumour,39,52,55  nodal involvement,27,39,55  the cancer 
treatment received (e.g. type of treatment, regime, dose, cycles, length of treatment, 
treatment burden).5,6,8,16,20,22,27,32,34,39,40,44, 46,47,49,50-53,55,86,87 However, five studies found a 
positive association between postcancer fatigue and intensity of cancer treatments.5,6,8,37,54  
Servaes et al. found a relation between persistent fatigue and duration of cancer treatment.6  
Patients who finished treatment within 1 month were less fatigued than patients of whom the 
treatment proved to be longer than 1 month. This is in agreement with the results of another 
study of Servaes et al. in which a relation was found between post-treatment fatigue and 
number of former operations.37 Patients whose surgery had been without complications and 
who had not received any adjuvant therapy were less at risk of developing severe fatigue 
than other patients. Bower et al. showed in a longitudinal study that women treated with 
either radiation or chemotherapy alone showed a small improvement in fatigue compared 
with patients who received a combination treatment of both radiation and chemotherapy.8 
This finding is in agreement with the results of Woo et al. who found that patients who 
received combination therapy had the highest fatigue scores.54 In a cross-sectional study of 
Gielissen et al. no natural recovery of fatigue was found, even up to 15 years after finishing 
SCT.5 The percentage of survivors experiencing postcancer fatigue remained high.  
Two studies found an association between postcancer fatigue and the presence of B-
symptoms during cancer treatment20,36 (B-symptoms: fever; drenching sweats, especially at 
night; unintentional weight loss of >10% of normal body weight over a period of 6 month or 
less). 
In conclusion: Previous disease and treatment characteristics are unrelated to postcancer 
fatigue. However, there is some evidence that patients who are treated with only a surgery 
are less at risk for postcancer fatigue and survivors who are treated with more aggressive 
treatments are more at risk. 
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Are demographic variables related to postcancer fatigue? 
Nine studies found an association between postcancer fatigue and age.19,25,34,36,38,45,48,54,87  
On the contrary, ten studies did not find such relationship.5,8,16,27,32,37,43,51-53,55 The relation 
between age and fatigue is complicated by an inconsistency in the direction of the 
association. Five studies found that older survivors experience more fatigue,25,34,36,38,48  
whereas four studies reported that younger survivors experience more fatigue.19,45,54,87  
Only a few studies found that education,48,50  income25,38,50 and marital status25 were related 
to fatigue, most studies did not find such relationship. 
In conclusion: There is no clear relationship between demographic characteristics and 
postcancer fatigue. 
 
Is current somatic co-morbidity related to postcancer fatigue? 
As a consequence of cancer treatment, survivors can be at risk for a number of long term 
side effects, some of which may contribute to the persistence of fatigue. Servaes et al. found 
that fatigue severity was predicted by the number of oncological complications after cancer 
treatment.37 Hodgkin’s disease survivors with pulmonary dysfunction were more fatigued 
than those with normal pulmonary function.43,47  In addition, two studies found an association 
with fatigue and cardiac problems.8,16 However, Knobel et al. did not find such relationship.43 
Three studies did not detect an association between well treated hypothyroidism and 
postcancer fatigue.16,43,47 This finding is not surprising, because a well treated hypothyroidism 
is even not an exclusion criterion for the diagnosis of chronic fatigue syndrome.89  
Women often become menopausal as a result of chemotherapy. Menopausal symptoms 
seem to be both more prevalent and more severe in cancer survivors than in healthy 
women90,91 and is associated with postcancer fatigue.6,22,30,45,51  Current tamoxifen use was 
unrelated to fatigue severity.6,819,22,27,45,51,52,55,87  
Patients with current co-morbidity (related or unrelated to the cancer treatment) were 
significantly more fatigued than patients without co-morbidity.5 Gielissen et al. found no 
difference in fatigue between survivors without medication, with antibiotics or with beta 
blockers.5 In contrary, Ng et al. found that medications for a mood disorder was an 
independent factor for Hodgkin’s disease survivors in explaining fatigue.16
In conclusion: Current co-morbidity, related as well as unrelated to the previous cancer 
treatment, might be a factor in the persistence of the fatigue.  
 
Is depression related to postcancer fatigue? 
All studies examining the association of depression to fatigue concluded that a relationship 
exists1,2,8,19  This suggest that fatigue is closely linked to depression in cancer survivors. 
Does this also mean that depression is the explanation of postcancer fatigue?  
First, it is important to realize that all studies that found an association between postcancer 
fatigue and depression used a depression questionnaires and did not diagnose a clinical 
depression with the DSM IV criteria assessed by a psychologist or psychiatrist.  This means 
that there is a positive association between depressive mood and postcancer fatigue. But if 
there may be a relation between clinical depression and postcancer fatigue has not been 
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answered by the existing literature. Second, the association between fatigue and depression 
is complex. Fatigue can occur as a symptom of depression or may precipitate feelings of 
depression because of its interference with mood, work and leisure activities. In agreement 
with this last viewpoint, some studies show that fatigue in cancer survivors could not be 
explained by depression alone. Servaes et al. reported that 12% of a group fatigued breast 
cancer survivors could be considered clinically depressed.40 This was measured with the 
Beck Depression Inventory for primary care (BDI-pc). The BDI-pc is composed of cognitive 
and affective items only to prevent an overlap between the physical aspects of fatigue with 
the somatic symptoms of depression.92 Still in 88% of the severe fatigued patients no 
diagnosis of depression could be made. In another study the breast cancer group and benign 
breast problems group did not differ with regard to depressive symptoms, while they did differ 
with respect to fatigue scores.50 Also Sugawara et al. found that a significant portion of 
cancer survivors without clinical depression experienced fatigue.27 In this last study, the 
diagnosis of past and current clinical depression was based on a semi structured clinical 
interview conducted by a psychiatrist (SCID).  
In conclusion: There is an association between depressive mood and postcancer fatigue. 
However, the majority of severely fatigued cancer survivors is not clinically depressed. 
Therefore, clinical depression is not a frequent perpetuating factor of postcancer fatigue.  
 
Other possible  perpetuating factors 
All studies that examined the association of anxiety to fatigue concluded that a relationship 
exists.1,2,6,8,19,27 Like depression, it is important to realize that all studies that found an 
association also used an anxiety questionnaires and did not diagnose anxiety disorders with 
the DSM IV criteria. Typically, feelings of anxiety in cancer survivors are higher than before 
the diagnosis, especially when a follow-up visit draws near.93  In some patients anxiety levels 
may be continually and excessively elevated. There is evidence that a subgroup of fatigued 
cancer survivors experience excessive fear of disease recurrence.5,19,37  
Some fatigued survivors coped poorly with the experience of having had cancer and cancer 
treatment. They continue to be (pre)occupied with what has happened to them (long) after 
the anti-cancer treatment has finished, exhibiting posttraumatic stress symptoms5,94  
Furthermore, severely fatigued cancer survivors tend to attribute their complaints to their 
having had cancer or to the subsequent treatment they have undergone. These somatic 
attributions can perpetuate the fatigue.3,5,37,40 Literature shows us that fatigued cancer 
survivors more frequently revert to ‘catastrophising’ as their coping strategy. Fatigue-related 
catastrophising cognitions sustain or even magnify the complaints.5,51  Self-efficacy, reflecting 
the extent to which a patient feels or thinks to be able to control his symptoms, may also be 
implicated and appears pivotal in cancer survivors, in whom a low or negative self-efficacy 
has been related to increases in fatigue levels.5,6,40  This relationship was also found in 
patients with chronic fatigue syndrome and in fatigued patients with multiple sclerosis.95  
Results of a study of Sugawara et al. demonstrated that fatigue in breast cancer survivors 
without depression was mainly predicted by neuroticism, explaining 25% of the variance.27 
On the contrary, two studies did not find an association between neuroticism and fatigue.19,53  
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Persisting sleep problems, irregular sleep patterns, poor quality of sleep is significantly 
related to postcancer fatigue in many studies.5,6,40,45,50,51,53,55,87  
Pain was reported in 4 studies.30,44,45,52 In these studies fatigue was significantly associated 
with pain. Servaes et al. demonstrated that patients with chronic fatigue syndrome reported 
more intense pain compared to fatigued cancer survivors.44
Significant associations between severe fatigue and self-reported physical functioning and 
physical activity was found in several studies.5,6,16,25,28,32,40,44,52,53 Worse physical functioning 
and lack of activity was associated with more fatigue. Here, a fear that activity will aggravate 
the fatigue may be implicated. However, some survivors can be physically overactive, an 
overly active patient tends to overtax himself continuously, with all the consequential physical 
and emotional adverse effects. Both over and inactivity may perpetuate the symptoms of 
fatigue.42,96 In addition, Young et al. found that negative beliefs about activity was 
significantly associated with fatigue.19  
Severely fatigued cancer survivors experienced an insufficiency of supporting interactions 
compared to non-fatigued cancer survivors.40  They have less social support than they would 
like. Lack of social support is a strong predictor for worse quality of life in cancer survivors.97
In conclusion: Anxiety, poor coping with cancer/cancer treatment, somatic attributions, 
catastrophizing, self-efficacy, sleep problems, pain and physical (in)activity, insufficiency of 
social support can perpetuate postcancer fatigue. 
 
Conclusion 
The reviewed studies in this paragraph support the model of  predisposing, precipitating and 
perpetuating factors of postcancer fatigue. Disease and treatment characteristics have been 
demonstrated to be unrelated to the severity of the postcancer fatigue. The proposed 
precipitating factors for fatigue occurring during cancer treatment, i.e. the disease itself and 
its treatment, do no longer explain the persistent post-treatment fatigue (except there is some 
evidence for a positive relation between postcancer fatigue and intensity of the cancer 
treatment). Other factors seem to be much more important in perpetuating fatigue. Therefore, 
these factors should be the main target in the management of somatically unexplained 
postcancer fatigue. 
 
4. Interventions to reduce post-cancer fatigue 
Given the adverse effect of fatigue on the life’s of cancer survivors development of 
interventions is critical. Especially because the population of cancer survivors is growing. 
Fortunately, the amount of research on the management of post-cancer fatigue increased 
considerably in the last years. Including papers on interventions in which survivors were a 
mean of 6 months after cancer treatment, 15 papers were found. All papers were published 
between 2003 and 2007. Two papers were published in 2003, two in 2004, three in 2005, 
seven in 2006 and at the time of writing one in 2007. Nine studies were pilot studies on 
management of postcancer fatigue. In this paragraph these published interventions for post 
cancer fatigue will be discussed. 
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4.a. Randomised controlled trials 
Randomized controlled trials (RCT’s) are widely considered the most reliable form of 
scientific evidence in assessing the effectiveness of interventions. Seven RCT’s investigated 
the effect of an intervention on postcancer fatigue, measured as a primary or secondary 
outcome. In Table 3 the seven RCT’s are elaborately described. Information is given on the 
content and duration of the intervention, patient’s characteristics, number of assessments, 
fatigue questionnaire used and the effect of the intervention on fatigue. 
Two RCT’s found positive effects in reducing fatigue. Pinto et al. investigated the effects of a 
home-based physical activity program24 and showed a beneficial effect on fatigue, with an 
effect size of 0.64. Cognitive behaviour therapy (CBT) especially designed for postcancer 
fatigue was found to be an effective treatment for cancer survivors with somatically 
unexplained fatigue (effect size 1.05; Chapter 4).11 This latter study is the only RCT that 
analyzed the data by intention to treat. The uncontrolled follow-up results described in 
Chapter 5 indicate that the positive results of CBT were maintained in patients who 
completed CBT after a mean follow-up period of about 2 years (effect size 1.7).  
Five RCT’s did not find positive effects in reducing fatigue. Courneya et al. reported on the 
efficacy of individualized aerobic training.33 Fatigue was measured as a secondary outcome. 
Although cardiopulmonary function increased, no significant change on fatigue was found. 
Basen-Engquist et al. investigated in a pilot study the effect of a lifestyle physical activity 
group program. The lifestyle group had significantly better physical endurance, however no 
increase was seen in physical activities. Also no effect was found on fatigue.7  
Bennet et al. evaluated the effect of a motivational interviewing (MI) on increasing physical 
activity and improving fatigue, measured at three time points (baseline, 3- and 6 months 
follow-up).4 The results of the MI intervention showed a significant increase in regular 
physical activities, but no improvement on fatigue could be found.  
Molassiotis et al. conducted a RCT and found that a two-week acupuncture program (and to 
a lesser extent acupressure) showed beneficial effects on fatigue compared with sham 
acupressure.15  However, after a two-week follow-up period this effect disappeared. In this 
study no data were collected about the exact time since end of cancer treatment (personal 
communication) and it was not possible to calculate the effect sizes. A second pilot study 
found no on effect on fatigue of a 7-week yoga programme.10
 
 
152     C
hapter 9 
Table 3   
Interventions on postcancer fatigue: content and duration of the intervention, patients characteristics, number of assessments, fatigue questionnaire used and 
the effect of the intervention on fatigue (Effect sizes /  ES) 
 
Intervention Patients characteristics Assessment 
content duration group (n); 
individual 
Specific 
characteristics  
patients  
(n) 
mean 
age in 
years 
time after 
diagnosis or 
treatment in 
months 
number of 
assessments 
fatigue 
instrument 
 
Effect 
on 
fatigue  
 
(1) Intervention:   
Exercise training on cycle ergo 
meters. 
15 minutes exercise for week 1 
through 3 and then 
systematically increased by 5 
minutes every 3 weeks 
thereafter to 35 minutes for 
weeks 13 through 15.  
 
Control:  
Waiting list condition 
 
 
 
3 times a 
week for 
15 
weeks 
 
 
individual 
 
 
breast cancer 
survivors 
  
 
 
I : 24 
 
C: 28  
 
 
59 (sd 5) 
 
58 (sd 6) 
 
Treatment: 
14 (sd 6) 
 
14 (sd 7) 
 
Two : 
T1: baseline 
 
T2: 15 weeks  
after baseline 
 
 
secondary 
outcome : 
FACT- FS 
 
no 
effect 
on 
fatigue 
 
 
 
 
 
(2) Intervention: 
Home-based physical activity 
program. Survivors were 
encouraged to exercise 10 
minutes on 2 days a week, 
then increased over the 12 
weeks to 30 minutes per day 
on 5 days per week.   
 
12 
phone 
calls in 
12 
weeks  
 
 
 
individual 
 
within 5 years of 
breast cancer   
diagnosis 
 
sedentary survivors: 
exercised  <  one time 
per week for 20 
minutes at vigorous 
intensity or  
 
I : 42 
 
C: 40 
 
 
 
53 (sd 9) 
 
53 (sd10) 
 
 
 
Diagnosis: 
20 (sd 18) 
 
23 (sd 17) 
Two: 
T1: baseline 
 
T2: 12 weeks  
after baseline 
 
Visual 
Analog 
Scale -  
10 cm 
 
 
effect 
on 
fatigue 
 
ES: 
0.64 
 
 
            
 Table 3 continued          
Intervention   Patients characteristics   Assessment   
content duration group (n); 
individual 
Specific 
characteristics  
patients  
(n) 
mean 
age in 
years 
time after 
diagnosis or 
treatment in 
months 
number of 
assessments 
fatigue 
instrument 
 
Effect 
on 
fatigue  
Study 2 continued          
Control: 
Were asked not to change 
their current level of activity. 
Phone calls to monitor 
problems that can affect 
normal activity of daily life 
12 
phone 
calls in 
12 
weeks 
 < two times per week 
for 30 minutes at 
moderate intensity for 
the past 6  
months 
      
 
(3) Intervention: 
Cognitive behaviour therapy  
focused on perpetuating 
factors of postcancer fatigue; 
poor coping with 
cancer/treatment, fear of 
disease recurrence, 
dysfunctional cognitions 
regarding fatigue, 
dysregulation of sleep and 
activity and low social support. 
 
Control: 
Waiting list condition 
 
 
13 
sessions 
of 60 
min in  6 
months  
 
 
individual 
 
 
Survivors who 
experienced 
somatically 
unexplained severe  
fatigue : CIS >=35   
 
completed curative 
treatment for cancer 
at least 1 year 
 
49% female 
 
cancer types: 31% 
breast, 26% testicular, 
17% hematologic, 
26% other solid 
tumors 
 
 
I : 50 
 
C: 48 
 
 
45(sd10) 
 
45(sd10) 
 
 
 
treatment: 
66 (sd 52) 
 
55 (sd 41) 
 
 
Three: 
T1: baseline 
 
T2: 6 months 
after baseline 
 
T3: 1.9 years 
after T2  
 
 
CIS- 
fatigue 
 
 
effect  
on 
fatigue 
 
T2 : 
ES: 1.1 
 
T3:  
ES: 1.7 
          
          
G
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Table 3 continued          
Intervention   Patients characteristics   Assessment   
content duration group (n); 
individual 
Specific 
characteristics  
patients  
(n) 
mean 
age in 
years 
time after 
diagnosis or 
treatment in 
months 
number of 
assessments 
fatigue 
instrument 
 
Effect 
on 
fatigue  
 
(4) Life-style physical activity 
intervention:  
teaching cognitive behavioural 
skills  related to exercise 
 
Guided discussion cancer- 
related topics 
 
Written informational material 
was  provided 
 
Control:  
Standard care plus two 
mailings of the same written 
material. 
 
 
 
21 
sessions 
of 90 
min. in 6 
months 
 
 
 
group;  
7 – 15  
 
 
 
within 7 years of 
breast cancer 
diagnosis  
 
not engaged in 
moderate physical 
activity for 30 minutes    
or more a day most 
days of the week 
 
 
 
I : 35  
 
C: 25 
 
 
 
56(sd11) 
 
54(sd12) 
   
 
 
diagnosis: 
39 (sd17)  
 
37 (sd. 14) 
 
Two: 
T1: baseline 
 
T2: 6 months    
after baseline 
 
 
SF-36 
Vitality  
 
 
no 
effect 
on 
fatigue 
 
 
 
(5) Intervention:  
Yoga according to a strict yoga 
protocol 
 
 
 
 
Control:  
Waiting-list condition 
  
 
? 
sessions 
of 75 
min. in 7 
weeks  
 
 
group; 
max. 10 
 
 
minimum of 3 months 
post treatment  
 
95% female 
 
85% breast cancer 
survivors 
 
 
I : 20 
C: 18 
total 38 
 
 
+/- 50  
 
diagnosis: 
+/- 56  
 
Two: 
T1: baseline 
 
T2: 7 weeks 
after baseline 
 
 
Subscale 
fatigue of 
EORTC 
QlQ-C30  
 
 
no 
effect 
on 
fatigue 
 
          
    
 
      
         
 
  
Table 3 continued          
Intervention   Patients characteristics   Assessment   
content duration group (n); 
individual 
Specific 
characteristics  
patients  
(n) 
mean 
age in 
years 
time after 
diagnosis or 
treatment in 
months 
number of 
assessments 
fatigue 
instrument 
 
Effect 
on 
fatigue  
 
(6) Intervention: 
Motivational interviewing, to 
help to explore solutions to 
behavioural change to engage 
in moderate-intensity planned 
physical activity for 30 minutes 
on most days of the week 
 
 
Control: 
Were asked to maintain their 
current levels of physical 
activity. The calls were used to 
set times for measurement 
appointments and for brief 
social conversation. 
 
 
one 
session 
inperson 
2 phone 
calls of 
20 min in 
4.5 
months 
 
 
2 phone 
calls in 
4.5 
months 
 
 
individual 
 
 
survivors who 
experienced fatigued 
 
were under active: 
engaged in  planned 
exercise < 3 days a 
week for 20 minutes  
 
89%  breast cancer 
survivors 
 
 
I : 28 
 
C: 28 
 
 
56 (sd 9) 
 
60 (sd11) 
 
treatment: 
34 (sd 31) 
 
50 (sd54) 
 
Three: 
T1: baseline 
 
T2: 3 months 
after baseline 
 
T3: 6 months 
after baseline 
 
Schwartz 
Cancer 
Fatigue 
Scale 
 
no 
effect 
on 
fatigue 
 
(7) Intervention: 
Acupuncture: Based on the 
Traditional Chinese Medicine, 
points for ‘energy’ were 
punctured 
 
 
6 
sessions 
of 20 
min. in  
2 weeks 
 
 
individual 
 
 
 
 
 
 
survivors who 
experienced moderate 
to severe fatigue: 
≥ 5 on a 0 – 10 scale 
 
68% female 
 
I : 15 
 
 
 
 
53 (sd13) 
 
 
post chemo 
and up to 5 
years after 
diagnosis  
Three: 
T1: baseline 
 
T2: 2 weeks 
after baseline 
G
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MFI 
 (20 items) 
 
 
effect 
of both 
interve
ntions 
on 
fatigue 
at T2  
          
           
  
Table 3          
Intervention   Patients characteristics   Assessment   
content duration group (n); 
individual 
Specific 
characteristics  
patients  
(n) 
mean 
age in 
years 
time after 
diagnosis or 
treatment in 
months 
number of 
assessments 
fatigue 
instrument 
 
Effect 
on 
fatigue  
Intervention 7 continued          
Acupressure:  
Survivors were taught to 
massage/press the points that 
are associated with ‘energy’ 
 
one 
session, 
daily 
1min at 
home 
 cancer types: 36% 
lymphoma, 32% 
breast, 15% 
gastrointestinal, 11% 
lung, 4% 
gynaecological, 2% 
brain. 
I : 16   T3: 4 weeks 
after baseline 
 effect 
lost at 
T3 
 
ES: ?? 
Control: 
Sham acupressure: were 
taught to apply pressure in 
three points that are not 
associated with ‘energy’ 
one 
session, 
daily 
1min  
at home 
  
 
   
C: 16 
 
 
total 47 
 
 
  
 
   
 
Studies: 
1. Courneya et al. Randomized controlled trial of exercise training in postmenopausal breast cancer survivors: cardiopulmonary and quality of life outcomes. J Clin 
Oncol 2003; 21(9): 1660-1668 
2. Pinto et al. Home-based physical activity intervention for breast cancer patients. J Clin Oncol 2005; 23(15): 3577-3587. 
3. Gielissen et al: Chapter 4 and Chapter 5. 
4. Basen-Engquist et al. Randomized pilot test of lifestyle physical activity intervention for breast cancer survivors. Patient Educ Couns 2006; 64: 225-234. 
5. Culos-Reed et al. A pilot study of yoga for breast cancer survivors: physical and psychological benefits. Psycho-Oncol 2006; 15: 891-897. 
6. Bennett et al. Motivational interviewing to increase physical activity in long-term cancer survivors. Nursing Research 2007; 56(1): 18-27. 
7. Molassiotis et al. The management of cancer-related fatigue after chemotherapy with acupuncture and acupressure : a randomised controlled trial. Complement 
Ther Med, in press 
 
Number: 
I : intervention condition 
C: control condition 
Fatigue questionnaires: SF 36 – Short Form 36, EORTC QLQ C30 – European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30; 
FACT-FS - Functional Assessment of Cancer Therapy – Fatigue Scale ; MFI – Multidimensional Fatigue Inventory ; CIS- Checklist Individual Strength. 
Effectsize (ES): 
Post-treatment assessment of both conditions were used in the calculation Cohen’s d. In study 3 the follow-up ES is calculated using the pre-treatment and follow-up 
assessment. 
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4.b. Non-randomised/non-controlled studies 
Nine non-randomised/non-controlled studies reported about the efficacy of an intervention on 
postcancer fatigue.9,12,14,18,21,26,29,31,35  
Fatigue affects the majority of patients actively undergoing cancer treatment, with proportions 
of as high as 99% having been reported.1,2 As indicated earlier in this review, the proportion 
of fatigued cancer survivors range from 16%-39% on the long term. This demonstrates that a 
majority of the patients recover from fatigue in the first years after treatment. Therefore, if an 
intervention is given just after cancer treatment, it is particularly essential to compare patients 
in the intervention group with patients in a control group. Otherwise the results can well be 
based on natural recovery. All nine non-randomized/non-controlled also included patients 
who were less than 1 year after curative treatment  
Lindemalm et al. reported on the effect of a group intervention on fatigue severity and was 
focused on multidisciplinary education and support groups.21 An effect was found on fatigue, 
however this effect was no longer present at a 3 months follow-up. This study is the only 
non-randomized/non-controlled that included a follow-up assessment. Four pilot studies 
reported on the efficacy of exercise training on fatigue. Two of them were pilot studies and 
investigated the effect of individualized aerobic exercise.9,35  Both studies found a significant 
improvement of fatigue severity. The two other pilot studies described the effect of a home 
based physical activity programmes.26,29  Wilson et al. showed a beneficial effect on 
postcancer fatigue,26 Christopher et al. did not.29 Two studies demonstrated the positive 
effect of a rehabilitation group program, combining physical exercise and psycho-
education.14,18 One pilot study reported on the effect of acupuncture and showed an 
improvement on postcancer fatigue.31  A study on the effect of methylphenidate, a psycho 
stimulant that blocks the presynaptic dopamine uptake, showed a decrease in fatigue 
severity.12  
 
Conclusion 
Although research on management of postcancer fatigue has increased, there are still just 
seven RCT’s with their own shortcomings and only two RCT show positive effects in 
reducing fatigue. When conducting intervention studies follow-up assessments are essential. 
It is important to know if the benefits remain over time after the intervention has finished. 
Only one of the two effective RCT’s included a follow-up assessment3. In Chapter 5 it is 
demonstrated that the positive effects of CBT were maintained at about 2 years after 
finishing the therapy. However, this long term effect was investigated in an uncontrolled 
design.3 Two other RCT’s also included a follow-up assessment. Bennett et al.4 and 
Molassiotis et al.15 reported no positive effects at follow-up.  
The existing evidence suggest that until now CBT especially designed for postcancer 
fatigue3,11 and a home-based physical activity intervention 24 are effective in treating 
postcancer fatigue. A common element in those two interventions lies within the area of 
physical activity. However, two different kinds of activity enhancement were investigated, 
graded exercise and graded activity. Graded exercise is a program of usually 12 weeks 
aimed at increasing fitness. Patient engage in intensive to strenuous exercise and the 
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intensity is often monitored with a hart-rate recorder. Graded activity is a program with 
gradual increase in physical activity, without striving for increase of fitness. In the two positive 
trials different goals of physical activity were used. Pinto et al.24 investigated a home-based 
graded exercise program and recommendations were done for moderate-intensity physical 
activities with the aim of increasing physical fitness (brisk walking, biking, swimming, or use 
of home exercise equipment). Graded activity is one of the treatment modules of the CBT for 
postcancer fatigue.11 Forty-nine percent of the CBT time was spent on issues around graded 
activity (Chapter 3). These studies seem to suggest that some increase in physical activity is 
necessary to relieve fatigue, although the exact mechanism by which activity enhancement 
decreases fatigue remains to be determined. On the contrary, three RCT’s show an increase 
in physical activities or physical fitness but no decrease in fatigue complaints.4,7,33 CBT for 
postcancer fatigue addresses also other factors besides physical activity. Therefore we think 
that other factors are also important in relieving fatigue, supported by the larger effect size of 
the CBT-study compared to the graded exercise study. Future studies should be aimed at 
investigating how important the role of physical activity is in decreasing fatigue.  
Within the context of prevention, more longitudinal studies (design: pre-cancer treatment, 
post-cancer treatment and follow-up) are required to determine more accurately the 
developing of postcancer fatigue. This kind of research will enable us to identify early 
determinants and risk factors of postcancer fatigue and may facilitate the development of 
new and the improvement of existing interventions. Ultimately, this hopefully leads to 
preventing persistent fatigue in cancer survivors by delivering early interventions to those 
most in need. 
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              Summary 
 
 
Earlier and more accurate diagnosis and improved observation and treatment have resulted 
in an increased number of people that has been successfully treated for cancer. Despite the 
fact that these persons have been cured from cancer, a substantial minority of the cancer 
survivors experience severe fatigue long after the cancer treatment has ended. From 1996, 
the Expert Centre Chronic Fatigue studied causes, natural course, consequences and 
factors relating to postcancer fatigue. Based on these studies the model of precipitating and 
perpetuating factors is believed to be useful in understanding postcancer fatigue. The 
assumption is that cancer itself and/or cancer treatment may have triggered fatigue 
(precipitating factors), but other factors are responsible for persistence of fatigue complaints 
(perpetuating factors). These perpetuating factors should be the target in the management of 
postcancer fatigue.  
This dissertation consists of two studies on the subject of postcancer fatigue complaints, 
three on the management of postcancer fatigue and two on the assessment of fatigue. 
The goal of Chapter 2 was to investigated in a longitudinal study the prevalence of persistent 
fatigue in 121 breast cancer survivors, whether fatigue was related to former treatment 
modalities and to investigate possible predictors of persistent fatigue. Patients were 
assessed at 2.4 years and 4.5 years after curative treatment on psychological, physical, 
social, cognitive and behavioral aspects. Furthermore, patients filled out a monthly fatigue 
questionnaire during a two-year period. Based on the monthly fatigue questionnaires, 24% of 
the cancer survivors experienced persistent fatigue. Persistent fatigue seemed to be related 
to the duration of former treatment but unrelated to type of surgery, type of adjuvant therapy 
and time since treatment finished. We found that patients who did not receive any kind of 
adjuvant therapy and who did not experience any kind of complications during treatment, i.e. 
those patients that completed treatment for cancer within one month, were at lower risk for 
persistent fatigue. High anxiety, high impairment in role functioning and low sense of control 
over fatigue symptoms at the first assessment were predictors of persistent fatigue. These  
predictors of persistent fatigue were used, among others, in the development of a cognitive 
behavioral intervention for postcancer fatigue. The treatment protocol of this intervention is 
presented in Chapter 3. The treatment protocol encompasses six modules that coincide with 
the six factors assumed to perpetuate the symptoms of fatigue, such as poor or inappropriate 
coping skills, a heightened fear of a recurrence of the cancer, dysfunctional fatigue-related 
cognitions, dysregulatory sleep-wake cycles, dysregulatory activity patterns, and insufficient 
social support and negative interactions. The perpetuating factors are not the same for each 
patient. To determine the key factors for each patient, the patient completes several 
assessment instruments. Based on the tools’ norm scores it is determined whether the 
patient has a deviant or problem score. Subsequently, founded on the outcomes of the 
assessment instruments and the patient-therapist interview an individually tailored treatment 
plan is drawn up comprising only the patient-relevant modules. In this chapter the rationale of 
each module is discussed, followed by the relevant assessment instrument and the proposed 
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course of action. Explanation of the model of perpetuating factors, challenging fatigue-related 
cognitions, attaining and maintaining a base level of physical activity, gradual increase of 
physical activity were modules that became part of the tailored treatment plan of all patients. 
The regulation of sleep-wake rhythm, by encouraging to adhere to fixed bedtimes and wake-
up times and instilling more realistic expectations toward the patient’s social support group 
were part of the treatment protocol for the majority of the patients. Acquiring better coping 
with the experience of cancer and challenging the thoughts of fear of disease recurrence 
were necessary for a subgroup of the patients.  
The next step was studying the effectiveness of cognitive behaviour therapy (CBT) for 
postcancer fatigue. This study is presented in Chapter 4. In a randomised controlled trial we 
compared CBT with a waiting list condition. At the time of participation in the trial cancer 
survivors completed curative treatment at least 1 year previously and had no evidence of 
disease recurrence. Data of 112 cancer survivors with somatically unexplained fatigue were 
analyzed on an intention-to-treat basis and the last observation was carried forward if data 
were missing. Both conditions were assessed two times, at baseline and 6 months later. 
Results showed that CBT was significantly more effective than the waiting list condition for 
the two primary outcome variables, fatigue severity and functional impairment and for the 
secondary outcome variable, psychological distress. Furthermore, the proportion of patients 
in the intervention condition with clinically significant improvement on fatigue severity (54%), 
functional impairment (50%), and self-rated improvement (66%) was significantly higher than 
in the waiting list condition (respectively, 4%, 18%, 21%).  
Patients in the waiting list condition were informed beforehand that, if desired, they could 
start therapy directly after the waiting period of 6 months. In Chapter 5 the long term effects 
of CBT were investigated in patients that were involved in the RCT described in Chapter 4 
and completed CBT, including patients in the intervention condition and patients who had 
been treated after the 6 months waiting list. Therefore, this chapter describes the results of 
an uncontrolled follow-up study. Furthermore, predictors of fatigue severity at follow-up were 
exploratory investigated. In total 68 fatigued cancer survivors completed CBT and were 
assessed at pre-treatment, post-treatment and at follow-up. The mean length of time 
between completion of therapy and the follow-up assessment was 1.9 years (sd=1.0) with a 
range of 6 months to 4 years.  Improvements on fatigue severity, functional impairment and 
psychological distress after CBT appeared to remain stable during the follow-up period.  
Patients who were not fatigued anymore at follow-up had the same level of fatigue, functional 
impairment and a lower level of psychological distress compared to a reference group of 
non-fatigued cancer survivors. The explorative regression analysis showed a trend that more 
fatigue, higher psychological distress and stronger somatic attributions at pre-treatment 
contributed to persistent fatigue severity at follow-up. These results suggest that if a patients 
continues to think that the cancer itself and/or cancer treatment is responsible for the 
experienced fatigue, the chance on recovery is lowered. Somatic attributions should receive 
more attention during the CBT. Because somatic attributions in fatigued cancer survivors can 
be reinforced by inaccurate information delivery about the cause of postcancer fatigue, the 
chance of improvement with CBT can be increased by (further) education on postcancer 
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fatigue for professionals working in cancer care. In addition, fatigued cancer survivors with 
high scores on psychological distress (probably indicative of psychiatric comorbidity) proved 
to have hardly any chance to improve with CBT for postcancer fatigue.  
Literature suggests that cancer survivors with more aggressive treatments are more at risk 
for postcancer fatigue. Therefore, we investigated in Chapter 6 ninety-eight cancer survivors 
after completion of  a highly aggressive and demanding medical intervention, a stem cell 
transplantation (SCT). Diagnoses included were acute myeloid or lymphatic leukaemia in first 
complete remission, chronic myeloid leukaemia in first chronic phase, Non-Hodgkin 
lymphoma in first complete remission. The conditioning regime included total body 
irradiation. All patients had to be in persistent complete remission for at least one year after 
SCT. Furthermore, patients with Graft versus Host Disease (GVHD) grade III and IV, acute 
GVHD or extensive chronic GVHD were excluded. Also patients with a hemoglobin (Hb) 
concentration of 10 g/dl and lower were not eligible for this study. We studied the prevalence 
of fatigue, the association between medical variables and fatigue and if the model of 
perpetuating factors of postcancer fatigue derived from previous studies in cancer survivors, 
without SCT,  is applicable in SCT survivors. Thirty-five percent of the patients experienced 
severe fatigue, while an additional 12 patients (12%) had heightened fatigue scores. The 
percentage cancer survivors with severe fatigue remained stable during the years after 
transplantation, even after more than 15 years. Previous literature suggest that fatigue 
complaints continue to decrease during the first 3 – 4 years after curative treatment and 
remains a persistent problem for about a quarter of the cancer survivors. In patients after a 
SCT the percentage of fatigue remains high. This finding is in agreement with the 
assumption that patients with more aggressive treatments are more at risk for persistent 
fatigue. We found no associations with fatigue severity and characteristics of the medical 
history (e.g. diagnose, transplantation type, time since transplantation, grade of GVHD, 
hospitalization and complications) and current medical characteristics (e.g. medication use, 
Hb-concentration, body mass index). There was one exception, patients with a current 
medical comorbidity scored higher on fatigue severity compared to patients without a current 
medical comorbidity. The model of perpetuating factors derived from previous studies in 
cancer survivors, not undergoing transplantation, appeared to be applicable in SCT cancer 
survivors as well. Persistent fatigue was well predicted by the supposed perpetuating factors: 
poor coping with the experience of cancer, fear of disease recurrence, dysfunctional 
cognitions concerning fatigue, dysregulation of sleep, dysregulation of activity and 
insufficiency in social support. In total 68% of the variance of fatigue severity was explained 
by the six factors. These results suggests that in the absence of clear medical causes, the 
CBT especially designed for fatigued cancer survivors after conservative treatment, could 
also be used in the management of fatigue after SCT. 
Chapter 7 offers encouraging data for the use of the Pictorial Representation of Illness 
Measure (PRISM) as a tool in fatigue research and clinical practice. Patients were shown a 
A4 shaped paper with a yellow fixed disk at the bottom-right hand corner and were asked to 
imagine that the paper represents his/her life as it is at the moment. The disk represents the 
subjects’ self. Detachable disks was used to represent the fatigue and illness. Subjects were 
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asked: ‘where would you put fatigue/illness to reflect its importance in your life at this 
moment? We tried to get a better understanding of suffering associated with fatigue using 
this simple, graphic instrument in three different samples of fatigued patients; 60 chronic 
fatigue syndrome patients, 82 fatigued cancer survivors and 68 fatigued patients with various 
neuromuscular disorders. The objective was to investigate if suffering was a separate 
dimension of chronic fatigue, if there was a difference in suffering between different fatigued 
patient groups, if it was possible to discriminate within a patient between suffering due to an 
illness and suffering due to fatigue and if suffering diminished following treatment for chronic 
fatigue. We did not find high correlations, indicative for a parallel test, with other dimensions 
of fatigue (fatigue severity, functional impairment, physical activity, psychological distress, 
sleep disturbances, concentration problems, social functioning, self-efficacy, causal 
attributions). Therefore, the PRISM contributes uniquely to the dimensions of fatigue. We 
found differences between the samples in the position of the fatigue disk and the illness disk. 
Fatigue is a symptom which frequently occurs in combination with physical illnesses and it’s 
difficult to determine when fatigue leads to suffering or when another symptom is more 
important to a patient. The PRISM was able to discriminate between different kinds of 
suffering. Furthermore, the PRISM showed sensitivity to change in patients who recovered of 
severe fatigue after CBT.  
Chapter 8 reports about the development and psychometric testing the Fatigue Quality List 
(FQL). Fatigue measurements are mostly used to assess fatigue severity. However, fatigue 
severity does not reflect a persons’ perception and appraisal of the fatigue. Therefore, the 
quantitative way of assessing fatigue fails to capture the nuances and differences in the 
experience of fatigue. The primary objective of Chapter 8 was to develop an adjective 
checklist aimed at assessing different perceptions of fatigue. The FQL consisted of 28 
adjectives describing the experience of the fatigue. Subjects were instructed to mark with a 
cross which of the 28 adjectives fit their experienced fatigue. Multiple answers were possible 
Nine-hundred-sixty-one fatigued and non-fatigued participants filled out the FQL (cancer 
survivors, CFS-patients, employees on sick leave, various neuromuscular disorders, 
pancreatitis, healthy persons). A component and confirmatory factor analyses were 
performed and demonstrated four coherent factors (18 adjectives), which were named: 
Frustrating, Exhausting, Pleasant and Frightening. Furthermore, the data of this study 
showed that the FQL had adequate psychometric properties and sensitivity to change. The 
FQL can therefore be a helpful tool in clinical practice, for example to define recovery. When 
a decrease is seen in fatigue severity and the perception of the fatigue stays negative, which 
implicates that a patients still suffers and is disabled due to the fatigue, a patient can not be 
seen as fully recovered. To reach recovery not only the fatigue severity has to change but 
also the perception of fatigue. 
Finally, in Chapter 9 the results of the studies presented in this dissertation were placed into 
the perspective of the existing international literature of postcancer fatigue. Different topics 
were discussed; measurements, prevalence and course of postcancer fatigue, the 
predisposing, precipitating and perpetuating factors of postcancer fatigue and existing 
interventions on postcancer fatigue.  
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Het eerder en nauwkeuriger diagnostiseren van de ziekte kanker en een verbeterde 
behandeling heeft ertoe geleid dat steeds meer mensen met succes behandeld worden voor 
kanker. Maar ondanks het feit dat deze mensen genezen zijn van kanker, blijkt lang na het 
einde van de behandeling van kanker (minimaal 1 jaar) een substantieel deel van deze 
ziekte-vrije oncologie patiënten ernstige vermoeidheidsklachten te ervaren. Vanaf 1996 heeft 
het Nijmeegs Kenniscentrum Chronische Vermoeidheid (NKCV) de oorzaken, natuurlijk 
beloop, consequenties en factoren die samen gaan met deze vermoeidheid onderzocht. 
Gebaseerd op deze studies is gebleken dat voor het begrijpen van vermoeidheid lang na 
curatieve behandeling van kanker er onderscheid gemaakt dient te worden tussen 
uitlokkende factoren en huidige, instandhoudende factoren. Ziekte- en 
behandelingskenmerken blijken namelijk geen relatie te vertonen met de ernst van de 
vermoeidheid lang na het afsluiten van de behandeling. M.a.w. de veronderstelde 
uitlokkende factoren voor vermoeidheid tijdens de behandeling van kanker, nl. de kanker zelf 
of de behandeling ervoor, vormen  lang na de behandeling geen verklaring meer voor de 
vermoeidheid. Het is aannemelijk dat de vermoeidheid wel geïnitieerd is door de 
behandeling, maar dat na verloop van tijd andere factoren ervoor zijn gaan zorgen dat de 
klachten blijven bestaan. Een behandeling voor vermoeidheid na kanker zou gericht moeten 
zijn op deze instandhoudende factoren.  
In dit proefschrift zijn twee hoofdstukken opgenomen die gericht zijn op het in kaart brengen 
van de aard van vermoeidheid na kanker (hoofdstuk 2 en 6), drie hoofdstukken over de 
cognitieve gedragstherapie speciaal ontwikkeld voor vermoeidheid na behandeling van 
kanker (hoofdstuk 3, 4 en 5) en twee hoofdstukken over het meten van vermoeidheid 
(hoofdstuk 7 en 8).  
Het doel van Hoofdstuk 2 was om in een longitudinaal studie de prevalentie van 
aanhoudende vermoeidheid te onderzoeken in een cohort van 121 ziekte-vrije borstkanker 
patiënten. Bovendien wilden we weten of de aanhoudende vermoeidheid gerelateerd  was 
aan de eerdere oncologische behandeling en wilden we onderzoeken welke factoren 
bijdroegen aan de instandhouding van de vermoeidheid. Patiënten werden onderzocht 2.4 
jaar en 4.5 jaar na het einde van de curatieve behandeling van kanker op psychologische, 
fysieke, sociale, cognitieve en gedragsmatige aspecten. Verder hebben alle deelnemers aan 
de studie gedurende twee jaar maandelijks een vermoeidheidsvragenlijst ingevuld. 
Gebaseerd op deze maandelijkse vermoeidheidsvragenlijsten vonden we dat 24% van de 
ziekte-vrije borstkankerpatiënten aanhoudende klachten van vermoeidheid ervoer. De 
aanhoudende vermoeidheid bleek gerelateerd aan de duur van de oncologische 
behandeling, maar niet aan het type operatie, type adjuvante behandeling en tijd sinds het 
einde van de behandeling. We vonden dat  persisterende vermoeidheidsklachten minder 
vaak voor komt bij patiënten bij wie de behandeling relatief kort heeft geduurd, waarbij de 
behandeling binnen één maand afgerond is. Hierbij moet men dus denken aan patiënten die 
een chirurgische behandeling (borstbesparende operatie of amputatie) hebben ondergaan 
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zonder complicaties en zonder nabehandeling (radiotherapie en/of chemotherapie). Deze 
patiënten lijken dus minder kans te hebben op persisterende vermoeidheidsklachten. Angst,  
beperkingen met betrekking tot het uitvoeren van dagelijkse activiteiten thuis of op het werk 
en het idee weinig controle te hebben over de vermoeidheidsklachten bleken voorspellers 
van aanhoudende vermoeidheid te zijn. O.a. deze voorspellers werden gebruikt in de 
ontwikkeling van een cognitief gedragsmatige behandeling. Het protocol van deze cognitief 
gedragsmatige behandeling staat beschreven in Hoodfstuk 3. Het behandelprotocol bestaat 
uit zes modulen die gebaseerd zijn op de zes factoren waarvan verondersteld wordt dat ze 
de vermoeidheid in stand houden; verwerking van het feit dat men kanker heeft gehad, angst 
voor het terugkeren van de ziekte, opvattingen rondom vermoeidheid, het slaap waak ritme, 
(lichamelijke) activiteitenpatroon en ervaren sociale steun en interacties. De 
instandhoudende factoren zijn niet voor iedere vermoeide patiënt dezelfde. Om te bepalen 
welke factoren bij welke patiënt van belang zijn, worden meetinstrumenten gebruikt. Op 
basis van normgegevens voor deze meetinstrumenten kan vastgesteld worden of er sprake 
is van een problematische score van de betreffende patiënt. Op grond van de vragenlijsten 
en het gesprek tussen therapeut en patiënt wordt er voor elke patiënt een individueel 
behandelplan gemaakt bestaande uit de modulen die voor de betreffende patiënt relevant 
zijn. In dit hoofdstuk 3 wordt per module eerst de verantwoording van de module besproken, 
vervolgens welk meetinstrument hierbij gebruikt wordt en tenslotte de werkwijze in de 
behandeling. De modulen, uitleg over het model van uitlokkende en instandhoudende 
factoren, opvattingen rondom vermoeidheid, activiteitenregulatie en opbouw van fysieke 
activiteit bleken bij iedere patiënten onderdeel van het behandelprotocol (65 patiënten). Bij 
een meerderheid van de patiënten was regulatie van slaap-waak ritme en het bevorderen 
van realistische verwachtingen ten aanzien van de omgeving van de patiënt onderdeel van 
het protocol. Verwerking van het feit dat de patiënt kanker heeft gehad en hiervoor 
behandeld is en verhoogde angst voor het terugkeren van de ziekte was slechts voor een 
minderheid van de patiënten nodig om te behandelen. 
Na de ontwikkeling van het protocol ‘cognitieve gedragstherapie (CGT) voor vermoeidheid 
na behandeling van kanker’ zijn we gaan onderzoeken of deze behandeling effectief is in het 
verminderen van de vermoeidheidsklachten en beperkingen in ziekte-vrije 
oncologiepatiënten. Deze studie wordt in Hoofdstuk 4 gepresenteerd. In een gerandomiseerd 
gecontroleerd onderzoek wordt naar het effect gekeken van CGT door patiënten die therapie 
hebben gehad te vergeleken met patiënten die wachten op deze behandeling. Op het 
moment van deelname aan de studie hadden de ziekte-vrije oncologie patiënten de 
behandeling van kanker minimaal 1 jaar geleden afgerond en waren er geen aanwijzingen 
voor een recidief. Metingen voor beide groepen vond op twee momenten plaats: bij de start 
van het onderzoek en na 6 maanden. Data van 112 patiënten met lichamelijk onverklaarde 
vermoeidheidsklachten zijn geanalyseerd. De resultaten lieten zien dat CGT effectiever is 
dan op een wachtlijst staan van 6 maanden, zowel op de twee primaire uitkomstmaten 
vermoeidheid en beperkingen als op de secundaire uitkomstmaat psychisch welbevinden. 
Het aantal patiënten met een klinisch relevante verbetering op de drie uitkomstmaten was 
groter voor de patiënten die de CGT hadden gevolgd dan voor de patiënten die op de 
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behandeling wachten, namelijk voor vermoeidheid 54% versus 4%, beperkingen 66% versus 
18% en psychisch welbevinden 66% versus 21%. CGT speciaal gericht op de 
instandhoudende factoren van vermoeidheid na kanker blijkt dus een effectieve behandeling. 
Aan de patiënten in de wachtlijst groep werd aan het begin van het onderzoek vermeld dat 
zij, als zij dat wilden, meteen na de wachtlijst, ook de CGT konden volgen. In Hoofdstuk 5  
wordt verslag gedaan van het lange termijn effect van CGT voor vermoeidheid na kanker. Dit 
effect is onderzocht bij patiënten die deelnamen aan het onderzoek beschreven in Hoofdstuk 
4 en die volledig de behandeling hebben gevolgd. Het gaat hier om zowel patiënten die in de 
CGT groep zaten als patiënten die na een periode van 6 maanden zijn behandeld. Verder 
werd er ook nog exploratief gekeken naar voorspellers van vermoeidheid op lange termijn. In 
totaal hadden 68 patiënten volledig de CGT voor vermoeidheid na kanker afgerond. De 
vermoeidheid van deze patiënten werd op drie momenten in kaart gebracht, voor de CGT 
(voormeting), na afloop van de behandeling (nameting) en op lange termijn (follow-up 
meting). De gemiddelde tijd van het einde van de CGT tot aan de follow-up meting bedroeg 
1.9 jaar (sd=1.0) met een spreiding van 6 maanden tot 4 jaar. De verbeteringen op 
vermoeidheid, beperkingen en psychisch welbevinden gemeten net na de CGT bleven 
gehandhaafd tot aan 1.9 jaar na de therapie. Patiënten die helemaal geen 
vermoeidheidsklachten meer ervoeren ten tijde van de follow-up meting waren even 
vermoeid, hadden evenveel beperkingen en een hoger psychisch welbevinden vergeleken 
met een referentie groep van niet vermoeide ziekte-vrije oncologiepatiënten. Verder was er 
een trend te zien dat meer vermoeidheidsklachten, minder psychisch welbevinden en een 
sterke somatische attributie bij de voormeting voorspellers waren van meer vermoeidheid 
tijdens de follow-up meting. Deze resultaten lijken erop te wijzen dat als een patiënt blijft 
denken dat de kanker en/of de behandeling van kanker nu nog steeds verantwoordelijk is 
voor de vermoeidheid, de kans op herstel lager is. Tijdens de CGT zou daarom meer 
aandacht besteed moeten worden aan somatische attributies. Daarnaast kunnen somatische 
attributies bekrachtigd worden door verstrekking van onjuiste informatie aan de patiënt over 
de oorzaak van vermoeidheid na kanker. De kans op herstel door middel van CGT zou dus 
ook kunnen worden vergroot door kennis over vermoeidheid na kanker over te dragen aan 
professionals die werken in de zorg voor oncologie patiënten. Verder blijkt dat vermoeide 
patiënten met een lage score op psychisch welbevinden (mogelijk een signaal voor 
psychiatrische co-morbiditeit) weinig kans hebben om te herstellen met CGT.  
Er zijn aanwijzingen in de internationale literatuur dat ziekte-vrije oncologie patiënten die een 
agressieve behandeling hebben ondergaan voor kanker meer kans op hebben op ernstige 
vermoeidheid lang na het einde van deze behandeling. In Hoofdstuk 6 hebben we 98 ziekte-
vrije oncologie patiënten onderzocht die een extreem agressieve en veeleisende 
behandeling hebben ondergaan, namelijk een stamceltransplantatie (SCT). Dit waren 
patiënten gediagnosticeerd met acute myeloide of lymfatische leukemie in eerste complete 
remissie, chronische myeloide leukemie in eerste chronische fase, Non-Hodgkin lymfomen in 
eerste complete remissie. Alle patiënten hadden een totale lichaamsbestraling ondergaan. 
Patiënten met een Graft versus Host Disease (GVHD) graad van III en IV, acute GVHD of 
een uitgebreide chronische GVDH werden ge-excludeerd van de studie. Ook patiënten met 
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een hemoglobine (Hb) concentratie van 10 g/dl en lager werden niet toegelaten in de studie. 
De prevalentie van vermoeidheid en de relatie tussen medische factoren en vermoeidheid  
werden onderzocht. Daarnaast werd gekeken of het model van instandhoudende factoren 
van vermoeidheid na kanker voortgekomen uit de vorige studies vanuit het NKCV ook 
toepasbaar was bij patiënten na een SCT. Vijf-en-dertig procent van de deelnemers aan de 
studie ervoeren ernstige vermoeidheidsklachten en nog eens 12% had een verhoogde 
vermoeidheidsscore. Literatuur over vermoeidheid na kanker laat zien dat in de eerste 3-4 
jaar na de behandeling van kanker het percentage patiënten met ernstige 
vermoeidheidsklachten afneemt en dat het een aanhoudend probleem blijft voor ongeveer 
een kwart van de ziekte-vrije oncologie patiënten. Maar het percentage ernstig vermoeide 
patiënten na een SCT bleef hoog, zelfs bij patiënten die meer dan 15 jaar geleden een SCT 
hadden ondergaan. Dit is in overeenstemming met de assumptie dat patiënten die een 
agressievere behandeling voor kanker hebben ondergaan, meer kans hebben op ernstige 
vermoeidheid. We vonden geen relatie met vermoeidheid en het medisch verleden van de 
patient (zoals diagnose, transplantatie type, tijd sinds transplantatie, GVHD graad, opname 
duur en complicaties). Ook werd er geen relatie gevonden met vermoeidheid en huidige 
medische factoren (zoals medicatie gebruik, Hb concentratie en Body Mass Index). De enige 
relatie die gevonden werd, was dat patiënten met een huidige lichamelijk co-morbiditeit een 
hogere vermoeidheidsscore hadden ten opzichte van patiënten zonder huidige lichamelijke 
co-morbiditeit.  Verder bleek het model van instandhoudende factoren goed toepasbaar te 
zijn op ziekte-vrije patiënten na een SCT.  Vermoeidheid werd namelijk goed voorspeld door 
de veronderstellede instandhoudende factoren: verwerking van het feit dat men kanker heeft 
gehad, angst voor het terugkeren van de ziekte, opvattingen rondom vermoeidheid, het slaap 
waak ritme, (lichamelijke) activiteitenregulatie en ervaren sociale steun. In totaal werd 68% 
van de variantie voorklaard door de zes instandhoudende factoren. De resultaten van deze 
studie laten zien dat in de afwezigheid van een lichamelijke oorzaak, CGT speciaal 
ontwikkeld voor vermoeidheid na kanker ook gebruikt kan worden in de behandeling van 
vermoeide patiënten na een SCT.  
Hoofdstuk 7 laat bemoedigende resultaten zien in het gebruik van de Pictorial 
Representation of Illness Measure (PRISM) als meetinstrument in vermoeidheidsonderzoek 
en in de klinische praktijk. Bij drie verschillende groepen van vermoeide patiënten werd de 
PRISM afgenomen; 60 patiënten met het chronisch vermoeidheidssyndroom (CVS), 82 
vermoeide ziekte-vrije oncologie patiënten, en 68 patiënten met een neuromusculaire 
aandoening. Deze patiënten kregen een A4 papier te zien met een gele cirkel in de rechter 
onderhoek en werden gevraagd zich voor te stellen dat het papier hun leven was op dit 
moment. De gele cirkel staat voor de persoon zelf, de “ik-cirkel”.  Er zijn ook nog twee losse 
cirkels, die voor “vermoeidheid” en “ziekte” staan. Aan de patiënt werd gevraagd: “Waar zou 
u op dit moment uw vermoeidheid/ziekte plaatsen in uw leven?”  Met de PRISM, een simpel, 
grafisch instrument wilde we meer inzicht krijgen in het lijden van de patiënt gerelateerd aan 
vermoeidheid. We onderzochten of lijden een aparte dimensie was van chronische 
vermoeidheid, of er verschillen waren in lijden tussen de drie verschillende groepen 
patiënten, en of het mogelijk was om onderscheid te maken tussen het lijden veroorzaakt 
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door de ziekte en lijden veroorzaakt door vermoeidheid. Als laatste werd er gekeken of lijden 
verminderd na behandeling voor chronische vermoeidheid. Voor alle vraagstellingen werden 
positieve resultaten gevonden. 
In Hoofdstuk 8 wordt de ontwikkeling en psychometrische toetsting van de Fatigue Quality 
List (FQL) beschreven. De meeste vermoeidheidsvragenlijsten worden gebruikt om de ernst 
van vermoeidheid in kaart te brengen. Echter, de ernst van vermoeidheid geeft niet de 
perceptie weer die een patiënt heeft van vermoeidheid. Hierdoor faalt de kwantitatieve 
manier van het meten van vermoeidheid met het in kaart brengen van nuances and 
verschillen in de ervaring van vermoeidheid. Het belangrijkste doel van Hoofdstuk 8 was om 
een checklist met bijvoeglijke naamwoorden te ontwikkelen die verschillende percepties van 
vermoeidheid omschrijft. De orginele FQL bestond uit 28 bijvoeglijke naamwoorden. De 
proefpersoon moest aangeven met een kruisje welke van de bijvoeglijke naamwoorden het 
beste past bij zijn/haar beleving van vermoeidheid. Meerdere antwoorden mochten gegeven 
worden. 961 vermoeide en niet-vermoeide deelnemers aan het onderzoek hebben de FQL 
ingevuld (ziekte-vrije oncologie patiënten, CVS patiënten, werknemers in de ziekte-wet, 
patiënten met neuromusculaire aandoeningen, patiënten met pancreatitis, en gezonden 
personen). Een componenten en een confirmatorische factor analyse werden uitgevoerd en 
toonde aan  dat de checklist uit vier samenhangende factoren bestond (18 bijvoeglijke 
naamwoorden), welke de naam kregen: Frustrerend, Uitputtend, Aangenaam en 
Beangstigend. Verder liet deze studie zien dat de FQL adequate psychometrische 
eigenschappen heeft. The FQL kan daarom als een waardevol instrument gezien worden 
voor de klinische praktijk, bijvoorbeeld om herstel aan te tonen. Als er een afname gezien 
wordt in de ernst van de vermoeidheid, maar de perceptie van de patiënt van de 
vermoeidheid blijft negatief, dan kan deze patiënt niet als volledig hersteld gezien worden. 
Om herstel te bereiken moet niet alleen de ernst van de vermoeidheid afnemen maar ook de 
perceptie van vermoeidheid moet veranderen. 
In Hoofdstuk 9 worden de resultaten die in dit proefschrift zijn beschreven in perspectief 
gezet met de bestaande internationale literatuur over vermoeidheid na kanker. Verschillende 
onderwerpen komen aanbod: meetinstrumenten, prevalentie en beloop, de predisponerende, 
precipiterende en perpetuerende factoren van vermoeidheid na kanker en interventies 
gericht op vermoeidheid na kanker. 
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Op deze laatste bladzijden van mijn proefschrift wil ik graag een aantal mensen bedanken 
die op verschillende manieren hebben bijgedragen aan de voltooiing van dit proefschrift. 
  
Ten eerste zijn er natuurlijk alle patiënten die hebben deelgenomen aan het onderzoek 
beschreven in dit proefschrift. Door hun inzet bestaat er nu een succesvolle therapie voor 
vermoeidheid na behandeling van kanker en is er meer inzicht verkregen in het probleem 
vermoeidheid bij ziekte-vrije kankerpatiënten. Tevens wil ik ook alle artsen bedanken die 
geholpen hebben bij de benadering en het motiveren van patiënten voor het onderzoek.  
 
Graag wil ik mijn (co)promotoren Gijs Bleijenberg en Stans Verhagen bedanken voor de 
stimulerende begeleiding. Gijs en Stans, jullie expertise, enorme enthousiasme voor de 
wetenschap en kritische houding hebben gemaakt dat ik trots kan zijn op mijn proefschrift. 
Daarnaast ben ik dankbaar voor jullie vertrouwen in mijn capaciteiten. Jullie steun als 
begeleiders van mijn KWF fellowship, geeft mij de kans me verder te ontwikkelen op het 
gebied van vermoeidheid in de psychosociale oncologische zorg en wetenschappelijk 
onderzoek. Ik leer nog steeds veel van jullie en hoop daarom nog lang met jullie samen te 
mogen werken. 
Zonder het vertrouwen van mijn promotor Prof. dr. Pieter de Mulder in de samenwerking 
tussen Medische Oncologie en het Nijmeegs Kenniscentrum Chronische Vermoeidheid, was 
mijn onderzoek nooit mogelijk geweest. Hij heeft ervoor gezorgd dat vermoeidheid na 
behandeling van kanker in de afgelopen 10 jaar onder de aandacht kwam en bleef op de 
afdeling Medische Oncologie. Bedankt hiervoor. 
  
De motiverende samenwerking met dr. Ton Schattenberg en de medewerkers van het 
datacentrum van de afdeling Hematologie hebben geleid tot de publicatie beschreven in 
hoofdstuk 6. Ton, bedankt dat jij je enthousiasme over je vakgebied met mij hebt willen 
delen.  
 
Uiteraard ben ik mijn (oud)collega’s veel dank verschuldigd. Mijn promotie onderzoek heeft 
even geduurd en dankzij de gezelligheid en goede sfeer op de afdeling ga ik elke dag met 
veel plezier naar mijn werk. Op de eerste plaats een bedankje voor de onderzoekers Korine, 
Gerard, Hans (de kroonprins), Martine, Dewy, Marlies, Marcia, Sanne, Joke, Harmen, Petra, 
en Judith. Hoogtepunten waren (en zijn) de gezellige pauzemomenten waarop de dagelijkse 
beslommeringen besproken worden, de borrels ter ere van de publicaties, de etentjes (met 
name de BBQ’s bij familie The), en natuurlijk ook het maandagochtend overleg.  
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Voor onderzoek naar het effect van een therapie is een goede samenwerking tussen 
onderzoeker en therapeuten onmisbaar. Ik ben dan ook in het bijzonder veel dank 
verschuldigd aan Thea, Hein en Ellen, die als therapeuten de cognitieve gedragstherapie 
voor vermoeidheid na kanker hebben uitgevoerd voor mijn onderzoek. Jullie essentiële 
bijdrage aan dit proefschrift lijkt me duidelijk. Thea, in welk buurthuis zal ons volgende 
broodje kroket zich bevinden?  
Een speciale dank gaat uit naar Tiny, voor de dataverzameling en dataverwerking, maar ook 
om onze gezellige gesprekken. Ook de psychologisch medewerkers Carel, Lianne, Judith, 
Ria en Danielle wil ik bedanken voor hun bijdrage aan een ontspannen sfeer op de afdeling. 
Er wordt altijd gelachen op jullie kamer (in ieder geval het hardst gelachen!), daarom is het 
niet raar dat iedereen graag (waaronder ik) bij jullie binnen loopt voor enige afleiding. Hierbij 
wil ik ook Liesbeth betrekken, onze secretaresse met de gezellige huisdieren (stofluis wat het 
toch?) en Agaat, Henriëtte, Annemarie, Pauline en Inge.  
Kortom, ik heb altijd met veel plezier met jullie alle samengewerkt en daardoor een 
fantastische promotietijd gehad.  
 
Als laatste het belangrijkste gedeelte van mijn leven, mijn familie en vrienden. 
Mijn paranimfen Kim en Maaike, jullie zijn niet voor niets mijn paranimfen. Jullie weten zelf 
wel waarom. Ik ben trots dat jullie mij steunen op deze dag en trots op de vriendschap die we 
hebben. Lieve vrienden en vriendinnen, bedankt allemaal voor jullie interesse in mijn werk, 
maar nog belangrijker bedankt voor alle gezellige etentjes, het theeleuten, sporten (haha), 
uitjes en de weekendjes weg. 
 
Muttie, Yvonne, Stefan, Britt en Cas. Bedankt dat jullie er altijd voor me zijn!!!  Pap, ik mis je. 
Hein, Leny, Koen, Sjouke, Tijs, Ine en Anne. Jullie zijn een geweldige schoonfamilie. Koen, 
bedankt voor je creativiteit en voornamelijk geduld tijdens het ontwerpen van de kaft. 
 
Lieve Geert, samen eindexamen, samen naar Nijmegen, samen afstuderen, samen 
promoveren en dan nu van samen naar met zijn drieën. Ik weet dat we in de toekomst net zo 
gelukkig zullen zijn, als in de jaren hiervoor. Dank je wel voor heel veel! 
 
 
 
 
 
 
Curriculum Vitae      181 
Curriculum Vitae 
 
 
Marieke Gielissen werd op 26 oktober 1977 geboren in Deurne. In 1996 behaalde zij het 
VWO diploma aan het College Asten Someren te Asten. Zij studeerde psychologie aan de 
Katholieke Universiteit Nijmegen en ronde in 2000 de studie  af in de neuro- en 
revalidatiepsychologie. Vervolgens was zij onderzoeksassistent van een longitudinaal 
onderzoek naar vroege kenmerken van dyslexie bij de interfacultaire werkgroep voor Taal- 
en Spraakgedrag van de Radboud Universiteit Nijmegen. Vanaf 2001 was zij werkzaam als 
junior onderzoeker bij het Nijmeegs Kenniscentrum Chronische Vermoeidheid (NKCV) van 
het Universitair Medisch Centrum St. Radboud. Dit onderzoek, getiteld “Cognitieve 
gedragstherapie om ernstige vermoeidheid en beperkingen in het dagelijks leven te 
verminderen na curatieve behandeling van kanker” werd mogelijk gemaakt met een subsidie 
van KWF Kankerbestrijding en staat beschreven in dit proefschrift. In maart 2006 heeft ze 
van KWF Kankerbestrijding een fellowship gehoneerd gekregen voor sociaal-oncologisch 
onderzoek, met het NKCV als werkplek. Hierdoor krijgt ze de mogelijkheid om zich verder te 
ontwikkelen op het gebied van vermoeidheid in de psychosociale oncologische zorg en in het 
wetenschappelijk onderzoek.  
Marieke Gielissen woont in Nijmegen en is getrouwd met Geert Corstens. Samen 
verwachten ze in maart 2008 een zoon. 
 
 
 
 
 
 
